Pathway,SearchURL,ImageURL,SVG_URL,SVG_FileName,Category,Drugs,Title,Description,SMPD_Category,Created,Last_Updated,Sub_Category,References,Timestamp
11-beta-Hydroxylase Deficiency (CYP11B1),https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000575,http://smpdb.ca/view/SMP0000575/download?type=full_vector_image,httpsmpdbcaviewSMP0000575.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",11-beta-Hydroxylase Deficiency (CYP11B1),"11-beta-Hydroxylase Deficiency, also called congenital adrenal hyperplasia (CAH), is an autosomal recessive disorder and caused by a defective 11-beta-hydroxylase. 11-beta-hydroxylase catalyzes the conversion of cortexolone into cortisol which is useful for maintaining blood sugar levels and suppressing inflammation. This disorder is characterized by a large accumulation of cortexolone in the endoplasmic reticulum (ER). Symptoms of the disorder include abnormality of hair growth rate and menstrual cycle. It is estimated that 11-beta-hydroxylase deficiency affects 1 in 100,000 to 200,000 newborns.",Homo sapiens,2013-08-29,2019-09-13,Disease Pathway,"{'9221273': 'http://www.ncbi.nlm.nih.gov/pubmed/9221273', '19029289': 'http://www.ncbi.nlm.nih.gov/pubmed/19029289', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 21:59:11.578910
17-alpha-Hydroxylase Deficiency (CYP17),https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000566,http://smpdb.ca/view/SMP0000566/download?type=full_vector_image,httpsmpdbcaviewSMP0000566.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",17-alpha-Hydroxylase Deficiency (CYP17),"17-alpha-hydroxylase deficiency, also known as congenital adrenal hyperplasia (CAH) due to 17-alpha-hydroxylase deficiency or congenital adrenal hyperplasia type 5, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of the steroidogenesis pathway. It is caused by a mutation in the CYP17A1 gene which encodes the enzyme steroid 17-alpha-hydroxylase. This enzyme hydroxylates both progesterone and pregnenolone into 17-hydroxyprogesterone and 17a-hydroxypregnenolone respectively in the mitochondria, as well as hydroxylating 21-deoxycortisol to 11b-hydroxyprogesterone within the endoplasmic reticulum. When mutated, it leads to an accumulation of pregnenolone, progesterone, deoxycorticosterone and 11-dehydrocorticosterone throughout the cell. 17-alpha hydroxylase deficiency is characterized by a deficiency of sex steroids, as well as glucocorticoids. Symptoms include male undervirilization, as well as lack of development during puberty including amenorrhea for females. Low levels of potassium in the blood due to the increased levels of mineralocorticoids can occur, as well as hypertension. Treatment with dexamethasone has been able to normalize blood pressure and blood potassium levels. It is estimated that 17-alpha-hydroxylase deficiency affects 1 in 1,000,000 individuals.",Homo sapiens,2013-08-29,2019-09-11,Disease Pathway,"{'9221272': 'http://www.ncbi.nlm.nih.gov/pubmed/9221272', '26862015': 'http://www.ncbi.nlm.nih.gov/pubmed/26862015', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 21:59:40.240758
17-beta Hydroxysteroid Dehydrogenase III Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000356,http://smpdb.ca/view/SMP0000356/download?type=full_vector_image,httpsmpdbcaviewSMP0000356.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Testosterone': 'https://go.drugbank.com/drugs/DB00624', 'Estrone': 'https://go.drugbank.com/drugs/DB00655', 'Estradiol': 'https://go.drugbank.com/drugs/DB00783', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Androstenedione': 'https://go.drugbank.com/drugs/DB01536', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Estrone sulfate': 'https://go.drugbank.com/drugs/DB04574', 'Prasterone sulfate': 'https://go.drugbank.com/drugs/DB05804', '5beta-dihydrotestosterone': 'https://go.drugbank.com/drugs/DB07447'}",17-beta Hydroxysteroid Dehydrogenase III Deficiency,"17-beta hydroxysteroid dehydrogenase III deficiency, also known as 17-KSR deficiency or male pseudohermaphroditism with gynecomastia (MPH), is as rare inborn error of metabolism (IEM) and autosomal recessive disorder of the androgen and estrogen metabolism pathway. It is caused by a mutation in the HSD17B3 gene, which encodes the enzyme testosterone 17-beta-dehydrogenase 3, which is responsible for catalyzing the reversible formation of androstenedione from testosterone. This leads to an accumulation of androstenedione and dehydroepiandrosterone in the body, as well as a lack of testosterone produced. 17-KSR deficiency is characterized by an absence of testosterone in the testis until puberty, where testosterone is produced outside of the gonads. Symptoms include infertility and external female genitalia until puberty, when secondary male sex characteristics occur, as well as gynecomastia. Due to this, many individuals with this disorder are raised as female despite being genetically male, until puberty. Treatment can include removal of testes before puberty, preventing any masculinization at puberty, as well as surgical treatment of genitalia. However, there is no known treatment for restoring the fertility of affected individuals. It is estimated that 17-KSR deficiency affects 1 in 150,000 individuals in The Netherlands, without much information for the rest of the world.",Homo sapiens,2013-08-01,2019-09-11,Disease Pathway,"{'8550739': 'http://www.ncbi.nlm.nih.gov/pubmed/8550739', '10599740': 'http://www.ncbi.nlm.nih.gov/pubmed/10599740', '8075637': 'http://www.ncbi.nlm.nih.gov/pubmed/8075637', '468973': 'http://www.ncbi.nlm.nih.gov/pubmed/468973', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 8613010', '8185618': 'http://www.ncbi.nlm.nih.gov/pubmed/8185618', '8530066': 'http://www.ncbi.nlm.nih.gov/pubmed/8530066', '7779757': 'http://www.ncbi.nlm.nih.gov/pubmed/7779757', '2973313': 'http://www.ncbi.nlm.nih.gov/pubmed/2973313', '3390233': 'http://www.ncbi.nlm.nih.gov/pubmed/3390233', '2848247': 'http://www.ncbi.nlm.nih.gov/pubmed/2848247', '2846351': 'http://www.ncbi.nlm.nih.gov/pubmed/2846351', '2779584': 'http://www.ncbi.nlm.nih.gov/pubmed/2779584', '2330005': 'http://www.ncbi.nlm.nih.gov/pubmed/2330005', '9675083': 'http://www.ncbi.nlm.nih.gov/pubmed/9675083', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:00:03.095785
2-Aminoadipic 2-Oxoadipic Aciduria,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000719,http://smpdb.ca/view/SMP0000719/download?type=full_vector_image,httpsmpdbcaviewSMP0000719.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Lysine': 'https://go.drugbank.com/drugs/DB00123', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'L-Saccharopine': 'https://go.drugbank.com/drugs/DB04207'}",2-Aminoadipic 2-Oxoadipic Aciduria,"2-Aminoadipic 2-oxoadipic aciduria is a disorder of lysine metabolism caused by a defective DHTKD1 gene. DHTKD1 is predicted to code for a component of a supercomplex similar to the 2-oxoglutarate dehydrogenase complex (OGDHc) which catalyzes the conversion of 2-oxoadipate into glutaryl-CoA. This disease is characterized by a large accumulation of 2-oxoadipate and 2-hydroxyadipate in the urine. Symptoms of the disease include mild to severe intellectual disability, developmental delay, ataxia, muscular hypotonia, and epilepsy. However, most cases are asymptomatic.",Homo sapiens,2014-06-23,2019-09-04,Disease Pathway,"{'23141293': 'http://www.ncbi.nlm.nih.gov/pubmed/23141293', '28545977': 'http://www.ncbi.nlm.nih.gov/pubmed/28545977', '10775527': 'http://www.ncbi.nlm.nih.gov/pubmed/10775527', '12853948': 'http://www.ncbi.nlm.nih.gov/pubmed/12853948', '463877': 'http://www.ncbi.nlm.nih.gov/pubmed/463877', '20207735': 'http://www.ncbi.nlm.nih.gov/pubmed/20207735', '17068770': 'http://www.ncbi.nlm.nih.gov/pubmed/17068770', '8088832': 'http://www.ncbi.nlm.nih.gov/pubmed/8088832', '12126930': 'http://www.ncbi.nlm.nih.gov/pubmed/12126930', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '9073515': 'http://www.ncbi.nlm.nih.gov/pubmed/9073515', '25125611': 'http://www.ncbi.nlm.nih.gov/pubmed/25125611', '26000322': 'http://www.ncbi.nlm.nih.gov/pubmed/26000322', '8687463': 'http://www.ncbi.nlm.nih.gov/pubmed/8687463', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '1979337': 'http://www.ncbi.nlm.nih.gov/pubmed/1979337', '1684944': 'http://www.ncbi.nlm.nih.gov/pubmed/1684944', '8954799': 'http://www.ncbi.nlm.nih.gov/pubmed/8954799', '9174363': 'http://www.ncbi.nlm.nih.gov/pubmed/9174363', '16421571': 'http://www.ncbi.nlm.nih.gov/pubmed/16421571', '11230163': 'http://www.ncbi.nlm.nih.gov/pubmed/11230163', '12948741': 'http://www.ncbi.nlm.nih.gov/pubmed/12948741'}",2022-01-17 22:00:25.560371
2-Hydroxyglutric Aciduria (D and L Form),https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000136,http://smpdb.ca/view/SMP0000136/download?type=full_vector_image,httpsmpdbcaviewSMP0000136.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'gamma-Aminobutyric acid': 'https://go.drugbank.com/drugs/DB02530', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'gamma-Glutamylcysteine': 'https://go.drugbank.com/drugs/DB03408', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",2-Hydroxyglutric Aciduria (D and L Form),"L-2-Hydroxyglutaric Aciduria (D-2-Hydroxyglutaric Aciduria ) is an autosomal recessive disease caused by a mutation in the L2HGDH gene which codes for L-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of L-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; and L-lysine in plasma and spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results.  D-2-Hydroxyglutaric Aciduria is an autosomal recessive disease caused by a mutation in the D2HGDH gene which does for D-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of D-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; oxoglutaric acid in urine; and gabba-aminobutyric acid in spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results.",Homo sapiens,2013-08-20,2019-08-16,Disease Pathway,"{'16601864': 'http://www.ncbi.nlm.nih.gov/pubmed/16601864', '22391998': 'http://www.ncbi.nlm.nih.gov/pubmed/22391998', '25763823': 'http://www.ncbi.nlm.nih.gov/pubmed/25763823', '26635200': 'http://www.ncbi.nlm.nih.gov/pubmed/26635200', '11181995': 'http://www.ncbi.nlm.nih.gov/pubmed/11181995', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10620514': 'http://www.ncbi.nlm.nih.gov/pubmed/10620514', '12444921': 'http://www.ncbi.nlm.nih.gov/pubmed/12444921', '1460020': 'http://www.ncbi.nlm.nih.gov/pubmed/1460020', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '21269460': 'http://www.ncbi.nlm.nih.gov/pubmed/21269460', '10824116': 'http://www.ncbi.nlm.nih.gov/pubmed/10824116', '1979741': 'http://www.ncbi.nlm.nih.gov/pubmed/1979741', '15890648': 'http://www.ncbi.nlm.nih.gov/pubmed/15890648', '8619816': 'http://www.ncbi.nlm.nih.gov/pubmed/8619816', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '8380692': 'http://www.ncbi.nlm.nih.gov/pubmed/8380692', '8106516': 'http://www.ncbi.nlm.nih.gov/pubmed/8106516', '11110714': 'http://www.ncbi.nlm.nih.gov/pubmed/11110714', '8089153': 'http://www.ncbi.nlm.nih.gov/pubmed/8089153'}",2022-01-17 22:00:56.455383
2-Ketoglutarate Dehydrogenase Complex Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000549,http://smpdb.ca/view/SMP0000549/download?type=full_vector_image,httpsmpdbcaviewSMP0000549.svg,Disease,"{'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Citric acid': 'https://go.drugbank.com/drugs/DB04272', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299'}",2-Ketoglutarate Dehydrogenase Complex Deficiency,"2-Ketoglutarate dehydrogenase complex deficiency, also known as alpha-ketoglutarate dehydrogenase deficiency or oxoglutaric aciduria, is an autosomal recessive disorder of the Krebs cycle caused by a defective oxoglutarate dehydrogenase complex (OGDC). OGDC catalyzes the conversion of 2-ketoglutarate into succinyl-CoA. This disorder is characterized by a large accumulation of 2-ketoglutarate in the urine. Symptoms of the disorder include opisthotonus, ataxia, developmental delay, and seizures.",Homo sapiens,2013-08-29,2019-09-04,Disease Pathway,"{'1640293': 'http://www.ncbi.nlm.nih.gov/pubmed/1640293', '23475850': 'http://www.ncbi.nlm.nih.gov/pubmed/23475850', '16746382': 'http://www.ncbi.nlm.nih.gov/pubmed/16746382', '9765291': 'http://www.ncbi.nlm.nih.gov/pubmed/9765291', '18502856': 'http://www.ncbi.nlm.nih.gov/pubmed/18502856', '9325289': 'http://www.ncbi.nlm.nih.gov/pubmed/9325289', '171557': 'http://www.ncbi.nlm.nih.gov/pubmed/171557', '22628558': 'http://www.ncbi.nlm.nih.gov/pubmed/22628558', '2227443': 'http://www.ncbi.nlm.nih.gov/pubmed/2227443', '2748588': 'http://www.ncbi.nlm.nih.gov/pubmed/2748588', '3034892': 'http://www.ncbi.nlm.nih.gov/pubmed/3034892', '2323578': 'http://www.ncbi.nlm.nih.gov/pubmed/2323578', '1702713': 'http://www.ncbi.nlm.nih.gov/pubmed/1702713', '2376596': 'http://www.ncbi.nlm.nih.gov/pubmed/2376596', '16554811': 'http://www.ncbi.nlm.nih.gov/pubmed/16554811', '3174635': 'http://www.ncbi.nlm.nih.gov/pubmed/3174635', '3191998': 'http://www.ncbi.nlm.nih.gov/pubmed/3191998', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '9809442': 'http://www.ncbi.nlm.nih.gov/pubmed/9809442', '12549038': 'http://www.ncbi.nlm.nih.gov/pubmed/12549038', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '7755589': 'http://www.ncbi.nlm.nih.gov/pubmed/7755589', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10601238': 'http://www.ncbi.nlm.nih.gov/pubmed/10601238', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '9286695': 'http://www.ncbi.nlm.nih.gov/pubmed/9286695', '15772651': 'http://www.ncbi.nlm.nih.gov/pubmed/15772651', '1542694': 'http://www.ncbi.nlm.nih.gov/pubmed/1542694', '7622061': 'http://www.ncbi.nlm.nih.gov/pubmed/7622061'}",2022-01-17 22:01:20.048777
2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000137,http://smpdb.ca/view/SMP0000137/download?type=full_vector_image,httpsmpdbcaviewSMP0000137.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency,"2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.",Homo sapiens,2013-08-01,2019-09-06,Disease Pathway,"{'12112118': 'http://www.ncbi.nlm.nih.gov/pubmed/12112118', '12872843': 'http://www.ncbi.nlm.nih.gov/pubmed/12872843', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:01:52.024008
21-Hydroxylase Deficiency (CYP21),https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000576,http://smpdb.ca/view/SMP0000576/download?type=full_vector_image,httpsmpdbcaviewSMP0000576.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",21-Hydroxylase Deficiency (CYP21),"Congenital adrenal hyperplasia (CAH) refers to any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the steps of biosynthesis of cortisol from cholesterol in the adrenal glands, also known as steroidogenesis. 21-hydroxylase deficiency, also known as CYP21 deficiency or CAH1, is an autosomal recessive disorder that accounts for the vast majority of cases of CAH. This deficiency affects cells in the adrenal cortex of the adrenal glands, and due to the deficiency in an enzyme used in many pathways. This prevents the completion of several hormone biosynthesis pathways, including those producing aldosterone and cortisol, and leads to a buildup of their precursors, including 17a-hydroxypregnenolone, which are then processed by the pathways that produce androgen hormones including testosterone.
This disorder can vary in severity, depending on the amount of functional enzyme present. The most severe form is known as the salt-wasting form of 21-hydroxylase, and is caused by a complete lack of functional enzyme. This form is called the salt-wasting form, as the lack of aldosterone produced leads to high levels of sodium excreted in the urine, causing infant blood volume to decrease. High potassium levels in blood are also often observed, but if properly diagnosed, saline solution and hydrocortisone can restore normal blood levels and sodium content. In addition, males are typically visually unaffected, but females often possess ambiguous genitalia due to the excess exposure to testosterone during development. The second most severe form is known as the simple virilising form, which does not involve the salt loss of the salt-wasting form, due to a partially functional 21-hydroxylase enzyme. However, the androgen hormones build up similarly, leading to females with some amount of virilisation, or some amount of male characteristics, including ambiguous genitalia. The third and least severe form, known as the non-classical or late onset form, has the highest function in 21-hydroxylase enzymes, and leads to the smallest buildup of androgen hormones. This means that females exhibit little to no virilisation at birth, but as they age can experience male-associated hair growth and baldness, as well as decreased fertility and menstruation irregularities. It can also lead to an early puberty in both males and females, though treatment can help prevent this if it is caught in time.",Homo sapiens,2013-08-29,2019-08-30,Disease Pathway,"{'9238271': 'http://www.ncbi.nlm.nih.gov/pubmed/9238271', '15731361': 'http://www.ncbi.nlm.nih.gov/pubmed/15731361', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:02:18.814828
27-Hydroxylase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000720,http://smpdb.ca/view/SMP0000720/download?type=full_vector_image,httpsmpdbcaviewSMP0000720.svg,Disease,"{'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Taurine': 'https://go.drugbank.com/drugs/DB01956', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholic Acid': 'https://go.drugbank.com/drugs/DB02659', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Palmitic Acid': 'https://go.drugbank.com/drugs/DB03796', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Taurocholic acid': 'https://go.drugbank.com/drugs/DB04348', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Chenodeoxycholic acid': 'https://go.drugbank.com/drugs/DB06777', 'Taurochenodeoxycholic acid': 'https://go.drugbank.com/drugs/DB08833'}",27-Hydroxylase Deficiency,"Sterol 27-hydroxylase is a mitochondrial cytochrome P-450 species (CYP27) that catalyzes the first step in the degradation of steroid side chain in cholesterol to produce bile acids in the liver. When there are low concentrations of 27-Hydroxylase, patients will exhibit cerebrotendinous xanthomatosis, an autosomal recessive disorder characterized by the accumulation of cholestanol and cholesterol due to the inability to break down the lipids. The formation of xanthomas (deposits of lipids) in the nervous system and tendons will cause symptoms such as dementia, ataxia, and cataracts. Other symptoms may include damaged liver cells and body tissues.",Homo sapiens,2014-06-23,2019-08-16,Disease Pathway,"{'10856919': 'http://www.ncbi.nlm.nih.gov/pubmed/10856919', '29325602': 'http://www.ncbi.nlm.nih.gov/pubmed/29325602', '8078928': 'http://www.ncbi.nlm.nih.gov/pubmed/8078928', '23897684': 'http://www.ncbi.nlm.nih.gov/pubmed/23897684', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '21411718': 'http://www.ncbi.nlm.nih.gov/pubmed/21411718', '1708392': 'http://www.ncbi.nlm.nih.gov/pubmed/1708392', '7690968': 'http://www.ncbi.nlm.nih.gov/pubmed/7690968', '10479480': 'http://www.ncbi.nlm.nih.gov/pubmed/10479480', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15057824': 'http://www.ncbi.nlm.nih.gov/pubmed/15057824', '11060344': 'http://www.ncbi.nlm.nih.gov/pubmed/11060344', '10655068': 'http://www.ncbi.nlm.nih.gov/pubmed/10655068', '15880524': 'http://www.ncbi.nlm.nih.gov/pubmed/15880524', '27647924': 'http://www.ncbi.nlm.nih.gov/pubmed/27647924', '8943006': 'http://www.ncbi.nlm.nih.gov/pubmed/8943006', '7487879': 'http://www.ncbi.nlm.nih.gov/pubmed/7487879', '9089413': 'http://www.ncbi.nlm.nih.gov/pubmed/9089413', '9880674': 'http://www.ncbi.nlm.nih.gov/pubmed/9880674'}",2022-01-17 22:02:51.978490
3-beta-Hydroxysteroid Dehydrogenase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000718,http://smpdb.ca/view/SMP0000718/download?type=full_vector_image,httpsmpdbcaviewSMP0000718.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",3-beta-Hydroxysteroid Dehydrogenase Deficiency,"3-beta-hydroxysteroid dehydrogenase (HSD) deficiency is an extremely rare inborn error of metabolism (IEM) and autosomal recessive disorder of the steroidogenesis pathway. It is caused by an defect in the HSD3B2 gene which encodes for the 3 beta-hydroxysteroid dehydrogenase enzyme, which is responsible for forming cortisol from 11b,17a,21-trihydroxypregnenolone. When the enzyme is not correctly produced, cortisol levels in the cell are lowered, and as cortisol is used in the production of other steroids, it may affect their levels as well. 3-beta-HSD deficiency is characterized by low levels of cortisol produced in the adrenal glands. Symptoms include abnormal genitalia for both males and females, as well as infertility. There is also a more severe salt-wasting form of this deficiency, characterized by dehydration. Treatment for 3-beta-HSD deficiency includes steroid replacement, as well as sex hormone replacement during puberty to allow proper development. Surgery can also be used to correct any genital abnormalities that may occur. It is estimated that 3-beta-HSD deficiency affects less than 1 in 1,000,000 individuals, with around 60 cases reported.",Homo sapiens,2014-06-23,2019-09-10,Disease Pathway,"{'7626445': 'http://www.ncbi.nlm.nih.gov/pubmed/7626445', '12050224': 'http://www.ncbi.nlm.nih.gov/pubmed/12050224', '23026940': 'http://www.ncbi.nlm.nih.gov/pubmed/23026940', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:03:17.094066
3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000138,http://smpdb.ca/view/SMP0000138/download?type=full_vector_image,httpsmpdbcaviewSMP0000138.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency,"3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (3-Hydroxy-3-methylglutaric acidemia; Leucine metabolism, defect in, HMG-CoA lyase deficiency) is an autosomal recessive disease caused by a mutation in the HMGCL gene which codes for hydroxymethylglutaryl-CoA lyase. A deficiency in this enzyme results in accumulation of 3-hydroxymethylglutaric acid, 3-hydroxyisovaleric acid, 3-methylcrotonylglycine and 3-methylglutaconic acid (cis and trans form), and methylglutaric acid in urine; and ammonia in blood. Symptoms include cardiomyopathy, dehydration, hypotonia, lactic acidosis, and pancreatitis. Treatment includes a low-fat, low-protein, high-carbohydrate diet.",Homo sapiens,2013-08-01,2019-09-06,Disease Pathway,"{'2116546': 'http://www.ncbi.nlm.nih.gov/pubmed/2116546', '1000872': 'http://www.ncbi.nlm.nih.gov/pubmed/1000872', '11129331': 'http://www.ncbi.nlm.nih.gov/pubmed/11129331', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '9817922': 'http://www.ncbi.nlm.nih.gov/pubmed/9817922', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:03:42.786532
3-Hydroxyisobutyric Acid Dehydrogenase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000521,http://smpdb.ca/view/SMP0000521/download?type=full_vector_image,httpsmpdbcaviewSMP0000521.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Hydroxyisobutyric Acid Dehydrogenase Deficiency,"3-Hydroxyisobutyric acid dehydrogenase deficiency (3-hydroxyisobutyric aciduria) is an extremely rare inborn error of metabolism (IEM), potentially caused by numerous mechanisms. It is currently thought to be autosomal recessively inherited. At least two cases of 3-hydroxyisobutyric aciduria were determined to be caused by a mutation in the ALDH6A1 gene, which encodes acylating methylmalonate-semialdehyde dehydrogenase. This enzyme converts 2-methyl-3-oxopropanoate, CoA and water into propanoyl-CoA, using NAD+ as an oxidizing agent, and producing a hydrogen ion and hydrogencarbonate as byproducts. Other forms of 3-hydroxyisobutyric aciduria may be caused by a mutation in the gene encoding 3-hydroxyisobutyrate dehydrogenase, which forms (S)-methylmalonic acid semialdehyde from (S)-3-hydroxyisobutyric acid. This mutation leads to an accumulation of (S)-3-hydroxyisobutyric acid, as no other processes in the pathway use it. 3-hydroxyisobutyric aciduria is characterized by elevated levels of 3-hydroxyisobutyric acid excreted in the urine. Symptoms of the disorder include dysmorphic features, developmental delays and intellectual disabilities. Treatments are not currently well researched due to the rarity of the condition, but protein-restricted diets may be helpful. It is estimated that 3-hydroxyisobutyric aciduria affects less than 1 in 1,000,000 people, with only 12 cases having been reported by 2006.",Homo sapiens,2013-08-29,2019-09-06,Disease Pathway,"{'16466957': 'http://www.ncbi.nlm.nih.gov/pubmed/16466957', '9590056': 'http://www.ncbi.nlm.nih.gov/pubmed/9590056', '21863277': 'http://www.ncbi.nlm.nih.gov/pubmed/21863277', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:04:08.827925
3-Hydroxyisobutyric Aciduria,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000522,http://smpdb.ca/view/SMP0000522/download?type=full_vector_image,httpsmpdbcaviewSMP0000522.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Hydroxyisobutyric Aciduria,"3-Hydroxyisobutyric aciduria, also called HIBA, is an extremely rare inherited inborn error of metabolism (IEM) of valine metabolism. Only 12-13 patients have been identified with this condition. It is an autosomal recessive disorder that may be caused, in some cases, by a defective aldehyde dehydrogenase 6 family member A1 (ALDH6A1) gene which codes for methylmalonate semialdehyde dehydrogenase (MMSDH). MMSDH is a mitochondrial methylmalonate semialdehyde dehydrogenase that plays a role in the valine and pyrimidine catabolism. This protein catalyzes the irreversible oxidative decarboxylation of malonate and methylmalonate semialdehydes to acetyl- and propionyl-CoA. Another possible cause of the disorder is a mutation in 3-hydroxyisobutyrate dehydrogenase, a mitochondrial enzyme which catalyzes the conversion of 3-hydroxyisobutyrate into methylmalonic semialdehyde, or in the conversion of the semialdehyde to propionyl-CoA. Individuals with this disorder have very high levels of 3-hydroxyisobutyric acid secreted in their urine. Other indications of organic acidemia are also present. Signs and symptoms of 3-hydroxyisobutyric aciduria include developmental delay, dysmorphic facial features, and brain abnormalities. The excretion of 3-hydroxyisobutyric acid in the urine can range from 170 to 390 mmol/mol of creatinine. Concentrations of free carnitine are also low, and esterified carnitine can be elevated in patients. Protein-restricted diets and carnitine supplementation have been tried with varying degrees of success.",Homo sapiens,2013-08-29,2019-09-06,Disease Pathway,"{'1956714': 'http://www.ncbi.nlm.nih.gov/pubmed/1956714', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:04:36.405957
3-Methylcrotonyl-CoA Carboxylase Deficiency Type I,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000237,http://smpdb.ca/view/SMP0000237/download?type=full_vector_image,httpsmpdbcaviewSMP0000237.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Methylcrotonyl-CoA Carboxylase Deficiency Type I,"3-Methylcrotonyl-Coenzyme A Carboxylase Deficiency Type I also called 3-MCC Deficiency is a rare inborn error of metabolism (IEM) and is the result of defective pair of genes. More specifically defects in genes MCCC1 and MCCC2 cause 3-MCC Deficiency. 3-MCC has a very important role in protein metabolism in the body. In particular, the said enzyme is pivotal in one of the many steps which constitute the breakdown of leucine. Mutations in the aforementioned genes leads to a reduction in the activity of 3-MCC. As would naturally be expected, this causes the body to be unable to uptake and breakdown leucine properly. Consequently, this leads to the build up of toxic byproducts which are not processed as the breakdown of leucine is left incomplete. If these toxic byproducts manifest themselves in sufficiently high levels they can be very harmful, damaging the brain and nervous system. Symptoms include recurring episodes of vomiting and diarrhea, lethargy, hypotonia, seizures, and coma.",Homo sapiens,2013-08-01,2019-09-08,Disease Pathway,"{'15868465': 'http://www.ncbi.nlm.nih.gov/pubmed/15868465', '15359379': 'http://www.ncbi.nlm.nih.gov/pubmed/15359379', '11181649': 'http://www.ncbi.nlm.nih.gov/pubmed/11181649', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:05:05.303498
3-Methylglutaconic Aciduria Type I,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000139,http://smpdb.ca/view/SMP0000139/download?type=full_vector_image,httpsmpdbcaviewSMP0000139.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Methylglutaconic Aciduria Type I,"3-Methylglutaconic aciduria type 1 (3-Methylglutaconicaciduria; Aciduria, 3-methylglutaconic type I) is an autosomal recessive disease caused by a mutation in the AUH gene which codes for methylglutaconyl-CoA hydratase. A deficiency in this enzyme results in accumulation of 3-hydroxyisovaleric acid, 3-methylglutaconic acid, and methylglutaric acid in urine. Symptoms include hypoglycemia, low birth weight, coma, seizures, and mental retardation. Treatment includes a low protein diet.",Homo sapiens,2013-08-01,2019-09-06,Disease Pathway,"{'6181239': 'http://www.ncbi.nlm.nih.gov/pubmed/6181239', '1710267': 'http://www.ncbi.nlm.nih.gov/pubmed/1710267', '12434311': 'http://www.ncbi.nlm.nih.gov/pubmed/12434311', '10070612': 'http://www.ncbi.nlm.nih.gov/pubmed/10070612', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:05:38.185444
3-Methylglutaconic Aciduria Type III,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000140,http://smpdb.ca/view/SMP0000140/download?type=full_vector_image,httpsmpdbcaviewSMP0000140.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Methylglutaconic Aciduria Type III,"3-Methylglutaconic aciduria type 3 (Costeff syndrome; Optic atrophy plus syndrome) is an autosomal recessive disease caused by a deficiency in the OPA3 code which does for optic atrophy 3 protein. A deficiency of this enzyme results in accumulation of 3-methylglutaconic acid and methylglutaric acid. Symptoms include ataxia, dysarthria, optic atrophy, and neurological deterioration.",Homo sapiens,2013-08-01,2019-09-06,Disease Pathway,"{'2494568': 'http://www.ncbi.nlm.nih.gov/pubmed/2494568', '11668429': 'http://www.ncbi.nlm.nih.gov/pubmed/11668429', '1382150': 'http://www.ncbi.nlm.nih.gov/pubmed/1382150', '12126933': 'http://www.ncbi.nlm.nih.gov/pubmed/12126933', '21613372': 'http://www.ncbi.nlm.nih.gov/pubmed/21613372', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:06:08.364191
3-Methylglutaconic Aciduria Type IV,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000141,http://smpdb.ca/view/SMP0000141/download?type=full_vector_image,httpsmpdbcaviewSMP0000141.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",3-Methylglutaconic Aciduria Type IV,"3-Methylglutaconic Aciduria Type IV, also called MGA, Type IV and MGA4, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder and caused by a defective methylglutaconyl-CoA hydratase. Methylglutaconyl-CoA hydratase catalyzes the conversion of 3-Methylglutaconyl-CoA into 3-Hydroxy-3-methylglutaryl-CoA which is the substrate of hydroxymethylglutaryl-CoA lyase. This disorder is characterized by increased urinary excretion of 3-methylglutaconic acid. Symptoms of the disorder include poor growth and  neurological degression. Currently, there is no effective treatment for 3-MGA type IV.",Homo sapiens,2013-08-20,2019-09-13,Disease Pathway,"{'1382150': 'http://www.ncbi.nlm.nih.gov/pubmed/1382150', '19015156': 'http://www.ncbi.nlm.nih.gov/pubmed/19015156', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:06:38.771911
3-Methylthiofentanyl Action Pathway,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000679,http://smpdb.ca/view/SMP0000679/download?type=full_vector_image,httpsmpdbcaviewSMP0000679.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', '3-Methylthiofentanyl': 'https://go.drugbank.com/drugs/DB01439'}",3-Methylthiofentanyl Action Pathway,"Methadyl Acetate  (also known as Acetylmethadol) is analgesic that can bind to mu-type opioid receptor to activate associated G-protein in the sensory neurons of central nervous system (CNS), which will reduce the level of intracellular cAMP by inhibiting adenylate cyclase. The binding of methadyl acetate  will eventually lead to reduced pain because of decreased nerve conduction and release of neurotransmitter. Hyperpolarization of neuron is caused by inactivation of calcium channels and activation of potassium channels via facilitated by G-protein.",Homo sapiens,2014-04-21,2019-08-16,Drug Action Pathway,"{'2841104': 'http://www.ncbi.nlm.nih.gov/pubmed/2841104', '7905839': 'http://www.ncbi.nlm.nih.gov/pubmed/7905839', '7957926': 'http://www.ncbi.nlm.nih.gov/pubmed/7957926', '7891175': 'http://www.ncbi.nlm.nih.gov/pubmed/7891175', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:06:57.430101
3-Phosphoglycerate Dehydrogenase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000721,http://smpdb.ca/view/SMP0000721/download?type=full_vector_image,httpsmpdbcaviewSMP0000721.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Serine': 'https://go.drugbank.com/drugs/DB00133', 'Methionine': 'https://go.drugbank.com/drugs/DB00134', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Creatine': 'https://go.drugbank.com/drugs/DB00148', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Aminolevulinic acid': 'https://go.drugbank.com/drugs/DB00855', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'N,N-dimethylglycine': 'https://go.drugbank.com/drugs/DB02083', 'Glycocyamine': 'https://go.drugbank.com/drugs/DB02751', '3-Hydroxypyruvic Acid': 'https://go.drugbank.com/drugs/DB02951', 'Orotidylic acid': 'https://go.drugbank.com/drugs/DB02957', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Pyruvaldehyde': 'https://go.drugbank.com/drugs/DB03587', 'Formaldehyde': 'https://go.drugbank.com/drugs/DB03843', '2-Amino-3-Ketobutyric Acid': 'https://go.drugbank.com/drugs/DB03915', 'D-Serine': 'https://go.drugbank.com/drugs/DB03929', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Glyoxylic acid': 'https://go.drugbank.com/drugs/DB04343', 'Dexfosfoserine': 'https://go.drugbank.com/drugs/DB04522', '2-Oxobutanoic Acid': 'https://go.drugbank.com/drugs/DB04553'}",3-Phosphoglycerate Dehydrogenase Deficiency,"3-Phosphoglycerate dehydrogenase deficiency is a disorder of L-serine biosynthesis that is characterized by congenital microcephaly, psychomotor retardation, and seizures.The disorder is caused by homozygous or compound heterozygous or homozygous mutation in the gene encoding phosphoglycerate dehydrogenase on chromosome 1p12. Defects in the gene lead to a decrease of Glycine and Serine.",Homo sapiens,2014-06-23,2019-08-30,Disease Pathway,"{'23564319': 'http://www.ncbi.nlm.nih.gov/pubmed/23564319', '14645240': 'http://www.ncbi.nlm.nih.gov/pubmed/14645240', '3418353': 'http://www.ncbi.nlm.nih.gov/pubmed/3418353', '3387449': 'http://www.ncbi.nlm.nih.gov/pubmed/3387449', '1886775': 'http://www.ncbi.nlm.nih.gov/pubmed/1886775', '8561277': 'http://www.ncbi.nlm.nih.gov/pubmed/8561277', '3582651': 'http://www.ncbi.nlm.nih.gov/pubmed/3582651', '3562250': 'http://www.ncbi.nlm.nih.gov/pubmed/3562250', '10712613': 'http://www.ncbi.nlm.nih.gov/pubmed/10712613', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10591208': 'http://www.ncbi.nlm.nih.gov/pubmed/10591208', '10767172': 'http://www.ncbi.nlm.nih.gov/pubmed/10767172', '11231903': 'http://www.ncbi.nlm.nih.gov/pubmed/11231903', '10444331': 'http://www.ncbi.nlm.nih.gov/pubmed/10444331', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '1996985': 'http://www.ncbi.nlm.nih.gov/pubmed/1996985', '1993704': 'http://www.ncbi.nlm.nih.gov/pubmed/1993704', '7916605': 'http://www.ncbi.nlm.nih.gov/pubmed/7916605', '8188235': 'http://www.ncbi.nlm.nih.gov/pubmed/8188235', '29180469': 'http://www.ncbi.nlm.nih.gov/pubmed/29180469', '29452640': 'http://www.ncbi.nlm.nih.gov/pubmed/29452640', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312'}",2022-01-17 22:07:26.506726
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000243,http://smpdb.ca/view/SMP0000243/download?type=full_vector_image,httpsmpdbcaviewSMP0000243.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'gamma-Aminobutyric acid': 'https://go.drugbank.com/drugs/DB02530', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'gamma-Glutamylcysteine': 'https://go.drugbank.com/drugs/DB03408', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency,"4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency (SSADH; Gamma-hydroxybutyric acidemia) inhibits the formation of succinate from GABA. This deficiency results in urinary excretion of 4-hydroxybutyric acid. In vivo proton MR also indicates elevated GABA levels as compared with an age-matched control. Symptoms include ataxia, chorea or athetosis, motor retardation, seizures, macrocephaly and delayed or abnormal speech development.",Homo sapiens,2013-08-01,2019-08-16,Disease Pathway,"{'14635103': 'http://www.ncbi.nlm.nih.gov/pubmed/14635103', '16542398': 'http://www.ncbi.nlm.nih.gov/pubmed/16542398', '9093300': 'http://www.ncbi.nlm.nih.gov/pubmed/9093300', '9553943': 'http://www.ncbi.nlm.nih.gov/pubmed/9553943', '6627675': 'http://www.ncbi.nlm.nih.gov/pubmed/6627675', '11544478': 'http://www.ncbi.nlm.nih.gov/pubmed/11544478', '26635200': 'http://www.ncbi.nlm.nih.gov/pubmed/26635200', '11181995': 'http://www.ncbi.nlm.nih.gov/pubmed/11181995', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10620514': 'http://www.ncbi.nlm.nih.gov/pubmed/10620514', '12444921': 'http://www.ncbi.nlm.nih.gov/pubmed/12444921', '1460020': 'http://www.ncbi.nlm.nih.gov/pubmed/1460020', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '21269460': 'http://www.ncbi.nlm.nih.gov/pubmed/21269460', '10824116': 'http://www.ncbi.nlm.nih.gov/pubmed/10824116', '1979741': 'http://www.ncbi.nlm.nih.gov/pubmed/1979741', '15890648': 'http://www.ncbi.nlm.nih.gov/pubmed/15890648', '8619816': 'http://www.ncbi.nlm.nih.gov/pubmed/8619816', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '8380692': 'http://www.ncbi.nlm.nih.gov/pubmed/8380692', '8106516': 'http://www.ncbi.nlm.nih.gov/pubmed/8106516', '11110714': 'http://www.ncbi.nlm.nih.gov/pubmed/11110714', '8089153': 'http://www.ncbi.nlm.nih.gov/pubmed/8089153'}",2022-01-17 22:07:50.371184
5-Oxoprolinase Deficiency,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000500,http://smpdb.ca/view/SMP0000500/download?type=full_vector_image,httpsmpdbcaviewSMP0000500.svg,Disease,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Pidolic acid': 'https://go.drugbank.com/drugs/DB03088', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'gamma-Glutamylcysteine': 'https://go.drugbank.com/drugs/DB03408', 'S-Methyl glutathione': 'https://go.drugbank.com/drugs/DB04701'}",5-Oxoprolinase Deficiency,"5-Oxoprolinase deficiency, also called OPLAHD, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of glutathione metabolism caused by a defective 5-oxoprolinase. 5-Oxoprolinase catalyzes the conversion of 5-oxoproline into glutamate which is an important neurotransmitter. This disorder is characterized by a large accumulation of 5-oxoproline in the urine. Symptoms of the disorder include enterocolitis, mental retardation, kidney stone formation, and hypoglycemia. 5-Oxoprolinase deficiency has been reported in approximately 8 people.",Homo sapiens,2013-08-29,2019-09-05,Disease Pathway,"{'21651516': 'http://www.ncbi.nlm.nih.gov/pubmed/21651516', '25129617': 'http://www.ncbi.nlm.nih.gov/pubmed/25129617', '4514988': 'http://www.ncbi.nlm.nih.gov/pubmed/4514988', '22995213': 'http://www.ncbi.nlm.nih.gov/pubmed/22995213', '9875551': 'http://www.ncbi.nlm.nih.gov/pubmed/9875551', '3890714': 'http://www.ncbi.nlm.nih.gov/pubmed/3890714', '18796312': 'http://www.ncbi.nlm.nih.gov/pubmed/18796312', '3053703': 'http://www.ncbi.nlm.nih.gov/pubmed/3053703', '23206830': 'http://www.ncbi.nlm.nih.gov/pubmed/23206830', '7646467': 'http://www.ncbi.nlm.nih.gov/pubmed/7646467', '19672693': 'http://www.ncbi.nlm.nih.gov/pubmed/19672693', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '2185014': 'http://www.ncbi.nlm.nih.gov/pubmed/2185014', '10708558': 'http://www.ncbi.nlm.nih.gov/pubmed/10708558', '20628807': 'http://www.ncbi.nlm.nih.gov/pubmed/20628807', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '18357469': 'http://www.ncbi.nlm.nih.gov/pubmed/18357469', '10676659': 'http://www.ncbi.nlm.nih.gov/pubmed/10676659', '2901990': 'http://www.ncbi.nlm.nih.gov/pubmed/2901990', '2564851': 'http://www.ncbi.nlm.nih.gov/pubmed/2564851', '8521391': 'http://www.ncbi.nlm.nih.gov/pubmed/8521391', '8576161': 'http://www.ncbi.nlm.nih.gov/pubmed/8576161', '8567622': 'http://www.ncbi.nlm.nih.gov/pubmed/8567622'}",2022-01-17 22:08:09.945538
5-Oxoprolinuria,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000143,http://smpdb.ca/view/SMP0000143/download?type=full_vector_image,httpsmpdbcaviewSMP0000143.svg,Disease,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Pidolic acid': 'https://go.drugbank.com/drugs/DB03088', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'gamma-Glutamylcysteine': 'https://go.drugbank.com/drugs/DB03408', 'S-Methyl glutathione': 'https://go.drugbank.com/drugs/DB04701'}",5-Oxoprolinuria,"5-Oxoprolinuria (5-Oxoprolinase deficiency) is a result of a defect in the gamma-glutamyl cycle due to either 5-oxoprolinase or glutathione synthetase deficiency. In the case of glutathione synthetase deficiency, the glycine is not incorporated into gamma-glutamylcysteine. In the case of 5-oxoprolinase, however, pyroglutamic acid accumulates. Symptoms include anemia, mental retardation, metabolic acidosis, respiratory distress and urolithiasis.",Homo sapiens,2013-08-01,2019-08-30,Disease Pathway,"{'1770788': 'http://www.ncbi.nlm.nih.gov/pubmed/1770788', '15717202': 'http://www.ncbi.nlm.nih.gov/pubmed/15717202', '874680': 'http://www.ncbi.nlm.nih.gov/pubmed/874680', '15990954': 'http://www.ncbi.nlm.nih.gov/pubmed/15990954', '4514988': 'http://www.ncbi.nlm.nih.gov/pubmed/4514988', '22995213': 'http://www.ncbi.nlm.nih.gov/pubmed/22995213', '9875551': 'http://www.ncbi.nlm.nih.gov/pubmed/9875551', '3890714': 'http://www.ncbi.nlm.nih.gov/pubmed/3890714', '18796312': 'http://www.ncbi.nlm.nih.gov/pubmed/18796312', '3053703': 'http://www.ncbi.nlm.nih.gov/pubmed/3053703', '23206830': 'http://www.ncbi.nlm.nih.gov/pubmed/23206830', '7646467': 'http://www.ncbi.nlm.nih.gov/pubmed/7646467', '19672693': 'http://www.ncbi.nlm.nih.gov/pubmed/19672693', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '2185014': 'http://www.ncbi.nlm.nih.gov/pubmed/2185014', '10708558': 'http://www.ncbi.nlm.nih.gov/pubmed/10708558', '20628807': 'http://www.ncbi.nlm.nih.gov/pubmed/20628807', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '18357469': 'http://www.ncbi.nlm.nih.gov/pubmed/18357469', '10676659': 'http://www.ncbi.nlm.nih.gov/pubmed/10676659', '2901990': 'http://www.ncbi.nlm.nih.gov/pubmed/2901990', '2564851': 'http://www.ncbi.nlm.nih.gov/pubmed/2564851', '8521391': 'http://www.ncbi.nlm.nih.gov/pubmed/8521391', '8576161': 'http://www.ncbi.nlm.nih.gov/pubmed/8576161', '8567622': 'http://www.ncbi.nlm.nih.gov/pubmed/8567622'}",2022-01-17 22:08:28.648829
Abacavir Action Pathway,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000737,http://smpdb.ca/view/SMP0000737/download?type=full_vector_image,httpsmpdbcaviewSMP0000737.svg,Drug action,"{'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Abacavir': 'https://go.drugbank.com/drugs/DB01048', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Abacavir Action Pathway,"Abacavir (also known as Ziagen or Epzicom) is an antiviral agent that is used for treating HIV/AID. Cellular enzyme converts abacavir to its activate metabolite, carbovir triphosphate, for inhibiting HIV-1 reverse transcriptase (RT) by competing with dGTP, which is the natural substrate of RT. Without HIV-1 reverse transcriptase, complementary DNA (cDNA) could not be generated; therefore, viral DNA couldn't be completed.",Homo sapiens,2014-06-23,2019-08-16,Drug Action Pathway,{'23703656': 'http://www.ncbi.nlm.nih.gov/pubmed/23703656'},2022-01-17 22:08:42.867096
Abciximab Action Pathway,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000265,http://smpdb.ca/view/SMP0000265/download?type=full_vector_image,httpsmpdbcaviewSMP0000265.svg,Drug action,{'Abciximab': 'https://go.drugbank.com/drugs/DB00054'},Abciximab Action Pathway,"Abciximab (also known as c7E3 Fab) is integrin (integrin alpha-IIb and integrin beta-3) receptor antagonist. Binding of abciximab to integrin receptor will block any large molecule to attach on the receptor, which will lead to block any associated signal transduction pathways.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'17054247': 'http://www.ncbi.nlm.nih.gov/pubmed/17054247', '18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '2439501': 'http://www.ncbi.nlm.nih.gov/pubmed/2439501', '2345548': 'http://www.ncbi.nlm.nih.gov/pubmed/2345548', '2322558': 'http://www.ncbi.nlm.nih.gov/pubmed/2322558'}",2022-01-17 22:08:52.378023
Acebutolol Action Pathway,https://go.drugbank.com/pathways?page=1,http://smpdb.ca/view/SMP0000296,http://smpdb.ca/view/SMP0000296/download?type=full_vector_image,httpsmpdbcaviewSMP0000296.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acebutolol': 'https://go.drugbank.com/drugs/DB01193', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Acebutolol Action Pathway,"Acebutolol (also known as Sectral or Prent) is a selective β1 adrenergic receptor antagonist (beta blocker), which can be used for treatment of high blood pressure (hypertension) and irregular heartbeats (arrhythmias). Acebutolol also has the ability to mild intrinsic sympathomimetic activity (ISA) with effective range of dosage. Adrenaline (also known as epinephrine) can activate β1 adrenergic receptor so that the heart rate and output will be increased. Renin is a hormone that generated from kidney, which could lead to constriction of blood vessels. Beta blockers could efficiently prohibit renin release.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:09:12.540152
Acenocoumarol Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000269,http://smpdb.ca/view/SMP0000269/download?type=full_vector_image,httpsmpdbcaviewSMP0000269.svg,Drug action,"{'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Acenocoumarol': 'https://go.drugbank.com/drugs/DB01418'}",Acenocoumarol Action Pathway,"Acenocoumarol (also known as Nitrowarfarin or Sinthrome) is an anticoagulant that inhibit the liver enzyme vitamin K reductase, which cause Vitamin K1 2,3-epoxide could not be catalyzed by vitamin K reductase to form vitamin KH2, the reduced form of vitamin K. Vitamin K-dependent coagulation factors (II, VII, IX, and X) requires its cofactor, vitamin K to facilitate the activation and gamma-carboxylation. Inhibition of vitamin K reductase results in reduced concentration of vitamin KH2, which will ultimately lead to decreased coagulability of the blood and reduced cleavage of fibrinogen into fibrin.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '14765194': 'http://www.ncbi.nlm.nih.gov/pubmed/14765194', '20946155': 'http://www.ncbi.nlm.nih.gov/pubmed/20946155', '14765195': 'http://www.ncbi.nlm.nih.gov/pubmed/14765195', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:09:29.403633
Acetaminophen Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000710,http://smpdb.ca/view/SMP0000710/download?type=full_vector_image,httpsmpdbcaviewSMP0000710.svg,Drug action,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Acetaminophen': 'https://go.drugbank.com/drugs/DB00316', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Acetaminophen  Action Pathway,"Acetaminophen (also named paracetamol or APAP) is not a Nonsteroidal anti-inflammatory drugs (NSAIDs). However, it still can be used to treat pain and fever. Acetaminophen can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of acetaminophen.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'10422949': 'http://www.ncbi.nlm.nih.gov/pubmed/10422949', '8893104': 'http://www.ncbi.nlm.nih.gov/pubmed/8893104', '2512924': 'http://www.ncbi.nlm.nih.gov/pubmed/2512924', '1907252': 'http://www.ncbi.nlm.nih.gov/pubmed/1907252', '1734857': 'http://www.ncbi.nlm.nih.gov/pubmed/1734857', '8181472': 'http://www.ncbi.nlm.nih.gov/pubmed/8181472', '8473346': 'http://www.ncbi.nlm.nih.gov/pubmed/8473346', '1380156': 'http://www.ncbi.nlm.nih.gov/pubmed/1380156', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973'}",2022-01-17 22:09:57.897429
Acetaminophen Metabolism Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000640,http://smpdb.ca/view/SMP0000640/download?type=full_vector_image,httpsmpdbcaviewSMP0000640.svg,Drug metabolism,"{'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetaminophen': 'https://go.drugbank.com/drugs/DB00316', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435'}",Acetaminophen Metabolism Pathway,"Acetaminophen (APAP) is metabolized primarily in the liver. Glucuronidation is the main route, accounting for 45-55% of APAP metabolism, and is mediatied by UGT1A1, UGT1A6, UGT1A9, UGT2B15 in the liver and UGT1A10 in the gut. APAP can also by metabolized via sulfation, accounting for 30-35% of the metabolism. In the liver, this step is catalyzed by the sulfotransferases SULT1A1, SULT1A3, SULT1A4, SULT1E1 and SULT2A1. Moreover, APAP can also be activated to form the toxic N-acetyl-p-benzoquinone imine (NAPQI) under the mediation of CYP3A4, CYP2E1, CYP2D6 CYP1A2, CYP2E1 and CYP2A6.",Homo sapiens,2013-09-11,2019-08-16,Drug Metabolism Pathway,"{'11215692': 'http://www.ncbi.nlm.nih.gov/pubmed/11215692', '18232020': 'http://www.ncbi.nlm.nih.gov/pubmed/18232020', '8494539': 'http://www.ncbi.nlm.nih.gov/pubmed/8494539', '11714888': 'http://www.ncbi.nlm.nih.gov/pubmed/11714888', '21666065': 'http://www.ncbi.nlm.nih.gov/pubmed/21666065', '15781124': 'http://www.ncbi.nlm.nih.gov/pubmed/15781124', '16517757': 'http://www.ncbi.nlm.nih.gov/pubmed/16517757', '12439736': 'http://www.ncbi.nlm.nih.gov/pubmed/12439736', '6573904': 'http://www.ncbi.nlm.nih.gov/pubmed/6573904', '19219744': 'http://www.ncbi.nlm.nih.gov/pubmed/19219744', '11866476': 'http://www.ncbi.nlm.nih.gov/pubmed/11866476', '9058590': 'http://www.ncbi.nlm.nih.gov/pubmed/9058590', '9918138': 'http://www.ncbi.nlm.nih.gov/pubmed/9918138', '3782137': 'http://www.ncbi.nlm.nih.gov/pubmed/3782137', '2575218': 'http://www.ncbi.nlm.nih.gov/pubmed/2575218', '3755823': 'http://www.ncbi.nlm.nih.gov/pubmed/3755823', '3462722': 'http://www.ncbi.nlm.nih.gov/pubmed/3462722', '2574001': 'http://www.ncbi.nlm.nih.gov/pubmed/2574001', '15768052': 'http://www.ncbi.nlm.nih.gov/pubmed/15768052', '21289075': 'http://www.ncbi.nlm.nih.gov/pubmed/21289075', '11181494': 'http://www.ncbi.nlm.nih.gov/pubmed/11181494', '3460094': 'http://www.ncbi.nlm.nih.gov/pubmed/3460094', '3267210': 'http://www.ncbi.nlm.nih.gov/pubmed/3267210', '9409631': 'http://www.ncbi.nlm.nih.gov/pubmed/9409631', '2726448': 'http://www.ncbi.nlm.nih.gov/pubmed/2726448', '2748347': 'http://www.ncbi.nlm.nih.gov/pubmed/2748347', '1910331': 'http://www.ncbi.nlm.nih.gov/pubmed/1910331', '11434514': 'http://www.ncbi.nlm.nih.gov/pubmed/11434514', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '7835232': 'http://www.ncbi.nlm.nih.gov/pubmed/7835232', '9295060': 'http://www.ncbi.nlm.nih.gov/pubmed/9295060', '8399210': 'http://www.ncbi.nlm.nih.gov/pubmed/8399210', '29706351': 'http://www.ncbi.nlm.nih.gov/pubmed/29706351', '11147971': 'http://www.ncbi.nlm.nih.gov/pubmed/11147971', '10827079': 'http://www.ncbi.nlm.nih.gov/pubmed/10827079', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '16541075': 'http://www.ncbi.nlm.nih.gov/pubmed/16541075', '21269460': 'http://www.ncbi.nlm.nih.gov/pubmed/21269460'}",2022-01-17 22:10:17.883001
Acetylsalicylic Acid Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000083,http://smpdb.ca/view/SMP0000083/download?type=full_vector_image,httpsmpdbcaviewSMP0000083.svg,Drug action,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Acetylsalicylic acid': 'https://go.drugbank.com/drugs/DB00945', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Acetylsalicylic Acid Action Pathway,"Acetylsalicylic acid, also known as ASA or aspirin, belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). In addition to its anti-inflammatory properties, aspirin also acts as an analgesic, antipyretic and antithrombotic agent. Like most other NSAIDs, aspirin exerts its therapeutic effects by inhibiting prostaglandin G/H synthase 1 and 2, better known as cyclooxygenase-1 and -2 or simply COX-1 and -2. COX-1 and -2 catalyze the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of other prostaglandins, such as prostaglandin E2, involved in pain, fever and inflammation. The antipyretic properties of aspirin arise from inhibition of prostaglandin E2 synthesis in the preoptic region of the hypothalamus. Interference with adhesion and migration of granulocytes, polymorphonuclear leukocytes and macrophages at sites of inflammation account for its anti-inflammatory effects. The analgesic effects of aspirin likely occur due to peripheral action at the site of injury and possibly within the CNS.  Aspirin is unique from other NSAIDs in that it is an irreversible COX inhibitor. Aspirin irreversibly acetylates a serine side chain of COX rendering the enzyme inactive. Enzyme activity can only be regained by production of more cyclooxygenase. This unique property of aspirin and its higher selectivity for COX-1 over COX-2 makes it an effective antiplatelet agent. Platelets contain COX-1, a key enzyme in the production thromboxane A2 (TXA2), which is a potent inducer of platelet aggregation. Since platelets lack the ability to make more enzyme, TXA2 production is inhibited for the lifetime of the platelet (approximately 8 – 12 days). Aspirin is commonly used at low doses to prevent cardiovascular events such as strokes and heart attacks. At higher doses, aspirin may be used as an analgesic, anti-inflammatory and antipyretic. Aspirin may cause gastric irritation and bleeding by inhibiting the synthesis of prostaglandins that enhance and maintain the protective gastric mucous layer.",Homo sapiens,2013-08-04,2019-08-16,Drug Action Pathway,"{'12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973', '2512924': 'http://www.ncbi.nlm.nih.gov/pubmed/2512924', '1907252': 'http://www.ncbi.nlm.nih.gov/pubmed/1907252', '1734857': 'http://www.ncbi.nlm.nih.gov/pubmed/1734857', '8181472': 'http://www.ncbi.nlm.nih.gov/pubmed/8181472', '8473346': 'http://www.ncbi.nlm.nih.gov/pubmed/8473346', '1380156': 'http://www.ncbi.nlm.nih.gov/pubmed/1380156', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039'}",2022-01-17 22:10:45.020539
Acrivastine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0059881,http://smpdb.ca/view/SMP0059881/download?type=full_vector_image,httpsmpdbcaviewSMP0059881.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Acrivastine': 'https://go.drugbank.com/drugs/DB09488'}",Acrivastine H1-Antihistamine Action,"Acrivastine is a second-generation alkylamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '2570003': 'http://www.ncbi.nlm.nih.gov/pubmed/2570003', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:10:59.880576
Activation of PKC Through G Protein-Coupled Receptor,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000749,http://smpdb.ca/view/SMP0000749/download?type=full_vector_image,httpsmpdbcaviewSMP0000749.svg,Signaling,{'Calcium': 'https://go.drugbank.com/drugs/DB01373'},Activation of PKC Through G Protein-Coupled Receptor,"G protein-coupled receptors sense stimuli outside the cell and transmit signals across the plasma membrane. Activation of protein kinase C (PKC) is one of the common signaling pathways. When a class of GPCRs are activated by a ligand, they activate Gq protein to bind GTP instead of GDP. After the Gq becomes active, it activates phospholipase C (PLC) to cleave the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 can bind Ins3P receptor to open calcium channel by diffusion from cytoplasm to ER. Activated calcium channel will release the calcium from ER into cytoplasm. Calcium can activate the kinase activity of PKC.",Homo sapiens,2014-10-15,2019-08-16,Signaling Pathway,"{'9442012': 'http://www.ncbi.nlm.nih.gov/pubmed/9442012', '9121367': 'http://www.ncbi.nlm.nih.gov/pubmed/9121367', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '7945203': 'http://www.ncbi.nlm.nih.gov/pubmed/7945203', '7852357': 'http://www.ncbi.nlm.nih.gov/pubmed/7852357', '7500840': 'http://www.ncbi.nlm.nih.gov/pubmed/7500840', '2336401': 'http://www.ncbi.nlm.nih.gov/pubmed/2336401', '19054851': 'http://www.ncbi.nlm.nih.gov/pubmed/19054851', '16625196': 'http://www.ncbi.nlm.nih.gov/pubmed/16625196'}",2022-01-17 22:11:14.029998
Acute Intermittent Porphyria,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000344,http://smpdb.ca/view/SMP0000344/download?type=full_vector_image,httpsmpdbcaviewSMP0000344.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Aminolevulinic acid': 'https://go.drugbank.com/drugs/DB00855', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Protoporphyrin': 'https://go.drugbank.com/drugs/DB02285', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Coproporphyrinogen III': 'https://go.drugbank.com/drugs/DB04461', 'Farnesyl diphosphate': 'https://go.drugbank.com/drugs/DB07780'}",Acute Intermittent Porphyria,"Acute intermittent porphyria (AIP), also called Swedish porphyria, is a rare inborn error of metabolism (IEM) and autosomal dominant disorder of heme biosynthesis caused by a defective HMBS gene. The HMBS gene codes for the protein hydroxymethylbilane synthase (porphobilinogen deaminase) which catalyzes the synthesis of porphobilinogen into hydroxymethylbilane. This disorder is characterized by a large accumulation of 5-aminolevulinic acid or porphobilinogen in both urine and serum. Most patients are asymptomatic between attacks. Symptoms of the disorder include abdominal pain, constipation, vomiting, hypertension, muscle weakness, seizures, delirium, coma, and depression. Treatment involves undertaking a high-carbohydrate diet and, during severe attacks, a glucose 10% infusion. It is estimated that AIP affects 5.9 per 1 000 000 people.",Homo sapiens,2013-08-19,2019-09-05,Disease Pathway,"{'13658350': 'http://www.ncbi.nlm.nih.gov/pubmed/13658350', '7866402': 'http://www.ncbi.nlm.nih.gov/pubmed/7866402', '329053': 'http://www.ncbi.nlm.nih.gov/pubmed/329053', '2246851': 'http://www.ncbi.nlm.nih.gov/pubmed/2246851', '12372055': 'http://www.ncbi.nlm.nih.gov/pubmed/12372055', '20301372': 'http://www.ncbi.nlm.nih.gov/pubmed/20301372', '2263504': 'http://www.ncbi.nlm.nih.gov/pubmed/2263504', '3671094': 'http://www.ncbi.nlm.nih.gov/pubmed/3671094', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '17966070': 'http://www.ncbi.nlm.nih.gov/pubmed/17966070', '1716854': 'http://www.ncbi.nlm.nih.gov/pubmed/1716854', '3463993': 'http://www.ncbi.nlm.nih.gov/pubmed/3463993', '2875434': 'http://www.ncbi.nlm.nih.gov/pubmed/2875434', '3816774': 'http://www.ncbi.nlm.nih.gov/pubmed/3816774', '7916736': 'http://www.ncbi.nlm.nih.gov/pubmed/7916736', '3174619': 'http://www.ncbi.nlm.nih.gov/pubmed/3174619', '11112350': 'http://www.ncbi.nlm.nih.gov/pubmed/11112350', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8644733': 'http://www.ncbi.nlm.nih.gov/pubmed/8644733', '3015909': 'http://www.ncbi.nlm.nih.gov/pubmed/3015909', '7987309': 'http://www.ncbi.nlm.nih.gov/pubmed/7987309', '8806618': 'http://www.ncbi.nlm.nih.gov/pubmed/8806618', '10486317': 'http://www.ncbi.nlm.nih.gov/pubmed/10486317', '7713909': 'http://www.ncbi.nlm.nih.gov/pubmed/7713909', '11323407': 'http://www.ncbi.nlm.nih.gov/pubmed/11323407', '15201052': 'http://www.ncbi.nlm.nih.gov/pubmed/15201052'}",2022-01-17 22:11:42.127592
Adefovir Dipivoxil Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000418,http://smpdb.ca/view/SMP0000418/download?type=full_vector_image,httpsmpdbcaviewSMP0000418.svg,Drug action,{'ATP': 'https://go.drugbank.com/drugs/DB00171'},Adefovir Dipivoxil  Action Pathway,"Adefovir dipivoxil is an ester prodrug of adefovir, a nucleotide analogue used in the treatment of chronic hepatitis B. Adefovir dipivoxil is taken up into the liver cell and is cleaved into adefovir by intracellular esterases. Adefovir is subsequently phosphorylated first by adenylate kinases and then by nucleoside diphosphate kinases into adefovir diphosphate. Adefovir diphosphate is an analogue of deoxyadenosine triphosphate (dATP) and competes with dATP for binding to the viral DNA polymerase and subsequent incorporation into the growing DNA strand. Once incorporated into the DNA, adefovir causes chain termination, thus preventing viral replication.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,{'14498759': 'http://www.ncbi.nlm.nih.gov/pubmed/14498759'},2022-01-17 22:12:02.659801
Adefovir Dipivoxil Metabolism Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000629,http://smpdb.ca/view/SMP0000629/download?type=full_vector_image,httpsmpdbcaviewSMP0000629.svg,Drug metabolism,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adefovir dipivoxil': 'https://go.drugbank.com/drugs/DB00718', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Adefovir Dipivoxil Metabolism Pathway,"Adefovir dipivoxil is an ester prodrug of adefovir, a nucleotide analogue used in the treatment of chronic hepatitis B. Adefovir dipivoxil is taken up into the liver cell and is cleaved into adefovir by intracellular esterases. Adefovir is subsequently phosphorylated first by adenylate kinases and then by nucleoside diphosphate kinases into adefovir diphosphate. Adefovir diphosphate is an analogue of deoxyadenosine triphosphate (dATP) and competes with dATP for binding to the viral DNA polymerase and subsequent incorporation into the growing DNA strand. Once incorporated into the DNA, adefovir causes chain termination, thus preventing viral replication.",Homo sapiens,2013-09-11,2019-08-16,Drug Metabolism Pathway,"{'14498759': 'http://www.ncbi.nlm.nih.gov/pubmed/14498759', '183954': 'http://www.ncbi.nlm.nih.gov/pubmed/183954', '2542324': 'http://www.ncbi.nlm.nih.gov/pubmed/2542324', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8843353': 'http://www.ncbi.nlm.nih.gov/pubmed/8843353', '9504408': 'http://www.ncbi.nlm.nih.gov/pubmed/9504408', '9434148': 'http://www.ncbi.nlm.nih.gov/pubmed/9434148', '2509941': 'http://www.ncbi.nlm.nih.gov/pubmed/2509941', '1851158': 'http://www.ncbi.nlm.nih.gov/pubmed/1851158', '7916650': 'http://www.ncbi.nlm.nih.gov/pubmed/7916650', '1988104': 'http://www.ncbi.nlm.nih.gov/pubmed/1988104', '8392752': 'http://www.ncbi.nlm.nih.gov/pubmed/8392752'}",2022-01-17 22:12:16.539880
Adenine Phosphoribosyltransferase Deficiency (APRT),https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000535,http://smpdb.ca/view/SMP0000535/download?type=full_vector_image,httpsmpdbcaviewSMP0000535.svg,Disease,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenine': 'https://go.drugbank.com/drugs/DB00173', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'AICA ribonucleotide': 'https://go.drugbank.com/drugs/DB01700', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'Xanthine': 'https://go.drugbank.com/drugs/DB02134', 'Guanine': 'https://go.drugbank.com/drugs/DB02377', 'Cyclic adenosine monophosphate': 'https://go.drugbank.com/drugs/DB02527', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Guanosine': 'https://go.drugbank.com/drugs/DB02857', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Hypoxanthine': 'https://go.drugbank.com/drugs/DB04076', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', 'Inosine': 'https://go.drugbank.com/drugs/DB04335', ""2'-Deoxyguanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB04457'}",Adenine Phosphoribosyltransferase Deficiency (APRT),"Adenine phosphoribosyltransferase deficiency, which is also known as APRTD or APRT deficiency, is a rare inherited inborn error of metabolism (IEM) leading to the recurrent formation of kidney stones. It is an autosomal recessive disorder associated with a mutation in the enzyme adenine phosphoribosyltransferase (APRT). APRT is involved in the nucleotide salvage pathway, which provides an alternative, and energetically more efficient route to nucleotide biosynthesis in humans and most other animals.  A defect in this enzyme can lead to the accumulation of the insoluble purine known as 2,8-dihydroxyadenine. In particular, when APRT has reduced or nonexistent activity, adenine accumulates which is then degraded by xanthine dehydrogenase to 2,8-dihydroxyadenine (DHA). 2,8-Dihydroxyadenine is a derivative of adenine which accumulates in 2,8 dihydroxyadenine urolithiasis (kidney stones). Kidney and urinary tract stones can obstruct the urinary tract, resulting in pain and difficulty urinating. If left untreated, the condition can eventually produce kidney failure. APRTD was first diagnosed in 1976. There are two categories of APRTD: type I involves a complete loss of the APRT function while type II involves a partial loss and is mostly found in Japan. APRT deficiency is estimated to affect 1 in 27 000 people in Japan. APRTD is rarer in Europe, where it affects 1 in 50 000 to 100 000 people. A diagnosis of APRTD can be made by analyzing kidney stones or measuring DHA concentrations in urine. APRTD is treatable with regular doses of allopurinol, which inhibits xanthine dehydrogenase activity. APRTD can also be treated with a low-purine diet and a high fluid intake.",Homo sapiens,2013-08-29,2019-09-06,Disease Pathway,"{'22700886': 'http://www.ncbi.nlm.nih.gov/pubmed/22700886', '8643571': 'http://www.ncbi.nlm.nih.gov/pubmed/8643571', '30441833': 'http://www.ncbi.nlm.nih.gov/pubmed/30441833 ', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22531138', '7487923': 'http://www.ncbi.nlm.nih.gov/pubmed/7487923', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10453732': 'http://www.ncbi.nlm.nih.gov/pubmed/10453732', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '9676430': 'http://www.ncbi.nlm.nih.gov/pubmed/9676430', '10708485': 'http://www.ncbi.nlm.nih.gov/pubmed/10708485', '15698960': 'http://www.ncbi.nlm.nih.gov/pubmed/15698960', '16752921': 'http://www.ncbi.nlm.nih.gov/pubmed/16752921', '17095758': 'http://www.ncbi.nlm.nih.gov/pubmed/17095758', '12975309': 'http://www.ncbi.nlm.nih.gov/pubmed/12975309', '8647247': 'http://www.ncbi.nlm.nih.gov/pubmed/8647247', '8663313': 'http://www.ncbi.nlm.nih.gov/pubmed/8663313', '7999131': 'http://www.ncbi.nlm.nih.gov/pubmed/7999131', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '23043144': 'http://www.ncbi.nlm.nih.gov/pubmed/23043144', '8692979': 'http://www.ncbi.nlm.nih.gov/pubmed/8692979', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621'}",2022-01-17 22:12:48.602068
Adenosine Deaminase Deficiency,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000144,http://smpdb.ca/view/SMP0000144/download?type=full_vector_image,httpsmpdbcaviewSMP0000144.svg,Disease,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenine': 'https://go.drugbank.com/drugs/DB00173', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'AICA ribonucleotide': 'https://go.drugbank.com/drugs/DB01700', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'Xanthine': 'https://go.drugbank.com/drugs/DB02134', 'Guanine': 'https://go.drugbank.com/drugs/DB02377', 'Cyclic adenosine monophosphate': 'https://go.drugbank.com/drugs/DB02527', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Guanosine': 'https://go.drugbank.com/drugs/DB02857', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Hypoxanthine': 'https://go.drugbank.com/drugs/DB04076', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', 'Inosine': 'https://go.drugbank.com/drugs/DB04335', ""2'-Deoxyguanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB04457'}",Adenosine Deaminase Deficiency,"Adenosine deaminiase deficiency (immunodeficiency) is an autosomal recessive disease caused by a muation in the ADA gene which codes for adenosine deaminase. A deficiency in this enzyme results in immunodeficiency and a decreased concentration of lymphocytes in blood. Symptoms include diarrhea, severe or recurrent infections, vomiting and early onset in children, infants and newborns. Treatment includes bone-marrow transplants and enzyme replacement therapy.",Homo sapiens,2013-08-01,2019-08-30,Disease Pathway,"{'8099155': 'http://www.ncbi.nlm.nih.gov/pubmed/8099155', '11445793': 'http://www.ncbi.nlm.nih.gov/pubmed/11445793', '4014441': 'http://www.ncbi.nlm.nih.gov/pubmed/4014441', '29690908': 'http://www.ncbi.nlm.nih.gov/pubmed/29690908', '24439080': 'http://www.ncbi.nlm.nih.gov/pubmed/24439080', '30441833': 'http://www.ncbi.nlm.nih.gov/pubmed/30441833 ', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22531138', '7487923': 'http://www.ncbi.nlm.nih.gov/pubmed/7487923', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10453732': 'http://www.ncbi.nlm.nih.gov/pubmed/10453732', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '9676430': 'http://www.ncbi.nlm.nih.gov/pubmed/9676430', '10708485': 'http://www.ncbi.nlm.nih.gov/pubmed/10708485', '15698960': 'http://www.ncbi.nlm.nih.gov/pubmed/15698960', '16752921': 'http://www.ncbi.nlm.nih.gov/pubmed/16752921', '17095758': 'http://www.ncbi.nlm.nih.gov/pubmed/17095758', '12975309': 'http://www.ncbi.nlm.nih.gov/pubmed/12975309', '8647247': 'http://www.ncbi.nlm.nih.gov/pubmed/8647247', '8663313': 'http://www.ncbi.nlm.nih.gov/pubmed/8663313', '7999131': 'http://www.ncbi.nlm.nih.gov/pubmed/7999131', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '23043144': 'http://www.ncbi.nlm.nih.gov/pubmed/23043144', '8692979': 'http://www.ncbi.nlm.nih.gov/pubmed/8692979', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621'}",2022-01-17 22:13:23.133858
Adenylosuccinate Lyase Deficiency,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000167,http://smpdb.ca/view/SMP0000167/download?type=full_vector_image,httpsmpdbcaviewSMP0000167.svg,Disease,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenine': 'https://go.drugbank.com/drugs/DB00173', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'AICA ribonucleotide': 'https://go.drugbank.com/drugs/DB01700', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'Xanthine': 'https://go.drugbank.com/drugs/DB02134', 'Guanine': 'https://go.drugbank.com/drugs/DB02377', 'Cyclic adenosine monophosphate': 'https://go.drugbank.com/drugs/DB02527', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Guanosine': 'https://go.drugbank.com/drugs/DB02857', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Hypoxanthine': 'https://go.drugbank.com/drugs/DB04076', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', 'Inosine': 'https://go.drugbank.com/drugs/DB04335', ""2'-Deoxyguanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB04457'}",Adenylosuccinate Lyase Deficiency,"Adenylosuccinate Lyase Deficiency. (Adenylosuccinase Deficiency ; Adenylosuccinate monophosphate lyase deficiency) is a rare autosomal recessive disease caused by a mutation in the ADSL gene which codes for adenylosuccinate lyase. A deficiency in this enzyme results in accumulation of succinyladenosine in plasma, spinal fluid, and urine. Symptoms, which present at birth, include hyptonia, seizures, mental retardation, and encephalopathy. Treatment includes allopurinol.",Homo sapiens,2013-08-01,2019-08-30,Disease Pathway,"{'12833398': 'http://www.ncbi.nlm.nih.gov/pubmed/12833398', '1405483': 'http://www.ncbi.nlm.nih.gov/pubmed/1405483', '3234432': 'http://www.ncbi.nlm.nih.gov/pubmed/3234432', '10090474': 'http://www.ncbi.nlm.nih.gov/pubmed/10090474', '15114530': 'http://www.ncbi.nlm.nih.gov/pubmed/15114530', '25112391': 'http://www.ncbi.nlm.nih.gov/pubmed/25112391', '16839792': 'http://www.ncbi.nlm.nih.gov/pubmed/16839792', '30441833': 'http://www.ncbi.nlm.nih.gov/pubmed/30441833 ', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22531138', '7487923': 'http://www.ncbi.nlm.nih.gov/pubmed/7487923', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10453732': 'http://www.ncbi.nlm.nih.gov/pubmed/10453732', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '9676430': 'http://www.ncbi.nlm.nih.gov/pubmed/9676430', '10708485': 'http://www.ncbi.nlm.nih.gov/pubmed/10708485', '15698960': 'http://www.ncbi.nlm.nih.gov/pubmed/15698960', '16752921': 'http://www.ncbi.nlm.nih.gov/pubmed/16752921', '17095758': 'http://www.ncbi.nlm.nih.gov/pubmed/17095758', '12975309': 'http://www.ncbi.nlm.nih.gov/pubmed/12975309', '8647247': 'http://www.ncbi.nlm.nih.gov/pubmed/8647247', '8663313': 'http://www.ncbi.nlm.nih.gov/pubmed/8663313', '7999131': 'http://www.ncbi.nlm.nih.gov/pubmed/7999131', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '23043144': 'http://www.ncbi.nlm.nih.gov/pubmed/23043144', '8692979': 'http://www.ncbi.nlm.nih.gov/pubmed/8692979', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621'}",2022-01-17 22:13:56.131810
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000373,http://smpdb.ca/view/SMP0000373/download?type=full_vector_image,httpsmpdbcaviewSMP0000373.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency,"Adrenal hyperplasia type 3, also called Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, is caused by a defect in the CYP21A2 gene which codes for Steroid 21-hydroxylase (21-hydroxylase). Steroid 21-hydroxylase catalyzes hydroxylation of 17-hydroxyprogesterone to 11-deoxycortisol in the glucocorticoid pathway from pregnenolone to cortisol. It also catalyzes hydroxylation of progesterone to 11-deoxycorticosterone (DOC) in the mineralocorticoid pathway on its way from pregnenolone to aldosterone. A defect in this enzyme results in accumulation of 17-Hydroxyprogesterone, progesterone and 17a-Hydroxypregnenolone, androstenedione, and testosterone; decreased levels of cortexolone, deoxycorticosterone, aldosterone and cortisol. Symptoms include salt-wasting crises in infancy due to the lack of aldosterone, like spitting, poor weight gain, vomiting, severe dehydration, and circulatory collapse. The high level of testosterone results in virilization and genital ambiguity of female infants.",Homo sapiens,2013-08-19,2019-08-16,Disease Pathway,"{'8731325': 'http://www.ncbi.nlm.nih.gov/pubmed/8731325', '17666484': 'http://www.ncbi.nlm.nih.gov/pubmed/17666484', '9851787': 'http://www.ncbi.nlm.nih.gov/pubmed/9851787', '13968788': 'http://www.ncbi.nlm.nih.gov/pubmed/13968788', '11397874': 'http://www.ncbi.nlm.nih.gov/pubmed/11397874', '23044877': 'http://www.ncbi.nlm.nih.gov/pubmed/23044877', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:14:26.257710
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000372,http://smpdb.ca/view/SMP0000372/download?type=full_vector_image,httpsmpdbcaviewSMP0000372.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency,"Adrenal hyperplasia type 5 (AH5) also known as Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency	 is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of cortisol and sex steroids synthesis caused by a defect in the CYP17A1 gene which codes for Steroid 17-alpha-hydroxylase/17,20 lyase. These 2 enzymes catalyze pregnenolone and progesterone to their 17-hydroxy forms in steroidogenesis and mediate three key transformations in cortisol and sex steroid synthesis. This disorder is characterized by a decrease in both cortisol and sex steroids and increase in mineralocorticoids. Symptoms of the disorder include mild hypocortisolism, ambiguous genitalia in genetic males or failure of the ovaries to function at puberty in genetic females, and hypertension. Treatments for Hypertension and mineralocorticoid excess is done with glucocorticoid replacement. Genetically female patients need female hormone replacement to induce puberty and regulate menses. Surgery may be needed for males with ambiguous genitalia. Testosterone must be replaced for genetically males (XY) to induce puberty and continued throughout adult life. It is estimated that Adrenal hyperplasia type 5 affects 1 in 1 million individuals worldwide.",Homo sapiens,2013-08-19,2019-09-13,Disease Pathway,"{'8989231': 'http://www.ncbi.nlm.nih.gov/pubmed/8989231', '4288776': 'http://www.ncbi.nlm.nih.gov/pubmed/4288776', '9326943': 'http://www.ncbi.nlm.nih.gov/pubmed/9326943', '999330': 'http://www.ncbi.nlm.nih.gov/pubmed/999330', '30104848': 'http://www.ncbi.nlm.nih.gov/pubmed/30104848', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:14:54.345167
"Adrenoleukodystrophy, X-Linked",https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000516,http://smpdb.ca/view/SMP0000516/download?type=full_vector_image,httpsmpdbcaviewSMP0000516.svg,Disease,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Levocarnitine': 'https://go.drugbank.com/drugs/DB00583', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Lauric acid': 'https://go.drugbank.com/drugs/DB03017'}","Adrenoleukodystrophy, X-Linked","Adrenoleukodystrophy (ALD) is an X-linked recessive transmission disease. Central nervous system signs and symptoms have been consistently more prominent than signs of adrenal involvement. Behavioral changes are the most common initial finding and range from aggressive outbursts to withdrawal. Such behavior is generally accompanied by a gradually failing memory and poor school performance. Loss of vision is an early finding in some patients and is a prominent feature at some stage in most affected individuals. The initial visual loss appears as homonomous hemianopsia in some individuals and is usually associated with intact pupillary reflexes. Optic atrophy is less common as an initial finding but eventually develops in almost all cases. Gait disturbance is also an early finding and as is stiff-legged, unsteady and accompanied by hyperreflexia. In almost all cases there is spastic quadraplegia and a variable degree of decorticate posturing. Hearing loss, dysarthria and dysphagia develop at about the same time as gait disturbance. Seizures are a typical symptom in many affected individuals in the the end stages of the disease progression.",Homo sapiens,2013-08-29,2019-09-12,Disease Pathway,"{'20301491': 'http://www.ncbi.nlm.nih.gov/pubmed/20301491', '9256488': 'http://www.ncbi.nlm.nih.gov/pubmed/9256488', '444549': 'http://www.ncbi.nlm.nih.gov/pubmed/444549', '15466478': 'http://www.ncbi.nlm.nih.gov/pubmed/15466478', '10407780': 'http://www.ncbi.nlm.nih.gov/pubmed/10407780', '10051453': 'http://www.ncbi.nlm.nih.gov/pubmed/10051453', '11673457': 'http://www.ncbi.nlm.nih.gov/pubmed/11673457', '10527927': 'http://www.ncbi.nlm.nih.gov/pubmed/10527927', '1607358': 'http://www.ncbi.nlm.nih.gov/pubmed/1607358', '8584017': 'http://www.ncbi.nlm.nih.gov/pubmed/8584017', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10486279': 'http://www.ncbi.nlm.nih.gov/pubmed/10486279', '12853948': 'http://www.ncbi.nlm.nih.gov/pubmed/12853948', '12690205': 'http://www.ncbi.nlm.nih.gov/pubmed/12690205', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '7945262': 'http://www.ncbi.nlm.nih.gov/pubmed/7945262', '9399886': 'http://www.ncbi.nlm.nih.gov/pubmed/9399886', '9837782': 'http://www.ncbi.nlm.nih.gov/pubmed/9837782', '9600456': 'http://www.ncbi.nlm.nih.gov/pubmed/9600456', '1988962': 'http://www.ncbi.nlm.nih.gov/pubmed/1988962', '1961767': 'http://www.ncbi.nlm.nih.gov/pubmed/1961767'}",2022-01-17 22:15:17.289614
AICA-Ribosiduria,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000168,http://smpdb.ca/view/SMP0000168/download?type=full_vector_image,httpsmpdbcaviewSMP0000168.svg,Disease,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenine': 'https://go.drugbank.com/drugs/DB00173', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'AICA ribonucleotide': 'https://go.drugbank.com/drugs/DB01700', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'Xanthine': 'https://go.drugbank.com/drugs/DB02134', 'Guanine': 'https://go.drugbank.com/drugs/DB02377', 'Cyclic adenosine monophosphate': 'https://go.drugbank.com/drugs/DB02527', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Guanosine': 'https://go.drugbank.com/drugs/DB02857', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Hypoxanthine': 'https://go.drugbank.com/drugs/DB04076', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', 'Inosine': 'https://go.drugbank.com/drugs/DB04335', ""2'-Deoxyguanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB04457'}",AICA-Ribosiduria,"AICA-ribosiduria is a metabolic disease caused by a defect in final steps of purine de novo biosynthesis. This defect is caused by a mutation in the ATIC which codes for bifunctional purine biosynthesis protein PURH. A deficiency in this enzyme results in accumulation of 5-aminoimidazole-4-carboxamide in urine. Symptoms include mental retardation, epilepsy, dysmorphic features, and congenital blindness.",Homo sapiens,2013-08-01,2019-08-30,Disease Pathway,"{'11323713': 'http://www.ncbi.nlm.nih.gov/pubmed/11323713', '15114530': 'http://www.ncbi.nlm.nih.gov/pubmed/15114530', '30441833': 'http://www.ncbi.nlm.nih.gov/pubmed/30441833 ', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22531138', '7487923': 'http://www.ncbi.nlm.nih.gov/pubmed/7487923', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10453732': 'http://www.ncbi.nlm.nih.gov/pubmed/10453732', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '9676430': 'http://www.ncbi.nlm.nih.gov/pubmed/9676430', '10708485': 'http://www.ncbi.nlm.nih.gov/pubmed/10708485', '15698960': 'http://www.ncbi.nlm.nih.gov/pubmed/15698960', '16752921': 'http://www.ncbi.nlm.nih.gov/pubmed/16752921', '17095758': 'http://www.ncbi.nlm.nih.gov/pubmed/17095758', '12975309': 'http://www.ncbi.nlm.nih.gov/pubmed/12975309', '8647247': 'http://www.ncbi.nlm.nih.gov/pubmed/8647247', '8663313': 'http://www.ncbi.nlm.nih.gov/pubmed/8663313', '7999131': 'http://www.ncbi.nlm.nih.gov/pubmed/7999131', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '23043144': 'http://www.ncbi.nlm.nih.gov/pubmed/23043144', '8692979': 'http://www.ncbi.nlm.nih.gov/pubmed/8692979', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621'}",2022-01-17 22:15:51.418216
Alanine Metabolism,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000055,http://smpdb.ca/view/SMP0000055/download?type=full_vector_image,httpsmpdbcaviewSMP0000055.svg,Metabolic,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Glyoxylic acid': 'https://go.drugbank.com/drugs/DB04343'}",Alanine Metabolism,Alanine (L-Alanine) is an α-amino acid that is used for protein biosynthesis. Approximately 8% of human proteins have alanine in their structures. The reductive lamination of pyruvate is effected by alanine transaminase. L-Alanine can be converted to pyruvic acid by alanine aminotransferase 1 reversibly coupled with interconversion of oxoglutaric acid and L-glutamic acid. L-Alanine can also be produced by alanine-glyoxylate transaminase with coupled interconversion of glyoxylate and glycine. L-Alanine will be coupled with alanyl tRNA by alanyl-tRNA synthetase to perform protein biosynthesis. Alanine can also be used to provide energy under fasting conditions. There are two pathways that can facilitate this: (1) alanine is converted to pyruvate to synthesize glucose via the gluconeogenesis pathway in liver tissue or (2) alanine converted into pyruvate moves into the TCA cycle to be oxidized in other tissues.,Homo sapiens,2013-08-01,2019-08-20,Metabolic Pathway,"{'961915': 'http://www.ncbi.nlm.nih.gov/pubmed/961915', '888947': 'http://www.ncbi.nlm.nih.gov/pubmed/888947', '1249058': 'http://www.ncbi.nlm.nih.gov/pubmed/1249058', '1249059': 'http://www.ncbi.nlm.nih.gov/pubmed/1249059', '7654687': 'http://www.ncbi.nlm.nih.gov/pubmed/7654687', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15616553': 'http://www.ncbi.nlm.nih.gov/pubmed/15616553', '9119391': 'http://www.ncbi.nlm.nih.gov/pubmed/9119391', '1931970': 'http://www.ncbi.nlm.nih.gov/pubmed/1931970', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '7918683': 'http://www.ncbi.nlm.nih.gov/pubmed/7918683', '8048912': 'http://www.ncbi.nlm.nih.gov/pubmed/8048912', '9192270': 'http://www.ncbi.nlm.nih.gov/pubmed/9192270', '10862087': 'http://www.ncbi.nlm.nih.gov/pubmed/10862087', '2253628': 'http://www.ncbi.nlm.nih.gov/pubmed/2253628', '24808023': 'http://www.ncbi.nlm.nih.gov/pubmed/24808023', '10574462': 'http://www.ncbi.nlm.nih.gov/pubmed/10574462', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '11042152': 'http://www.ncbi.nlm.nih.gov/pubmed/11042152', '10810093': 'http://www.ncbi.nlm.nih.gov/pubmed/10810093'}",2022-01-17 22:16:09.691210
Alcaftadine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0062881,http://smpdb.ca/view/SMP0062881/download?type=full_vector_image,httpsmpdbcaviewSMP0062881.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Alcaftadine': 'https://go.drugbank.com/drugs/DB06766'}",Alcaftadine H1-Antihistamine Action,"Alcaftadine is a second-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-24,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:16:27.326371
Alendronate Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000095,http://smpdb.ca/view/SMP0000095/download?type=full_vector_image,httpsmpdbcaviewSMP0000095.svg,Drug action,"{'Cholecalciferol': 'https://go.drugbank.com/drugs/DB00169', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Alendronic acid': 'https://go.drugbank.com/drugs/DB00630', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Dimethylallyl Diphosphate': 'https://go.drugbank.com/drugs/DB01785', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Geranyl Diphosphate': 'https://go.drugbank.com/drugs/DB02552', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Palmitic Acid': 'https://go.drugbank.com/drugs/DB03796', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'ISOPENTENYL PYROPHOSPHATE': 'https://go.drugbank.com/drugs/DB04714', 'Farnesyl diphosphate': 'https://go.drugbank.com/drugs/DB07780'}",Alendronate Action Pathway,"Alendronate (also known as alendronic acid) is a type of bisphosphonate medication with nitrogen that can inhibit FPP synthase, which can block the pathway that produce geranyl-PP and farnesyl pyrophosphate. Geranyl-PP and farnesyl pyrophosphate are the compounds that are required for small GTPase signalling proteins undergo post-translational farnesylation and geranylgeranylation. Therefore, lack the formation of geranyl-PP and farnesyl pyrophosphate can prevent osteoclast activity, which lead to prevention of reduced bone resorption and turnover.",Homo sapiens,2013-08-04,2019-08-16,Drug Action Pathway,"{'12590887': 'http://www.ncbi.nlm.nih.gov/pubmed/12590887', '1968462': 'http://www.ncbi.nlm.nih.gov/pubmed/1968462', '7584026': 'http://www.ncbi.nlm.nih.gov/pubmed/7584026', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '7911016': 'http://www.ncbi.nlm.nih.gov/pubmed/7911016', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '1358203': 'http://www.ncbi.nlm.nih.gov/pubmed/1358203', '7913309': 'http://www.ncbi.nlm.nih.gov/pubmed/7913309', '11313768': 'http://www.ncbi.nlm.nih.gov/pubmed/11313768', '14730012': 'http://www.ncbi.nlm.nih.gov/pubmed/14730012', '10369261': 'http://www.ncbi.nlm.nih.gov/pubmed/10369261', '8663599': 'http://www.ncbi.nlm.nih.gov/pubmed/8663599', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10191291': 'http://www.ncbi.nlm.nih.gov/pubmed/10191291', '8626466': 'http://www.ncbi.nlm.nih.gov/pubmed/8626466', '9392419': 'http://www.ncbi.nlm.nih.gov/pubmed/9392419', '8020941': 'http://www.ncbi.nlm.nih.gov/pubmed/8020941', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '10101267': 'http://www.ncbi.nlm.nih.gov/pubmed/10101267', '9741684': 'http://www.ncbi.nlm.nih.gov/pubmed/9741684', '10026212': 'http://www.ncbi.nlm.nih.gov/pubmed/10026212', '12602122': 'http://www.ncbi.nlm.nih.gov/pubmed/12602122'}",2022-01-17 22:16:55.950583
Alfentanil Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000413,http://smpdb.ca/view/SMP0000413/download?type=full_vector_image,httpsmpdbcaviewSMP0000413.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Alfentanil': 'https://go.drugbank.com/drugs/DB00802', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Alfentanil Action Pathway,"Alfentanil (also known as Alfenta or Rapifen) is analgesic that can bind to mu-type opioid receptor to activate associated G-protein in the sensory neurons of central nervous system (CNS), which will reduce the level of intracellular cAMP by inhibiting adenylate cyclase. The binding of alfentanil will eventually lead to reduced pain because of decreased nerve conduction and release of neurotransmitter. Hyperpolarization of neuron is caused by inactivation of calcium channels and activation of potassium channels via facilitated by G-protein.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18443637': 'http://www.ncbi.nlm.nih.gov/pubmed/18443637', '7905839': 'http://www.ncbi.nlm.nih.gov/pubmed/7905839', '7957926': 'http://www.ncbi.nlm.nih.gov/pubmed/7957926', '7891175': 'http://www.ncbi.nlm.nih.gov/pubmed/7891175', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:17:18.343673
Alimemazine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0059689,http://smpdb.ca/view/SMP0059689/download?type=full_vector_image,httpsmpdbcaviewSMP0059689.svg,Drug action,"{'Alimemazine': 'https://go.drugbank.com/drugs/DB01246', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Alimemazine H1-Antihistamine Action,"Alimemazine (trimeprazine) is a first-generation phenothiazine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:17:33.668153
Alkaptonuria,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000169,http://smpdb.ca/view/SMP0000169/download?type=full_vector_image,httpsmpdbcaviewSMP0000169.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Ascorbic acid': 'https://go.drugbank.com/drugs/DB00126', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Tyrosine': 'https://go.drugbank.com/drugs/DB00135', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Sapropterin': 'https://go.drugbank.com/drugs/DB00360', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Epinephrine': 'https://go.drugbank.com/drugs/DB00668', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Levodopa': 'https://go.drugbank.com/drugs/DB01235', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '2-(3,4-Dihydroxyphenyl)Acetic Acid': 'https://go.drugbank.com/drugs/DB01702', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Methylamine': 'https://go.drugbank.com/drugs/DB01828', '1,2-Dihydroxybenzene': 'https://go.drugbank.com/drugs/DB02232', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Pyrroloquinoline Quinone': 'https://go.drugbank.com/drugs/DB03205', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', '4-Hydroxyphenylpyruvic acid': 'https://go.drugbank.com/drugs/DB07718', 'Homogentisic acid': 'https://go.drugbank.com/drugs/DB08327'}",Alkaptonuria,"Alkaptonuria (Homogentisic acid oxidase deficiency) is an autosomal recessive disease caused by a mutation in the HGD gene which codes for homogentisate 1,2-dioxygenase. A mutation in this enzyme results in accumulation of homogentisic acid in urine. Symptoms, which present in adulthood, include arthritis, black or brown urine, and urolithiasis. Treatment includes a low-protein diet with vitamin C.",Homo sapiens,2013-08-19,2019-08-30,Disease Pathway,"{'9529363': 'http://www.ncbi.nlm.nih.gov/pubmed/9529363', '12872815': 'http://www.ncbi.nlm.nih.gov/pubmed/12872815', '8782815': 'http://www.ncbi.nlm.nih.gov/pubmed/8782815', '9154114': 'http://www.ncbi.nlm.nih.gov/pubmed/9154114', '12501223': 'http://www.ncbi.nlm.nih.gov/pubmed/12501223', '20301627': 'http://www.ncbi.nlm.nih.gov/pubmed/20301627', '23511227': 'http://www.ncbi.nlm.nih.gov/pubmed/23511227', '25635379': 'http://www.ncbi.nlm.nih.gov/pubmed/25635379', '6577005': 'http://www.ncbi.nlm.nih.gov/pubmed/6577005', '21633705': 'http://www.ncbi.nlm.nih.gov/pubmed/21633705', '7678807': 'http://www.ncbi.nlm.nih.gov/pubmed/7678807', '4387001': 'http://www.ncbi.nlm.nih.gov/pubmed/4387001', '16734418': 'http://www.ncbi.nlm.nih.gov/pubmed/16734418', '10652282': 'http://www.ncbi.nlm.nih.gov/pubmed/10652282', '23157446': 'http://www.ncbi.nlm.nih.gov/pubmed/23157446', '22745813': 'http://www.ncbi.nlm.nih.gov/pubmed/22745813', '1973834': 'http://www.ncbi.nlm.nih.gov/pubmed/1973834', '7908801': 'http://www.ncbi.nlm.nih.gov/pubmed/7908801', '7999802': 'http://www.ncbi.nlm.nih.gov/pubmed/7999802', '1974457': 'http://www.ncbi.nlm.nih.gov/pubmed/1974457', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '10942115': 'http://www.ncbi.nlm.nih.gov/pubmed/10942115', '7851880': 'http://www.ncbi.nlm.nih.gov/pubmed/7851880', '8521727': 'http://www.ncbi.nlm.nih.gov/pubmed/8521727', '9417084': 'http://www.ncbi.nlm.nih.gov/pubmed/9417084', '9396740': 'http://www.ncbi.nlm.nih.gov/pubmed/9396740', '9925947': 'http://www.ncbi.nlm.nih.gov/pubmed/9925947', '1998338': 'http://www.ncbi.nlm.nih.gov/pubmed/1998338', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '2590185': 'http://www.ncbi.nlm.nih.gov/pubmed/2590185', '1612608': 'http://www.ncbi.nlm.nih.gov/pubmed/1612608', '1540578': 'http://www.ncbi.nlm.nih.gov/pubmed/1540578', '1737758': 'http://www.ncbi.nlm.nih.gov/pubmed/1737758', '8493892': 'http://www.ncbi.nlm.nih.gov/pubmed/8493892', '1642278': 'http://www.ncbi.nlm.nih.gov/pubmed/1642278', '1903356': 'http://www.ncbi.nlm.nih.gov/pubmed/1903356', '2823263': 'http://www.ncbi.nlm.nih.gov/pubmed/2823263', '10490716': 'http://www.ncbi.nlm.nih.gov/pubmed/10490716', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '3443096': 'http://www.ncbi.nlm.nih.gov/pubmed/3443096'}",2022-01-17 22:18:04.013040
Alpha Linolenic Acid and Linoleic Acid Metabolism,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000018,http://smpdb.ca/view/SMP0000018/download?type=full_vector_image,httpsmpdbcaviewSMP0000018.svg,Metabolic,"{'alpha-Linolenic acid': 'https://go.drugbank.com/drugs/DB00132', 'Dihomo-gamma-linolenic acid': 'https://go.drugbank.com/drugs/DB00154', 'Icosapent': 'https://go.drugbank.com/drugs/DB00159', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Alpha Linolenic Acid and Linoleic Acid Metabolism,"Linoleic acid (LNA) is a polyunsaturated fatty acid (PUFA) precursor to the longer n−6 fatty acids commonly known as omega-6 fatty acids. Omega-6 fatty acids are characterized by a carbon-carbon double bond at the sixth carbon from the methyl group. Similarly, the PUFA alpha-linoleic acid (ALA) is the precursor to n-3 fatty acids known as omega-3 fatty acids which is characterized by a carbon-carbon double bond at the third carbon from the methyl group. 
Both LNA and ALA are essential dietary requirements for all mammals since they cannot be synthesized natively in the body. Both undergo a series of similar conversions to reach their final fatty acid form. LNA enters the cell and is catalyzed to gamma-linolenic acid (GLA) by acyl-CoA 6-desaturase (delta-6-desaturase/fatty acid desaturase 2). GLA is then converted to dihomo-gammalinolenic acid (DGLA) by elongation of very long chain fatty acids protein 5 (ELOVL5). DGLA is then converted to arachidonic acid (AA) by acyl-CoA (8-3)-desaturase (delta-5-desaturase/fatty acid desaturase 1). Arachidonic acid is then converted to a series of short lived metabolites called eicosanoids before finally reaching it's final fatty acid form.",Homo sapiens,2013-08-01,2019-08-13,Metabolic Pathway,"{'25774650': 'http://www.ncbi.nlm.nih.gov/pubmed/25774650', '19619583': 'http://www.ncbi.nlm.nih.gov/pubmed/19619583', '11483627': 'http://www.ncbi.nlm.nih.gov/pubmed/11483627', '10601301': 'http://www.ncbi.nlm.nih.gov/pubmed/10601301', '27496755': 'http://www.ncbi.nlm.nih.gov/pubmed/27496755', '25920364': 'http://www.ncbi.nlm.nih.gov/pubmed/25920364', '8386433': 'http://www.ncbi.nlm.nih.gov/pubmed/8386433', '9867867': 'http://www.ncbi.nlm.nih.gov/pubmed/9867867', '10860662': 'http://www.ncbi.nlm.nih.gov/pubmed/10860662', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '25065913': 'http://www.ncbi.nlm.nih.gov/pubmed/25065913', '10970790': 'http://www.ncbi.nlm.nih.gov/pubmed/10970790', '11230166': 'http://www.ncbi.nlm.nih.gov/pubmed/11230166', '10769175': 'http://www.ncbi.nlm.nih.gov/pubmed/10769175', '22100072': 'http://www.ncbi.nlm.nih.gov/pubmed/22100072', '12592226': 'http://www.ncbi.nlm.nih.gov/pubmed/12592226', '24566826': 'http://www.ncbi.nlm.nih.gov/pubmed/24566826'}",2022-01-17 22:18:20.675118
Alprenolol Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000297,http://smpdb.ca/view/SMP0000297/download?type=full_vector_image,httpsmpdbcaviewSMP0000297.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Alprenolol': 'https://go.drugbank.com/drugs/DB00866', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Alprenolol Action Pathway,"Alprenolol (also known as alfeprol, alpheprol or alprenololum) a beta blocker (non-selective) that block beta-1 adrenergic receptor in heart. Blocking beta-1 adrenergic receptor could prevent the binding of epinephrine and norepinephrine, which could efficiently reduce blood pressure and heart rate. In the juxtaglomerular apparatus, alprenolol can also bind to beta-2 receptors to prevent the production and release of renin (also known as angiotensinogenase). Without renin, angiotensin II and aldosterone could not be produced, which ultimately prevent water retention and vasoconstriction.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:18:42.738690
Alteplase Action Pathway,https://go.drugbank.com/pathways?page=2,http://smpdb.ca/view/SMP0000280,http://smpdb.ca/view/SMP0000280/download?type=full_vector_image,httpsmpdbcaviewSMP0000280.svg,Drug action,"{'Alteplase': 'https://go.drugbank.com/drugs/DB00009', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Alteplase Action Pathway,"Alteplase is the generic version of the drugs Activase and Actilyse. It is a thrombolytic drug prescribed to treat acute myocardial infarctions and other blood clotting conditions. Alteplase if often used to treat ischaemic stroke within hours of onset. The drug acts by breaking up blood clots. Alteplase binds fibrin in the blood clot to converts plasminogen to plasmin. Plasmin is a proteolytic enzyme that causing the degradation of fibrin. A side effect of the drug is bleeding, angioedema, allergic reactions and fever.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '29763152': 'http://www.ncbi.nlm.nih.gov/pubmed/29763152', '28780236': 'http://www.ncbi.nlm.nih.gov/pubmed/28780236 ', '2318848': 'http://www.ncbi.nlm.nih.gov/pubmed/2318848', '3030813': 'http://www.ncbi.nlm.nih.gov/pubmed/3030813', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:18:57.900899
Alvimopan Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000685,http://smpdb.ca/view/SMP0000685/download?type=full_vector_image,httpsmpdbcaviewSMP0000685.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Alvimopan': 'https://go.drugbank.com/drugs/DB06274'}",Alvimopan Action Pathway,"Alvimopan is prescribed to treat patient opioid-induced constipation, a common side effect of opioid therapy. This side effect results in delayed discharge for hospitalized patients following surgery. Alvimopan helps to increase gastrointestinal recovery following surgery for a shorter hospital stay. Opioids bind opioid receptors in the gut causing inhibition of gut motility which results in constipation. Alvimopan is a peripherally acting mu-opioid antagonist. The drug acts in the gastrointestinal tract by competing to bind the mu-opioid receptor. Alvimopan differs from other peripherally acting mu-receptor antagonists such as, methylnaltrexone, by the presence of a quaternary amine.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22643504', '28176913': 'http://www.ncbi.nlm.nih.gov/pubmed/28176913', '7905839': 'http://www.ncbi.nlm.nih.gov/pubmed/7905839', '7957926': 'http://www.ncbi.nlm.nih.gov/pubmed/7957926', '7891175': 'http://www.ncbi.nlm.nih.gov/pubmed/7891175', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:19:19.064383
Amikacin Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000253,http://smpdb.ca/view/SMP0000253/download?type=full_vector_image,httpsmpdbcaviewSMP0000253.svg,Drug action,"{'Histidine': 'https://go.drugbank.com/drugs/DB00117', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Methionine': 'https://go.drugbank.com/drugs/DB00134', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'Threonine': 'https://go.drugbank.com/drugs/DB00156', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Proline': 'https://go.drugbank.com/drugs/DB00172', 'Asparagine': 'https://go.drugbank.com/drugs/DB00174', 'Amikacin': 'https://go.drugbank.com/drugs/DB00479', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', ""Cytidine-5'-Triphosphate"": 'https://go.drugbank.com/drugs/DB02431', 'Uridine monophosphate': 'https://go.drugbank.com/drugs/DB03685', 'D-Serine': 'https://go.drugbank.com/drugs/DB03929', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Amikacin Action Pathway,"Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis. Amikacin binds irreversibly to the bacterial 30S ribosomal subunit protein and 16S rRNA and prevents the formation of the initiation complex with messenger RNA. More specifically, amikacin binds four nucleotides of the 16S rRNA and a single amino acid of protein S12. This interferes with the decoding site in the vicinity of nucleotide 1400 in 16S rRNA of the 30S subunit. This region interacts with the wobble base of the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so that incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides, and the breakup of polysomes into nonfunctional monosomes. Aminoglycosides are useful in treating infections from mycobacteria such as, tuberculosis, and aerobic Gram-negative bacteria including, Pseudomonas, Acinetobacter and Enterobacter. Aminoglycosides can also treat Gram-positive bacterial infections but are inferior to other available antibiotics. Aminoglycosides may be used in combination with penicillin type antibiotics. Aminoglycosides are not an effective treatment for anaerobic bacteria, fungi and viruses.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'27623706': 'http://www.ncbi.nlm.nih.gov/pubmed/27623706 ', '27252397': 'http://www.ncbi.nlm.nih.gov/pubmed/27252397'}",2022-01-17 22:19:50.007326
Amiloride Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000133,http://smpdb.ca/view/SMP0000133/download?type=full_vector_image,httpsmpdbcaviewSMP0000133.svg,Drug action,"{'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Amiloride': 'https://go.drugbank.com/drugs/DB00594', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Urea': 'https://go.drugbank.com/drugs/DB03904'}",Amiloride Action Pathway,"Amiloride is a diuretic that inhibits the sodium channels in the late distal convoluted tubule and collecting tube of the nephron where 1-2% of sodium reabsorption occurs. The inhibition of sodium reabsorption results in increased osmolarity in the lumen and decreased osmolarity in the interstitium of the nephron. This decreased osmotic gradient results in a modest diuresis. The drug is also potassium sparing. Potassium is typically excreted due to the electrochemical gradient produced by sodium reabsorption. Therefore, amiloride's inhibition of sodium reabsorption fails to produce an electrochemical gradient and therefore, inhibits potassium excretion. Amiloride causes an increase in sodium excretion and a decrease in potassium secretion. The drug is typically prescribed to patients with depleted potassium.",Homo sapiens,2013-08-22,2021-06-01,Drug Action Pathway,"{'10653443': 'http://www.ncbi.nlm.nih.gov/pubmed/10653443', '1092541': 'http://www.ncbi.nlm.nih.gov/pubmed/1092541', '8278374': 'http://www.ncbi.nlm.nih.gov/pubmed/8278374', '8023962': 'http://www.ncbi.nlm.nih.gov/pubmed/8023962', '9654208': 'http://www.ncbi.nlm.nih.gov/pubmed/9654208', '7490094': 'http://www.ncbi.nlm.nih.gov/pubmed/7490094', '7762608': 'http://www.ncbi.nlm.nih.gov/pubmed/7762608', '9813171': 'http://www.ncbi.nlm.nih.gov/pubmed/9813171', '7499195': 'http://www.ncbi.nlm.nih.gov/pubmed/7499195', '16423824': 'http://www.ncbi.nlm.nih.gov/pubmed/16423824', '19520916': 'http://www.ncbi.nlm.nih.gov/pubmed/19520916', '12107247': 'http://www.ncbi.nlm.nih.gov/pubmed/12107247', '9260930': 'http://www.ncbi.nlm.nih.gov/pubmed/9260930', '12089365': 'http://www.ncbi.nlm.nih.gov/pubmed/12089365', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8812482': 'http://www.ncbi.nlm.nih.gov/pubmed/8812482', '12112667': 'http://www.ncbi.nlm.nih.gov/pubmed/12112667', '8528245': 'http://www.ncbi.nlm.nih.gov/pubmed/8528245', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '25318757': 'http://www.ncbi.nlm.nih.gov/pubmed/25318757', '11473623': 'http://www.ncbi.nlm.nih.gov/pubmed/11473623', '24855283': 'http://www.ncbi.nlm.nih.gov/pubmed/24855283'}",2022-01-17 22:20:12.308185
Amino Sugar Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000045,http://smpdb.ca/view/SMP0000045/download?type=full_vector_image,httpsmpdbcaviewSMP0000045.svg,Metabolic,"{'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'N-Acetylglucosamine': 'https://go.drugbank.com/drugs/DB00141', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Glucosamine': 'https://go.drugbank.com/drugs/DB01296', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Phosphoenolpyruvate': 'https://go.drugbank.com/drugs/DB01819', ""Cytidine-5'-Triphosphate"": 'https://go.drugbank.com/drugs/DB02431', 'Acetic acid': 'https://go.drugbank.com/drugs/DB03166', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Amino Sugar Metabolism,"Amino sugars are sugar molecules containing an amine group. They make up many polysaccharides including, glycosaminoglycans or mucopolysaccharides.",Homo sapiens,2013-08-01,2019-08-13,Metabolic Pathway,"{'16748597': 'http://www.ncbi.nlm.nih.gov/pubmed/16748597', '7592832': 'http://www.ncbi.nlm.nih.gov/pubmed/7592832', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '1833974': 'http://www.ncbi.nlm.nih.gov/pubmed/1833974', '2933746': 'http://www.ncbi.nlm.nih.gov/pubmed/2933746', '2952641': 'http://www.ncbi.nlm.nih.gov/pubmed/2952641', '10824116': 'http://www.ncbi.nlm.nih.gov/pubmed/10824116', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '10810093': 'http://www.ncbi.nlm.nih.gov/pubmed/10810093', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '21269460': 'http://www.ncbi.nlm.nih.gov/pubmed/21269460', '9438414': 'http://www.ncbi.nlm.nih.gov/pubmed/9438414', '9714720': 'http://www.ncbi.nlm.nih.gov/pubmed/9714720', '7584044': 'http://www.ncbi.nlm.nih.gov/pubmed/7584044', '1460020': 'http://www.ncbi.nlm.nih.gov/pubmed/1460020', '24931394': 'http://www.ncbi.nlm.nih.gov/pubmed/24931394', '24589341': 'http://www.ncbi.nlm.nih.gov/pubmed/24589341', '24698316': 'http://www.ncbi.nlm.nih.gov/pubmed/24698316'}",2022-01-17 22:20:37.246652
Aminocaproic Acid Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000286,http://smpdb.ca/view/SMP0000286/download?type=full_vector_image,httpsmpdbcaviewSMP0000286.svg,Drug action,"{'Aminocaproic acid': 'https://go.drugbank.com/drugs/DB00513', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Aminocaproic Acid Action Pathway,"Aminocaproic acid, brand name Amicar, is a derivate of lysine and is an antifibrinolytic drug. Antifibrinolytics drugs are commonly used during major surgery to prevent significant blood loss. These drugs reversibly blocks the binding sites on plasminogen. This blockade inhibits plasminogen binding to fibrin and the conversion of plasminogen to plasmin. These prevents fibrin degradation and maintains the stability of fibrin clots.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '26596393': 'http://www.ncbi.nlm.nih.gov/pubmed/26596393', '28457777': 'http://www.ncbi.nlm.nih.gov/pubmed/28457777', '2318848': 'http://www.ncbi.nlm.nih.gov/pubmed/2318848', '3030813': 'http://www.ncbi.nlm.nih.gov/pubmed/3030813', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:20:52.757866
Amiodarone Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000665,http://smpdb.ca/view/SMP0000665/download?type=full_vector_image,httpsmpdbcaviewSMP0000665.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Amiodarone': 'https://go.drugbank.com/drugs/DB01118', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Amiodarone Action Pathway,"Amiodarone, trade name Cordarone and Nexterone, is an antianginal and a class III antiarrhythmic drug prescribed to treat irregular heart rhythms. The drug inhibits Na,K-activated myocardial adenosine triphosphatase, calcium and potassium channels and beta adrenergic receptors causing an increase in ventricular and atrial muscle action duration. This inhibition causes prevents repolarization of the cells causing heart rate to decrease and vascular resistance to decrease. Amiodarone exerts its antiarrhythmic effect by prolonging the duration of myocardial cell-action potentials. Amiodarone is unique to other class III antiarrhythmic drugs due to its effect on beta adrenergic receptors, calcium channels and sodium channels.",Homo sapiens,2014-04-20,2019-09-12,Drug Action Pathway,"{'793369': 'http://www.ncbi.nlm.nih.gov/pubmed/793369', '5485142': 'http://www.ncbi.nlm.nih.gov/pubmed/5485142', '6613843': 'http://www.ncbi.nlm.nih.gov/pubmed/6613843', '14020244': 'http://www.ncbi.nlm.nih.gov/pubmed/14020244', '14026835': 'http://www.ncbi.nlm.nih.gov/pubmed/14026835', '6349912': 'http://www.ncbi.nlm.nih.gov/pubmed/6349912', '29489285': 'http://www.ncbi.nlm.nih.gov/pubmed/29489285', '17286271': 'http://www.ncbi.nlm.nih.gov/pubmed/17286271', '23271651': 'http://www.ncbi.nlm.nih.gov/pubmed/23271651', '28740830': 'http://www.ncbi.nlm.nih.gov/pubmed/28740830', '24733689': 'http://www.ncbi.nlm.nih.gov/pubmed/24733689', '11034315': 'http://www.ncbi.nlm.nih.gov/pubmed/11034315', '11101505': 'http://www.ncbi.nlm.nih.gov/pubmed/11101505', '15368194': 'http://www.ncbi.nlm.nih.gov/pubmed/15368194', '19412172': 'http://www.ncbi.nlm.nih.gov/pubmed/19412172', '8159766': 'http://www.ncbi.nlm.nih.gov/pubmed/8159766', '9600240': 'http://www.ncbi.nlm.nih.gov/pubmed/9600240', '14525949': 'http://www.ncbi.nlm.nih.gov/pubmed/14525949', '16541075': 'http://www.ncbi.nlm.nih.gov/pubmed/16541075', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '1316612': 'http://www.ncbi.nlm.nih.gov/pubmed/1316612', '8392192': 'http://www.ncbi.nlm.nih.gov/pubmed/8392192', '7959794': 'http://www.ncbi.nlm.nih.gov/pubmed/7959794', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '3093273': 'http://www.ncbi.nlm.nih.gov/pubmed/3093273', '3131741': 'http://www.ncbi.nlm.nih.gov/pubmed/3131741', '3127824': 'http://www.ncbi.nlm.nih.gov/pubmed/3127824', '2843813': 'http://www.ncbi.nlm.nih.gov/pubmed/2843813', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:21:19.759066
Amlodipine Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000376,http://smpdb.ca/view/SMP0000376/download?type=full_vector_image,httpsmpdbcaviewSMP0000376.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Amlodipine': 'https://go.drugbank.com/drugs/DB00381', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Amlodipine Action Pathway,"Amlodipine, trade name Norvasc, is a dihydropyridine calcium channel blocker (CCB) prescribed to treat hypertension and exertion-related angina. The drug acts directly on vascular smooth muscle to cause peripheral vasodilation. Amlodipine inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle to bind calmodulin. Inhibition of calcium bound calmodulin prevents activation of myosin light chain kinase and phosphorylation of the regulatory light chain subunit of myosin, this inhibits an integral part of muscle contractions. The net effect is decreased contractility of arterial smooth muscle and increased vasodilation resulting in a decrease in blood pressure. Amlodipine has arterial selectivity due to alternative splicing of the channel and has little effect on cardiac muscle.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'26341621': 'http://www.ncbi.nlm.nih.gov/pubmed/26341621 ', '28598202': 'http://www.ncbi.nlm.nih.gov/pubmed/28598202', '1316612': 'http://www.ncbi.nlm.nih.gov/pubmed/1316612', '8392192': 'http://www.ncbi.nlm.nih.gov/pubmed/8392192', '7959794': 'http://www.ncbi.nlm.nih.gov/pubmed/7959794', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:21:42.255678
Ammonia Recycling,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000009,http://smpdb.ca/view/SMP0000009/download?type=full_vector_image,httpsmpdbcaviewSMP0000009.svg,Metabolic,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Histidine': 'https://go.drugbank.com/drugs/DB00117', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Serine': 'https://go.drugbank.com/drugs/DB00133', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Asparagine': 'https://go.drugbank.com/drugs/DB00174', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'trans-urocanic acid': 'https://go.drugbank.com/drugs/DB01971', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Ammonia Recycling,Ammonia can be rerouted from the urine and recycled into the body for use in nitrogen metabolism. Glutamate and glutamine play an important role in this process. There are many other processes that act to recycle ammonia. asparaginase recycles ammonia from asparagine. Glycine cleavage system generates ammonia from glycine. Histidine ammonia lyase forms ammonia from histidine. Serine dehydratase also produces ammonia by cleaving serine.,Homo sapiens,2013-08-01,2019-08-13,Metabolic Pathway,"{'4585091': 'http://www.ncbi.nlm.nih.gov/pubmed/4585091', '17189259': 'http://www.ncbi.nlm.nih.gov/pubmed/17189259', '20132793': 'http://www.ncbi.nlm.nih.gov/pubmed/20132793', '2674117': 'http://www.ncbi.nlm.nih.gov/pubmed/2674117', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '18342636': 'http://www.ncbi.nlm.nih.gov/pubmed/18342636', '11984834': 'http://www.ncbi.nlm.nih.gov/pubmed/11984834', '14654938': 'http://www.ncbi.nlm.nih.gov/pubmed/14654938', '2886907': 'http://www.ncbi.nlm.nih.gov/pubmed/2886907', '2565875': 'http://www.ncbi.nlm.nih.gov/pubmed/2565875', '8530107': 'http://www.ncbi.nlm.nih.gov/pubmed/8530107', '7916645': 'http://www.ncbi.nlm.nih.gov/pubmed/7916645', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '11181995': 'http://www.ncbi.nlm.nih.gov/pubmed/11181995', '3426581': 'http://www.ncbi.nlm.nih.gov/pubmed/3426581', '3377777': 'http://www.ncbi.nlm.nih.gov/pubmed/3377777', '3399399': 'http://www.ncbi.nlm.nih.gov/pubmed/3399399', '10620514': 'http://www.ncbi.nlm.nih.gov/pubmed/10620514', '12444921': 'http://www.ncbi.nlm.nih.gov/pubmed/12444921', '7916605': 'http://www.ncbi.nlm.nih.gov/pubmed/7916605', '8188235': 'http://www.ncbi.nlm.nih.gov/pubmed/8188235'}",2022-01-17 22:22:03.685957
Androgen and Estrogen Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000068,http://smpdb.ca/view/SMP0000068/download?type=full_vector_image,httpsmpdbcaviewSMP0000068.svg,Metabolic,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Testosterone': 'https://go.drugbank.com/drugs/DB00624', 'Estrone': 'https://go.drugbank.com/drugs/DB00655', 'Estradiol': 'https://go.drugbank.com/drugs/DB00783', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Androstenedione': 'https://go.drugbank.com/drugs/DB01536', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Estrone sulfate': 'https://go.drugbank.com/drugs/DB04574', 'Prasterone sulfate': 'https://go.drugbank.com/drugs/DB05804', '5beta-dihydrotestosterone': 'https://go.drugbank.com/drugs/DB07447'}",Androgen and Estrogen Metabolism,"This pathway describes the inactivation and catabolism of male (androgen) and female (estrogen) hormones. Many steroid hormones are transformed by sulfatases, dehydrogenases and glucuronide transferases to enhance their solubility and to facilitate their elimination. Inactivation means to convert an active compound into an inactive compound. Peripheral inactivation, which is inactivation caused by outside enzymes such as liver enzymes for example, is needed to maintain a steady-state level of plasma. This means that if either of these hormones are to be “chemical signals”, their half-life in the bloodstream has to be limited so that a variation in secretion rate can be emulated in the plasma. A large part of inactivation/catabolism occurs in the liver, although a little bit of catabolic activity does happen in the kidneys. Inactive androgens and estrogens are mostly eliminated in the urine. For this to happen, androgen and estrogen need to be converted to compounds that are less hydrophobic so that they are more soluble at higher concentrations. In this pathway, the conversion to a hydrophilic compound is an oxidation of a 17b-hydroxyl group. These hormones are needed for sexual development in both males and females.",Homo sapiens,2013-08-01,2019-08-27,Metabolic Pathway,"{'': 'http://www.ncbi.nlm.nih.gov/pubmed/ 8613010', '8185618': 'http://www.ncbi.nlm.nih.gov/pubmed/8185618', '8530066': 'http://www.ncbi.nlm.nih.gov/pubmed/8530066', '7779757': 'http://www.ncbi.nlm.nih.gov/pubmed/7779757', '2973313': 'http://www.ncbi.nlm.nih.gov/pubmed/2973313', '3390233': 'http://www.ncbi.nlm.nih.gov/pubmed/3390233', '2848247': 'http://www.ncbi.nlm.nih.gov/pubmed/2848247', '2846351': 'http://www.ncbi.nlm.nih.gov/pubmed/2846351', '2779584': 'http://www.ncbi.nlm.nih.gov/pubmed/2779584', '2330005': 'http://www.ncbi.nlm.nih.gov/pubmed/2330005', '9675083': 'http://www.ncbi.nlm.nih.gov/pubmed/9675083', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:22:28.199601
Androstenedione Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0030406,http://smpdb.ca/view/SMP0030406/download?type=full_vector_image,httpsmpdbcaviewSMP0030406.svg,Metabolic,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Testosterone': 'https://go.drugbank.com/drugs/DB00624', 'Estrone': 'https://go.drugbank.com/drugs/DB00655', 'Androstenedione': 'https://go.drugbank.com/drugs/DB01536', 'Androstanedione': 'https://go.drugbank.com/drugs/DB01561', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Aetiocholanolone': 'https://go.drugbank.com/drugs/DB02854', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Etiocholanedione': 'https://go.drugbank.com/drugs/DB07375'}",Androstenedione Metabolism,"Androstenedione is an endogenous weak androgen steroid hormone that is a precursor of testosterone and other androgens, as well as of estrogens like estrone . Its metabolism occurs primarily in the endoplasmic reticulum (membrane-associated enzymes are coloured dark green in the image). Conversion of androstenedione to testosterone requires the enzyme testosterone 17-beta-dehydrogenase 3. Conversion of androstenedione to estrone involves three successive reactions catalyzed by the enzyme aromatase (cytochrome P450 19A1). Androstenedione can also be converted into etiocholanolone glucuronide, androsterone glucuronide, and adrenosterone. The three-reaction subpathway to synthesize etiocholanolone glucuronide begins with the enzyme 3-oxo-5-beta-steroid 4-dehydrogenase catalyzing the conversion of androstenedione to etiocholanedione. This is followed by the conversion of etiocholanedione to etiocholanolone which is catalyzed by aldo-keto reductase family 1 member C4. Lastly, the large membrane-associated multimer UDP-glucuronosyltransferase 1-1 catalyzes the conversion of etiocholanolone to etiocholanolone glucuronide. The three-reaction subpathway to synthesize androsterone glucuronide begins with the conversion of androstenedione to androstanedione via 3-oxo-5-alpha-steroid 4-dehydrogenase 1. Anstrostanedione is then converted into androsterone via aldo-keto reductase family 1 member C4. The last reaction to form androsterone glucuronide is catalyzed by the large multimer UDP-glucuronosyltransferase 1-1. The two-reaction subpathway to synthesize adrenosterone begins in the mitochondrial inner membrane where androstenedione is first converted into 11beta-hydroxyandrost-4-ene-3,17-dione by the enzyme cytochrome P450 11B1. Following transport to the endoplasmic reticulum, 11beta-hydroxyandrost-4-ene-3,17-dione is converted into adrenosterone via corticosteroid 11-beta-dehydrogenase isozyme 1.",Homo sapiens,2017-07-20,2019-09-06,Metabolic Pathway,"{'27702664': 'http://www.ncbi.nlm.nih.gov/pubmed/27702664', '26545797': 'http://www.ncbi.nlm.nih.gov/pubmed/26545797', '2339109': 'http://www.ncbi.nlm.nih.gov/pubmed/2339109', '1686016': 'http://www.ncbi.nlm.nih.gov/pubmed/1686016', '10931946': 'http://www.ncbi.nlm.nih.gov/pubmed/10931946', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '29706351': 'http://www.ncbi.nlm.nih.gov/pubmed/29706351', '11147971': 'http://www.ncbi.nlm.nih.gov/pubmed/11147971', '10827079': 'http://www.ncbi.nlm.nih.gov/pubmed/10827079', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '16541075': 'http://www.ncbi.nlm.nih.gov/pubmed/16541075', '21269460': 'http://www.ncbi.nlm.nih.gov/pubmed/21269460', '2840249': 'http://www.ncbi.nlm.nih.gov/pubmed/2840249', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '11157797': 'http://www.ncbi.nlm.nih.gov/pubmed/11157797', '15616553': 'http://www.ncbi.nlm.nih.gov/pubmed/15616553', '2549034': 'http://www.ncbi.nlm.nih.gov/pubmed/2549034', '2002068': 'http://www.ncbi.nlm.nih.gov/pubmed/2002068', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '7590364': 'http://www.ncbi.nlm.nih.gov/pubmed/7590364', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621'}",2022-01-17 22:22:51.519670
Angiotensin Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000587,http://smpdb.ca/view/SMP0000587/download?type=full_vector_image,httpsmpdbcaviewSMP0000587.svg,Physiological,{'Zinc': 'https://go.drugbank.com/drugs/DB01593'},Angiotensin Metabolism,"Angiotensin is a peptide hormone that is part of the renin-angiotensin system responsible for regulating fluid homeostasis and blood pressure.   It is involved in various means to increase the body's blood pressure, hence why it is a target for many pharmceutical drugs that treat hypertension and cardiac conditions.  Angiotensin II, the primary agent to inducing an increased blood pressure, is formed in the general circulation when it is cleaved from a string of precursor molecules.  Angiotensinogen is converted into angiotensin I with the action of renin, an enzyme secreted from the kidneys.  From there, angiotensin I is converted to the central agent, angiotensin II, with the aid of angiotensin-converting enzyme (ACE) so that it is available in the circulation to act on numerous areas in the body when an increase in blood pressure is needed.  

Angiotensin II can act directly on receptors on the smooth muscle cells of the tunica media layer in the blood vessel to induce vasoconstriction and a subsequent increase in blood pressure.  However, it can also influence the blood pressure by aiding in an increase of the circulating blood volume.  Angiotensin II can cause vasopressin to be released, which is a hormone involved in regulating water reabsorption.  Vasopressin is created in the supraoptic nuclei and they travel down the neurosecretory neuron axon to be stored in the neuronal terminals within the posterior pituitary.  Angiotensin II in the cerebral circulation triggers the release of vasopressin from the posterior pituitary gland.  From there, vasopressin enters into the systemic blood circulation where it eventually binds to receptors on epithelial cells in the collecting ducts of the nephron.   The binding of vasopressin causes vesicles of epithelial cells to fuse with the plasma membrane.  These vesicles contain aquaporin II, which are proteins that act as water channels once they have bound to the plasma membrane.  As a result, the permeability of the collecting duct changes to allow for water reabsorption back into the blood circulation.  Angiotensin II also has an effect on the hypothalmus, where it helps trigger a thirst sensation.  Correspondingly, there will be an increase in oral water uptake into the body, which would then also increase the circulating blood volume.  Another way that angiotensin II helps increase the blood volume is by acting on the adrenal cortex to stimulate aldosterone release, which is responsible for increasing sodium reuptake in the distal convoluted tubules and the collecting duct.  It is formed when angiotensin II binds to receptors on the zona glomerulosa cells in the adrenal cortex, which triggers a signaling cascade that eventually activates the steroidogenic acute regulatory (StAR) protein to allow for cholesterol uptake into the mitochondria.  Cholesterol then undergoes a series of reactions during steroidogenesis, which is a process that ultimately leads to the synthesis of aldosterone from cholesterol. Aldosterone then goes to act on the distal convoluted tubule and the collecting duct to make them more permeable to sodium to allow for its reuptake.  Water subsequently follows sodium back into the system, which would therefore increase the circulating blood volume.  In addition, potassium and hydrogen are also being excreted into the urine simultaneously to maintain the electrolyte balance.",Homo sapiens,2013-09-04,2019-08-13,Physiological Pathway,"{'29190205': 'http://www.ncbi.nlm.nih.gov/pubmed/29190205', '23886814': 'http://www.ncbi.nlm.nih.gov/pubmed/23886814', '24459521': 'http://www.ncbi.nlm.nih.gov/pubmed/24459521', '19427492': 'http://www.ncbi.nlm.nih.gov/pubmed/19427492', '6324167': 'http://www.ncbi.nlm.nih.gov/pubmed/6324167', '3530608': 'http://www.ncbi.nlm.nih.gov/pubmed/3530608', '6391881': 'http://www.ncbi.nlm.nih.gov/pubmed/6391881', '6089875': 'http://www.ncbi.nlm.nih.gov/pubmed/6089875', '2924688': 'http://www.ncbi.nlm.nih.gov/pubmed/2924688', '1692023': 'http://www.ncbi.nlm.nih.gov/pubmed/1692023', '1649623': 'http://www.ncbi.nlm.nih.gov/pubmed/1649623', '10769174': 'http://www.ncbi.nlm.nih.gov/pubmed/10769174', '10969042': 'http://www.ncbi.nlm.nih.gov/pubmed/10969042'}",2022-01-17 22:23:19.569196
Anileridine Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000674,http://smpdb.ca/view/SMP0000674/download?type=full_vector_image,httpsmpdbcaviewSMP0000674.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Anileridine': 'https://go.drugbank.com/drugs/DB00913', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Anileridine Action Pathway,"Anileridine (also known as Leritine) is analgesic that can bind to mu-type opioid receptor to activate associated G-protein in the sensory neurons of central nervous system (CNS), which will reduce the level of intracellular cAMP by inhibiting adenylate cyclase. The binding of anileridine will eventually lead to reduced pain because of decreased nerve conduction and release of neurotransmitter. Hyperpolarization of neuron is caused by inactivation of calcium channels and activation of potassium channels via facilitated by G-protein.",Homo sapiens,2014-04-21,2019-08-16,Drug Action Pathway,"{'6310562': 'http://www.ncbi.nlm.nih.gov/pubmed/6310562', '2841104': 'http://www.ncbi.nlm.nih.gov/pubmed/2841104', '7905839': 'http://www.ncbi.nlm.nih.gov/pubmed/7905839', '7957926': 'http://www.ncbi.nlm.nih.gov/pubmed/7957926', '7891175': 'http://www.ncbi.nlm.nih.gov/pubmed/7891175', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:23:39.628381
Anistreplase Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000281,http://smpdb.ca/view/SMP0000281/download?type=full_vector_image,httpsmpdbcaviewSMP0000281.svg,Drug action,"{'Anistreplase': 'https://go.drugbank.com/drugs/DB00029', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Anistreplase Action Pathway,"Anistreplase, trade name Eminase, is a thrombolytic drug prescribed to treat acute myocardial infarction. The drug is an acylated streptokinase-plasminogen complex. The acylation of the drug renders it temporarily inactive, protecting it from plasmin inhibitors. Anistreplase is deacylated following injection, activating the drug to increase thrombolysis by increasing plasminogen's conversion to plasmin. Plasmin breaks down the fibrin of the thrombus to break up the clot and release arterial blockages. Anistreplase has been shown to be very effective when administered shortly after onset of chest pain. Compared to other thrombolytic drugs, Anistreplase has a longer plasma half-life. It also advantageous as it can be given as a single bolus intravenous injection.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '2198125': 'http://www.ncbi.nlm.nih.gov/pubmed/2198125', '2193460': 'http://www.ncbi.nlm.nih.gov/pubmed/2193460', '2318848': 'http://www.ncbi.nlm.nih.gov/pubmed/2318848', '3030813': 'http://www.ncbi.nlm.nih.gov/pubmed/3030813', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:23:55.421786
Antazoline H1-Antihistamine Action,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0057584,http://smpdb.ca/view/SMP0057584/download?type=full_vector_image,httpsmpdbcaviewSMP0057584.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Antazoline': 'https://go.drugbank.com/drugs/DB08799'}",Antazoline H1-Antihistamine Action,"Antazoline is a first-generation ethylenediamine H1-antihistamine.  H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-15,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:24:11.784991
Antipyrine Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000692,http://smpdb.ca/view/SMP0000692/download?type=full_vector_image,httpsmpdbcaviewSMP0000692.svg,Drug action,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Antipyrine': 'https://go.drugbank.com/drugs/DB01435', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Antipyrine Action Pathway,"Antipyrine (also named Fenazone or Phenazone) is often used for testing the effect of other drugs on drug-metabolizing enzymes in the liver. Antipyrine can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of antipyrine.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'1164824': 'http://www.ncbi.nlm.nih.gov/pubmed/1164824', '6849732': 'http://www.ncbi.nlm.nih.gov/pubmed/6849732', '8181472': 'http://www.ncbi.nlm.nih.gov/pubmed/8181472', '8473346': 'http://www.ncbi.nlm.nih.gov/pubmed/8473346', '1380156': 'http://www.ncbi.nlm.nih.gov/pubmed/1380156', '2512924': 'http://www.ncbi.nlm.nih.gov/pubmed/2512924', '1907252': 'http://www.ncbi.nlm.nih.gov/pubmed/1907252', '1734857': 'http://www.ncbi.nlm.nih.gov/pubmed/1734857', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973'}",2022-01-17 22:24:41.798106
Antrafenine Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000693,http://smpdb.ca/view/SMP0000693/download?type=full_vector_image,httpsmpdbcaviewSMP0000693.svg,Drug action,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Antrafenine': 'https://go.drugbank.com/drugs/DB01419', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Antrafenine Action Pathway,"Antrafenine (also named Stakane) acts as an anti-inflammatory and analgesic drug. It is not widely used as it has largely been replaced by newer drugs. Antrafenine can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of antrafenine.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'6342700': 'http://www.ncbi.nlm.nih.gov/pubmed/6342700', '6849732': 'http://www.ncbi.nlm.nih.gov/pubmed/6849732', '2512924': 'http://www.ncbi.nlm.nih.gov/pubmed/2512924', '1907252': 'http://www.ncbi.nlm.nih.gov/pubmed/1907252', '1734857': 'http://www.ncbi.nlm.nih.gov/pubmed/1734857', '8181472': 'http://www.ncbi.nlm.nih.gov/pubmed/8181472', '8473346': 'http://www.ncbi.nlm.nih.gov/pubmed/8473346', '1380156': 'http://www.ncbi.nlm.nih.gov/pubmed/1380156', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973'}",2022-01-17 22:25:11.531004
Apoptotic DNA Fragmentation and Tissue Homeostasis,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0063772,http://smpdb.ca/view/SMP0063772/download?type=full_vector_image,httpsmpdbcaviewSMP0063772.svg,Signaling,{'Zinc': 'https://go.drugbank.com/drugs/DB01593'},Apoptotic DNA Fragmentation and Tissue Homeostasis,"Apoptotic endonucleases degrade chromosomal DNA during programmed cell death. ICAD and CAD exist in the nucleus in normal cells and is a major endonuclease in apoptosis. Its activation is normally caspase dependent. EndoG resides in mitochondria in normal cells and travels to the nucleus, where it fragments chromosomal DNA upon activation of apoptosis. Once released from the mitochondrial intermembrane space, EndoG activity is caspase independent.",Homo sapiens,2018-06-13,2019-08-16,Protein Pathway,"{'11849972': 'http://www.ncbi.nlm.nih.gov/pubmed/11849972', '7789991': 'http://www.ncbi.nlm.nih.gov/pubmed/7789991', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '1979741': 'http://www.ncbi.nlm.nih.gov/pubmed/1979741', '15890648': 'http://www.ncbi.nlm.nih.gov/pubmed/15890648', '8619816': 'http://www.ncbi.nlm.nih.gov/pubmed/8619816', '9795238': 'http://www.ncbi.nlm.nih.gov/pubmed/9795238', '2845399': 'http://www.ncbi.nlm.nih.gov/pubmed/2845399', '8393377': 'http://www.ncbi.nlm.nih.gov/pubmed/8393377', '14532127': 'http://www.ncbi.nlm.nih.gov/pubmed/14532127', '15014079': 'http://www.ncbi.nlm.nih.gov/pubmed/15014079', '16855214': 'http://www.ncbi.nlm.nih.gov/pubmed/16855214', '12925773': 'http://www.ncbi.nlm.nih.gov/pubmed/12925773', '19965638': 'http://www.ncbi.nlm.nih.gov/pubmed/19965638', '1754403': 'http://www.ncbi.nlm.nih.gov/pubmed/1754403', '9108473': 'http://www.ncbi.nlm.nih.gov/pubmed/9108473', '10409614': 'http://www.ncbi.nlm.nih.gov/pubmed/10409614', '10497265': 'http://www.ncbi.nlm.nih.gov/pubmed/10497265'}",2022-01-17 22:25:24.837343
Apparent Mineralocorticoid Excess Syndrome,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000717,http://smpdb.ca/view/SMP0000717/download?type=full_vector_image,httpsmpdbcaviewSMP0000717.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Progesterone': 'https://go.drugbank.com/drugs/DB00396', 'Hydrocortisone': 'https://go.drugbank.com/drugs/DB00741', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Corticosterone': 'https://go.drugbank.com/drugs/DB04652', '20-hydroxycholesterol': 'https://go.drugbank.com/drugs/DB04704'}",Apparent Mineralocorticoid Excess Syndrome,"Apparent mineralocorticoid excess (AME), also known as cortisol 11-beta-ketoreductase deficiency, is an extremely rare inborn error of metabolism (IEM) and autosomal recessive disorder of the steroidogenesis pathway. It is caused by a mutation in the HSD11B2 gene which encodes for corticosteroid 11-beta-dehydrogenase isozyme 2, and enzyme that converts cortisol to cortisone in the cell. Without this enzyme being functional, an accumulation of tetrahydrocortisol builds up, while tetrahydrocortisone levels dissipate. AME is characterized excessive thirst and urination, and along with this, symptoms include low levels of aldosterone, failure to thrive and hypertension. Treatment with corticoids that suppress the secretion of cortisol within the body can affect blood pressure and aldosterone levels. Antihypertensive agents are also effective. It is estimated that AME affects less than 1 in 1,000,000 individuals, with less than 100 reported cases as of 2019.",Homo sapiens,2014-06-23,2019-09-10,Disease Pathway,"{'15761540': 'http://www.ncbi.nlm.nih.gov/pubmed/15761540', '10074485': 'http://www.ncbi.nlm.nih.gov/pubmed/10074485', '3061784': 'http://www.ncbi.nlm.nih.gov/pubmed/3061784', '13092959': 'http://www.ncbi.nlm.nih.gov/pubmed/13092959', '23770321': 'http://www.ncbi.nlm.nih.gov/pubmed/23770321', '1654556': 'http://www.ncbi.nlm.nih.gov/pubmed/1654556', '1944596': 'http://www.ncbi.nlm.nih.gov/pubmed/1944596', '29162485': 'http://www.ncbi.nlm.nih.gov/pubmed/29162485', '9226548': 'http://www.ncbi.nlm.nih.gov/pubmed/9226548', '6282849': 'http://www.ncbi.nlm.nih.gov/pubmed/6282849', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '1594605': 'http://www.ncbi.nlm.nih.gov/pubmed/1594605', '1346492': 'http://www.ncbi.nlm.nih.gov/pubmed/1346492', '8439335': 'http://www.ncbi.nlm.nih.gov/pubmed/8439335', '7903314': 'http://www.ncbi.nlm.nih.gov/pubmed/7903314', '2022736': 'http://www.ncbi.nlm.nih.gov/pubmed/2022736', '9302260': 'http://www.ncbi.nlm.nih.gov/pubmed/9302260', '1885595': 'http://www.ncbi.nlm.nih.gov/pubmed/1885595', '12414862': 'http://www.ncbi.nlm.nih.gov/pubmed/12414862', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3486422': 'http://www.ncbi.nlm.nih.gov/pubmed/3486422', '3487786': 'http://www.ncbi.nlm.nih.gov/pubmed/3487786', '3038528': 'http://www.ncbi.nlm.nih.gov/pubmed/3038528', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:25:54.888679
Aprotinin Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000288,http://smpdb.ca/view/SMP0000288/download?type=full_vector_image,httpsmpdbcaviewSMP0000288.svg,Drug action,"{'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Aprotinin': 'https://go.drugbank.com/drugs/DB06692'}",Aprotinin Action Pathway,"Aprotinin, trade name Trasylol is a bovine serine protease inhibitor of trypsin, chymotrypsin, kallikrein and plasmin. Aprotinin is administered prophylactically to patients undergoing surgery with a high risk of bleeding to block fibrinolysis and prevent the breakdown of blood clots. The inhibition of kallikrein inhibits factor XIIa production to reduce fibrinolysis and coagulation. Inhibition of plasmin slows down fibrinolysis. Hypersensitivity reactions may occur after repeat exposure to Aprotinin.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '9673304': 'http://www.ncbi.nlm.nih.gov/pubmed/9673304', '2318848': 'http://www.ncbi.nlm.nih.gov/pubmed/2318848', '3030813': 'http://www.ncbi.nlm.nih.gov/pubmed/3030813', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:26:10.234254
Arachidonic Acid Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000075,http://smpdb.ca/view/SMP0000075/download?type=full_vector_image,httpsmpdbcaviewSMP0000075.svg,Metabolic,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Arachidonic Acid Metabolism,"This pathway describes the production and subsequent metabolism of arachidonic acid, an omega-6 fatty acid. In resting cells arachidonic acid is present in the phospholipids (especially phosphatidylethanolamine and phosphatidylcholine) of membranes of the body’s cells, and is particularly abundant in the brain. Typically a receptor-dependent event, requiring a transducing G protein, initiates phospholipid hydrolysis and releases the fatty acid into the intracellular medium. Three enzymes mediate this deacylation reaction including phospholipase A2 (PLA2), phospholipase C (PLC), and phospholipase D (PLD). Once released, free arachidonate has three possible fates: 1) reincorporation into phospholipids, 2) diffusion outside the cell, and 3) metabolism. Arachidonate metabolism is carried out by three distinct enzyme classes: cyclooxygenases, lipoxygenases, and cytochrome P450’s. Specifically, the enzymes cyclooxygenase and peroxidase lead to the synthesis of prostaglandin H2, which in turn is used to produce the prostaglandins, prostacyclin, and thromboxanes. The enzyme 5-lipoxygenase leads to 5-HPETE, which in turn is used to produce the leukotrienes, hydroxyeicosatetraenoic acids (HETEs) and lipoxins. Some arachidonic acid is converted into midchain HETEs, omega-chain HETEs, dihydroxyeicosatrienoic acids (DHETs), and epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase hydroxylase activity. Several products of these pathways act within neurons to modulate the activities of ion channels, protein kinases, ion pumps, and neurotransmitter uptake systems, affecting processes such as cellular proliferation, inflammation, and hemostasis. The newly formed eicosanoids may also exit the cell of origin and bind to G-protein-coupled receptors present on nearby neurons or glial cells.",Homo sapiens,2013-08-01,2019-08-13,Metabolic Pathway,"{'12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '11165022': 'http://www.ncbi.nlm.nih.gov/pubmed/11165022', '14996743': 'http://www.ncbi.nlm.nih.gov/pubmed/14996743', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '1714723': 'http://www.ncbi.nlm.nih.gov/pubmed/1714723', '1730669': 'http://www.ncbi.nlm.nih.gov/pubmed/1730669', '7925341': 'http://www.ncbi.nlm.nih.gov/pubmed/7925341'}",2022-01-17 22:26:45.566021
Arbekacin Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000713,http://smpdb.ca/view/SMP0000713/download?type=full_vector_image,httpsmpdbcaviewSMP0000713.svg,Drug action,"{'Histidine': 'https://go.drugbank.com/drugs/DB00117', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Methionine': 'https://go.drugbank.com/drugs/DB00134', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'Threonine': 'https://go.drugbank.com/drugs/DB00156', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Proline': 'https://go.drugbank.com/drugs/DB00172', 'Asparagine': 'https://go.drugbank.com/drugs/DB00174', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', ""Cytidine-5'-Triphosphate"": 'https://go.drugbank.com/drugs/DB02431', 'Uridine monophosphate': 'https://go.drugbank.com/drugs/DB03685', 'D-Serine': 'https://go.drugbank.com/drugs/DB03929', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Arbekacin': 'https://go.drugbank.com/drugs/DB06696'}",Arbekacin Action Pathway,"Arbekacin, trade name Habekacin, is an aminoglycoside antibiotic derived from dibekacin that inhibits bacterial protein synthesis. Arbekacin is prescribed to patients with sepsis and pneumonia resulting from MRSA. Arbekacin binds the bacterial 50S and 30S ribosomal subunit proteins and prevents the formation of the initiation complex with messenger RNA. More specifically, Arbekacin binds four nucleotides of the 16S rRNA and a single amino acid of protein S12. This interferes with the decoding site in the vicinity of nucleotide 1400 in 16S rRNA of the 30S subunit. This region interacts with the wobble base of the anticodon of tRNA. This causes interference of the initiation complex, misreading of mRNA so that incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides, and the breakup of polysomes into nonfunctional monosomes. Arbekacin is effective at treating Gram-positive bacteria like Staphylococcus aureus and Staphylococcus epidermidis and Gram-negative bacteria such as Pseudomonas aeruginosa.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'25298740': 'http://www.ncbi.nlm.nih.gov/pubmed/25298740', '25801559': 'http://www.ncbi.nlm.nih.gov/pubmed/25801559'}",2022-01-17 22:27:07.735449
Arbutamine Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000664,http://smpdb.ca/view/SMP0000664/download?type=full_vector_image,httpsmpdbcaviewSMP0000664.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Arbutamine': 'https://go.drugbank.com/drugs/DB01102', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Arbutamine Action Pathway,"Arbutamine is a synthetic catecholamine used to initiate a cardiac stress response to mimic exercise to detect coronary artery disease. Arbutamine has nonselective beta and weak alpha-1-adrenergic activity which causes increased chronotropic activity (increase in heart rate) and inotropic activity (increase myocardial contractility). These effects mimic the cardiovascular effects of exercise. For patients with cardiovascular artery disease, arbutamine can induce myocardial ischemia. Arbutamine is delivered via a computer controlled closed-loop system. The infusion of arbutamine is based off the heart rate feedback. The system monitors heart rate and blood pressure throughout infusion with alarms for physiological changes or problems.",Homo sapiens,2014-04-19,2019-09-12,Drug Action Pathway,"{'11791807': 'http://www.ncbi.nlm.nih.gov/pubmed/11791807', '11175055': 'http://www.ncbi.nlm.nih.gov/pubmed/11175055', '7618620': 'http://www.ncbi.nlm.nih.gov/pubmed/7618620', '7594026': 'http://www.ncbi.nlm.nih.gov/pubmed/7594026', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:27:30.156586
Ardeparin Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000275,http://smpdb.ca/view/SMP0000275/download?type=full_vector_image,httpsmpdbcaviewSMP0000275.svg,Drug action,"{'Ardeparin': 'https://go.drugbank.com/drugs/DB00407', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Ardeparin Action Pathway,"Ardeparin, trade name Normiflo, is low molecular weight heparin with anticoagulant effects used to prevent thrombosis. Ardeparin binds and increases antithrombin III activity and inactivates thrombin, factor Xa and coagulation factors XIIa, XIa, plasmin and kallikrein to prevent clot formation. In addition, heparin cofactor II is bound by ardeparin to inhibit thrombin. Plasma proteins have a smaller affinity for low molecular weight heparins than unfractionated heparin. Low molecular weight heparins also don't undergo the rapid degradation of unfractionated heparins. These properties increase ardeparin's bioavailability and give a more predictable anticoagulant activity.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '10363865': 'http://www.ncbi.nlm.nih.gov/pubmed/10363865', '6298709': 'http://www.ncbi.nlm.nih.gov/pubmed/6298709', '6572945': 'http://www.ncbi.nlm.nih.gov/pubmed/6572945', '8476848': 'http://www.ncbi.nlm.nih.gov/pubmed/8476848', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:27:46.901378
Argatroban Action Pathway,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000276,http://smpdb.ca/view/SMP0000276/download?type=full_vector_image,httpsmpdbcaviewSMP0000276.svg,Drug action,"{'Argatroban': 'https://go.drugbank.com/drugs/DB00278', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Argatroban Action Pathway,"Argatroban is a synthetic derivate of L-arginine and a direct thrombin inhibitor anticoagulant prescribed to patients with heparin-induced thrombocytopenia. Direct thrombin inhibitors bind plasma and fibrin bound thrombin independently of co-factor antithrombin.The inhibition of thrombin reduces the stability of the clot and promotes clot break down. Argatroban does not effect serine proteases like, trypsin, factor Xa, plasmin, and kallikrein.  Argatroban is advantageous, particularly for renal failure patients, due to its short-half life and hepatic clearance.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '29206646': 'http://www.ncbi.nlm.nih.gov/pubmed/29206646 ', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:28:02.345934
Arginine and Proline Metabolism,https://go.drugbank.com/pathways?page=3,http://smpdb.ca/view/SMP0000020,http://smpdb.ca/view/SMP0000020/download?type=full_vector_image,httpsmpdbcaviewSMP0000020.svg,Metabolic,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Ornithine': 'https://go.drugbank.com/drugs/DB00129', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Creatine': 'https://go.drugbank.com/drugs/DB00148', 'Citrulline': 'https://go.drugbank.com/drugs/DB00155', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Proline': 'https://go.drugbank.com/drugs/DB00172', 'Sapropterin': 'https://go.drugbank.com/drugs/DB00360', 'Nitric Oxide': 'https://go.drugbank.com/drugs/DB00435', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Glycocyamine': 'https://go.drugbank.com/drugs/DB02751', '3,4-Dihydro-2h-Pyrrolium-5-Carboxylate': 'https://go.drugbank.com/drugs/DB02838', 'N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine': 'https://go.drugbank.com/drugs/DB03144', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Flavin mononucleotide': 'https://go.drugbank.com/drugs/DB03247', 'Urea': 'https://go.drugbank.com/drugs/DB03904', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', '4-Carboxy-4-Aminobutanal': 'https://go.drugbank.com/drugs/DB04388'}",Arginine and Proline Metabolism,"The arginine and proline metabolism pathway illustrates the biosynthesis and metabolism of several amino acids including arginine, ornithine, proline, citrulline, and glutamate in mammals. In adult mammals, the synthesis of arginine takes place primarily through the intestinal-renal axis (PMID: 19030957). In particular, the amino acid citrulline is first synthesized from several other amino acids (glutamine, glutamate, and proline) in the mitochondria of the intestinal enterocytes (PMID: 9806879). The mitochondrial synthesis of citrulline starts with the deamination of glutamine to glutamate via mitochondrial glutaminase. The resulting mitochondrial glutamate is converted into 1-pyrroline-5-carboxylate via pyrroline-5-carboxylate synthase (P5CS). Alternately, the 1-pyrroline-5-carboxylate can be generated from mitochondrial proline via proline oxidase (PO). Ornithine aminotransferase (OAT) then converts the mitochondrial 1-pyrroline-5-carboxylate into ornithine and the enzyme ornithine carbamoyltransferase (OCT -- using carbamoyl phosphate) converts the ornithine to citrulline (PMID: 19030957). After this, the mitochondrial citrulline is released from the small intestine enterocytes and into the bloodstream where it is taken up by the kidneys for arginine production. Once the citrulline enters the kidney cells, the cytosolic enzyme argininosuccinate synthetase (ASS) will combine citrulline with aspartic acid to generate argininosuccinic acid. After this step, the enzyme argininosuccinate lyase (ASL) will remove fumarate from argininosuccinic acid to generate arginine. The resulting arginine can either stay in the cytosol where it is converted to ornithine via arginase I (resulting in the production of urea) or it can be transported into the mitochondria where it is decomposed into ornithine and urea via arginase II.  The resulting mitochondrial ornithine can then be acted on by the enzyme ornithine amino transferase (OAT), which combines alpha-ketoglutarate with ornithine to produce glutamate and 1-pyrroline-5-carboxylate.  The mitochondrial enzyme pyrroline-5-carboxylate dehydrogenase (P5CD) acts on the resulting 1-pyrroline-5-carboxylate (using NADPH as a cofactor) to generate glutamate. Alternately, the mitochondrial 1-pyrroline-5-carboxylate can be exported into the kidney cell’s cytosol where the enzyme pyrroline-5-carboxylate reductase (P5CR) can convert it to proline. While citrulline-to-arginine production primarily occurs in the kidney, citrulline is readily converted into arginine in other cell types, including adipocytes, endothelial cells, myocytes, macrophages, and neurons.  Interestingly, chickens and cats cannot produce citrulline via glutamine/glutamate due to a lack of a functional pyrroline-5-carboxylate synthase (P5CS) in their enterocytes (PMID: 19030957).",Homo sapiens,2013-08-01,2019-08-30,Metabolic Pathway,"{'19030957': 'http://www.ncbi.nlm.nih.gov/pubmed/19030957', '9806879': 'http://www.ncbi.nlm.nih.gov/pubmed/9806879', '6194510': 'http://www.ncbi.nlm.nih.gov/pubmed/6194510', '6321498': 'http://www.ncbi.nlm.nih.gov/pubmed/6321498', '11941481': 'http://www.ncbi.nlm.nih.gov/pubmed/11941481', '3391281': 'http://www.ncbi.nlm.nih.gov/pubmed/3391281', '3463959': 'http://www.ncbi.nlm.nih.gov/pubmed/3463959', '2644168': 'http://www.ncbi.nlm.nih.gov/pubmed/2644168', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '3426581': 'http://www.ncbi.nlm.nih.gov/pubmed/3426581', '3377777': 'http://www.ncbi.nlm.nih.gov/pubmed/3377777', '3399399': 'http://www.ncbi.nlm.nih.gov/pubmed/3399399', '3456579': 'http://www.ncbi.nlm.nih.gov/pubmed/3456579', '3816496': 'http://www.ncbi.nlm.nih.gov/pubmed/3816496', '2507357': 'http://www.ncbi.nlm.nih.gov/pubmed/2507357', '8621661': 'http://www.ncbi.nlm.nih.gov/pubmed/8621661', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '15662599': 'http://www.ncbi.nlm.nih.gov/pubmed/15662599', '11891283': 'http://www.ncbi.nlm.nih.gov/pubmed/11891283', '9385373': 'http://www.ncbi.nlm.nih.gov/pubmed/9385373', '25865492': 'http://www.ncbi.nlm.nih.gov/pubmed/25865492'}",2022-01-17 22:28:31.080245
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency),https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000362,http://smpdb.ca/view/SMP0000362/download?type=full_vector_image,httpsmpdbcaviewSMP0000362.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Ornithine': 'https://go.drugbank.com/drugs/DB00129', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'Creatine': 'https://go.drugbank.com/drugs/DB00148', 'Citrulline': 'https://go.drugbank.com/drugs/DB00155', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Proline': 'https://go.drugbank.com/drugs/DB00172', 'Sapropterin': 'https://go.drugbank.com/drugs/DB00360', 'Nitric Oxide': 'https://go.drugbank.com/drugs/DB00435', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Glycocyamine': 'https://go.drugbank.com/drugs/DB02751', '3,4-Dihydro-2h-Pyrrolium-5-Carboxylate': 'https://go.drugbank.com/drugs/DB02838', 'N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine': 'https://go.drugbank.com/drugs/DB03144', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Flavin mononucleotide': 'https://go.drugbank.com/drugs/DB03247', 'Urea': 'https://go.drugbank.com/drugs/DB03904', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', '4-Carboxy-4-Aminobutanal': 'https://go.drugbank.com/drugs/DB04388'}",Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency),"Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency, Creatine Deficiency Syndrome, Creatine Deficiency due to AGAT Deficiency, GATM Deficiency) is caused by mutation in the GATM gene, which codes for L-arginine:glycine amidinotransferase, which catalyzes the reaction between L-arginine and glycine, transferring an amidino group from L-arginine to glycine, producing L-ornithine and guanidinoacetate, a precursor of creatine. A defect in this enzyme causes a decrease in concentration of creatine and guanidinoacetate in plasma and urine. Symptoms include mental and motor retardation, seizures, and delayed or abnormal speech development.",Homo sapiens,2013-08-01,2019-08-30,Disease Pathway,"{'16769397': 'http://www.ncbi.nlm.nih.gov/pubmed/16769397', '11555793': 'http://www.ncbi.nlm.nih.gov/pubmed/11555793', '12701824': 'http://www.ncbi.nlm.nih.gov/pubmed/12701824', '20625172': 'http://www.ncbi.nlm.nih.gov/pubmed/20625172', '28148286': 'http://www.ncbi.nlm.nih.gov/pubmed/28148286', '19030957': 'http://www.ncbi.nlm.nih.gov/pubmed/19030957', '9806879': 'http://www.ncbi.nlm.nih.gov/pubmed/9806879', '6194510': 'http://www.ncbi.nlm.nih.gov/pubmed/6194510', '6321498': 'http://www.ncbi.nlm.nih.gov/pubmed/6321498', '11941481': 'http://www.ncbi.nlm.nih.gov/pubmed/11941481', '3391281': 'http://www.ncbi.nlm.nih.gov/pubmed/3391281', '3463959': 'http://www.ncbi.nlm.nih.gov/pubmed/3463959', '2644168': 'http://www.ncbi.nlm.nih.gov/pubmed/2644168', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '3426581': 'http://www.ncbi.nlm.nih.gov/pubmed/3426581', '3377777': 'http://www.ncbi.nlm.nih.gov/pubmed/3377777', '3399399': 'http://www.ncbi.nlm.nih.gov/pubmed/3399399', '3456579': 'http://www.ncbi.nlm.nih.gov/pubmed/3456579', '3816496': 'http://www.ncbi.nlm.nih.gov/pubmed/3816496', '2507357': 'http://www.ncbi.nlm.nih.gov/pubmed/2507357', '8621661': 'http://www.ncbi.nlm.nih.gov/pubmed/8621661', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '15662599': 'http://www.ncbi.nlm.nih.gov/pubmed/15662599', '11891283': 'http://www.ncbi.nlm.nih.gov/pubmed/11891283', '9385373': 'http://www.ncbi.nlm.nih.gov/pubmed/9385373', '25865492': 'http://www.ncbi.nlm.nih.gov/pubmed/25865492'}",2022-01-17 22:29:01.110336
Argininemia,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000357,http://smpdb.ca/view/SMP0000357/download?type=full_vector_image,httpsmpdbcaviewSMP0000357.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Ornithine': 'https://go.drugbank.com/drugs/DB00129', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Citrulline': 'https://go.drugbank.com/drugs/DB00155', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Urea': 'https://go.drugbank.com/drugs/DB03904', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299'}",Argininemia,"Argininemia is caused by a mutation in the gene ARG, encoding liver arginase, which hydrolyses arginine to urea and ornithine in the last step of the urea cycle. A defect in liver arginase causes accumulation of ammonia in blood; arginine, creatine, guanidinoacetate, and homoarginine in plasma; urea nitrogen in serum; arginine and homoarginine in spinal fluid; and arginiosuccinate orotic acid, and uracil in urine. Symptoms include ataxia, cerebral atrophy, chorea, jaundice, and seizures.",Homo sapiens,2013-08-19,2019-08-16,Disease Pathway,"{'839368': 'http://www.ncbi.nlm.nih.gov/pubmed/839368', '2291040': 'http://www.ncbi.nlm.nih.gov/pubmed/2291040', '9762606': 'http://www.ncbi.nlm.nih.gov/pubmed/9762606', '9378897': 'http://www.ncbi.nlm.nih.gov/pubmed/9378897', '12052859': 'http://www.ncbi.nlm.nih.gov/pubmed/12052859', '8702519': 'http://www.ncbi.nlm.nih.gov/pubmed/8702519', '10051606': 'http://www.ncbi.nlm.nih.gov/pubmed/10051606', '10196349': 'http://www.ncbi.nlm.nih.gov/pubmed/10196349', '7896285': 'http://www.ncbi.nlm.nih.gov/pubmed/7896285', '26041762': 'http://www.ncbi.nlm.nih.gov/pubmed/26041762', '8101838': 'http://www.ncbi.nlm.nih.gov/pubmed/8101838', '9119391': 'http://www.ncbi.nlm.nih.gov/pubmed/9119391', '1931970': 'http://www.ncbi.nlm.nih.gov/pubmed/1931970', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10620514': 'http://www.ncbi.nlm.nih.gov/pubmed/10620514', '12444921': 'http://www.ncbi.nlm.nih.gov/pubmed/12444921', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3426581': 'http://www.ncbi.nlm.nih.gov/pubmed/3426581', '3377777': 'http://www.ncbi.nlm.nih.gov/pubmed/3377777', '3399399': 'http://www.ncbi.nlm.nih.gov/pubmed/3399399', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '3207426': 'http://www.ncbi.nlm.nih.gov/pubmed/3207426', '15616553': 'http://www.ncbi.nlm.nih.gov/pubmed/15616553', '6372096': 'http://www.ncbi.nlm.nih.gov/pubmed/6372096', '2836378': 'http://www.ncbi.nlm.nih.gov/pubmed/2836378', '19242930': 'http://www.ncbi.nlm.nih.gov/pubmed/19242930', '10369256': 'http://www.ncbi.nlm.nih.gov/pubmed/10369256', '12807890': 'http://www.ncbi.nlm.nih.gov/pubmed/12807890'}",2022-01-17 22:29:28.032112
Argininosuccinic Aciduria,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000003,http://smpdb.ca/view/SMP0000003/download?type=full_vector_image,httpsmpdbcaviewSMP0000003.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Ornithine': 'https://go.drugbank.com/drugs/DB00129', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Citrulline': 'https://go.drugbank.com/drugs/DB00155', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Urea': 'https://go.drugbank.com/drugs/DB03904', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299'}",Argininosuccinic Aciduria,"Argininosuccinic Aciduria, (Argininosuccinase Deficiency, Argininosuccinate Lyase Deficiency, ASL Deficiency) is an autosomal recessive disorder caused by a mutation in the ASL gene which codes for argininosuccinate lyase. It results in accumulation of citrulline, arginosuccinic acid, L-arginine, and L-glutamic acid in plasma as well as ammonia in blood. Infants are lethargic and unwilling to eat. They may develop seizures, coma, and failure to thrive as toxic ammonia accumulates.",Homo sapiens,2013-08-19,2019-08-16,Disease Pathway,"{'12408190': 'http://www.ncbi.nlm.nih.gov/pubmed/12408190', '6015896': 'http://www.ncbi.nlm.nih.gov/pubmed/6015896', '12384776': 'http://www.ncbi.nlm.nih.gov/pubmed/12384776', '23306800': 'http://www.ncbi.nlm.nih.gov/pubmed/23306800', '12559843': 'http://www.ncbi.nlm.nih.gov/pubmed/12559843', '8702519': 'http://www.ncbi.nlm.nih.gov/pubmed/8702519', '10051606': 'http://www.ncbi.nlm.nih.gov/pubmed/10051606', '10196349': 'http://www.ncbi.nlm.nih.gov/pubmed/10196349', '7896285': 'http://www.ncbi.nlm.nih.gov/pubmed/7896285', '26041762': 'http://www.ncbi.nlm.nih.gov/pubmed/26041762', '8101838': 'http://www.ncbi.nlm.nih.gov/pubmed/8101838', '9119391': 'http://www.ncbi.nlm.nih.gov/pubmed/9119391', '1931970': 'http://www.ncbi.nlm.nih.gov/pubmed/1931970', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10620514': 'http://www.ncbi.nlm.nih.gov/pubmed/10620514', '12444921': 'http://www.ncbi.nlm.nih.gov/pubmed/12444921', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3426581': 'http://www.ncbi.nlm.nih.gov/pubmed/3426581', '3377777': 'http://www.ncbi.nlm.nih.gov/pubmed/3377777', '3399399': 'http://www.ncbi.nlm.nih.gov/pubmed/3399399', '9711878': 'http://www.ncbi.nlm.nih.gov/pubmed/9711878', '12955727': 'http://www.ncbi.nlm.nih.gov/pubmed/12955727', '11474210': 'http://www.ncbi.nlm.nih.gov/pubmed/11474210', '3207426': 'http://www.ncbi.nlm.nih.gov/pubmed/3207426', '15616553': 'http://www.ncbi.nlm.nih.gov/pubmed/15616553', '6372096': 'http://www.ncbi.nlm.nih.gov/pubmed/6372096', '2836378': 'http://www.ncbi.nlm.nih.gov/pubmed/2836378', '19242930': 'http://www.ncbi.nlm.nih.gov/pubmed/19242930', '10369256': 'http://www.ncbi.nlm.nih.gov/pubmed/10369256', '12807890': 'http://www.ncbi.nlm.nih.gov/pubmed/12807890'}",2022-01-17 22:29:49.365377
Aromatase Deficiency,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000565,http://smpdb.ca/view/SMP0000565/download?type=full_vector_image,httpsmpdbcaviewSMP0000565.svg,Disease,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Testosterone': 'https://go.drugbank.com/drugs/DB00624', 'Estrone': 'https://go.drugbank.com/drugs/DB00655', 'Estradiol': 'https://go.drugbank.com/drugs/DB00783', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Androstenedione': 'https://go.drugbank.com/drugs/DB01536', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Estrone sulfate': 'https://go.drugbank.com/drugs/DB04574', 'Prasterone sulfate': 'https://go.drugbank.com/drugs/DB05804', '5beta-dihydrotestosterone': 'https://go.drugbank.com/drugs/DB07447'}",Aromatase Deficiency,"Aromatase deficiency is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of mutations in the CYP19A1 gene. The CYP19A1 gene encodes for the enzyme aromatase. Aromatase converts androgens to estrogens which is vital for bone growth and regulation of blood sugar levels. Symptoms of decrease in estrogen and increase androgens such as testosterone can cause impaired female sexual development, unusual bone growth, insulin resistance, and a variety of other symptoms. It presents with virilization of pregnant mothers during the antenatal period, and virilization of female fetuses at birth. Treatments include lifelong hormone therapy. There have been about 20 reported cases of Aromatase Deficiency worldwide.",Homo sapiens,2013-08-29,2019-09-13,Disease Pathway,"{'23329769': 'http://www.ncbi.nlm.nih.gov/pubmed/23329769', '8772541': 'http://www.ncbi.nlm.nih.gov/pubmed/8772541', '14623532': 'http://www.ncbi.nlm.nih.gov/pubmed/14623532', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 8613010', '8185618': 'http://www.ncbi.nlm.nih.gov/pubmed/8185618', '8530066': 'http://www.ncbi.nlm.nih.gov/pubmed/8530066', '7779757': 'http://www.ncbi.nlm.nih.gov/pubmed/7779757', '2973313': 'http://www.ncbi.nlm.nih.gov/pubmed/2973313', '3390233': 'http://www.ncbi.nlm.nih.gov/pubmed/3390233', '2848247': 'http://www.ncbi.nlm.nih.gov/pubmed/2848247', '2846351': 'http://www.ncbi.nlm.nih.gov/pubmed/2846351', '2779584': 'http://www.ncbi.nlm.nih.gov/pubmed/2779584', '2330005': 'http://www.ncbi.nlm.nih.gov/pubmed/2330005', '9675083': 'http://www.ncbi.nlm.nih.gov/pubmed/9675083', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '3025870': 'http://www.ncbi.nlm.nih.gov/pubmed/3025870', '3500022': 'http://www.ncbi.nlm.nih.gov/pubmed/3500022', '3274893': 'http://www.ncbi.nlm.nih.gov/pubmed/3274893'}",2022-01-17 22:30:13.628787
Aromatic L-Aminoacid Decarboxylase Deficiency,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000170,http://smpdb.ca/view/SMP0000170/download?type=full_vector_image,httpsmpdbcaviewSMP0000170.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Ascorbic acid': 'https://go.drugbank.com/drugs/DB00126', 'Tyrosine': 'https://go.drugbank.com/drugs/DB00135', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Epinephrine': 'https://go.drugbank.com/drugs/DB00668', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Levodopa': 'https://go.drugbank.com/drugs/DB01235', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Pyrroloquinoline Quinone': 'https://go.drugbank.com/drugs/DB03205'}",Aromatic L-Aminoacid Decarboxylase Deficiency,"Aromatic L-Aminoacid Decarboxylase Deficiency (DOPA decarboxylase; DDC) is an autosomal recessive disease caused by a mutation in the DDC gene which codes for aromatic-L-aminoacid decarboxylase. A deficiency in this enzyme results in accumulation of 3-methoxytyrosine, 5-hydroxy-L-tryptophan, and L-Dopa in plasma, spinal fluid, and urine; 3-methoxytyramine and dopamine in urine. It also results in decreased concentrations of homovanillic acid, S-adenosylmethionine, and 5-hydroxytryptophol in spinal fluid; and epinephrine, norepinephrine in plasma. Symptoms include temperature instability, hypotonia, mental and motor retardation, and cerebral atrophy.",Homo sapiens,2013-08-01,2019-09-12,Disease Pathway,"{'17240182': 'http://www.ncbi.nlm.nih.gov/pubmed/17240182', '12891654': 'http://www.ncbi.nlm.nih.gov/pubmed/12891654', '15079002': 'http://www.ncbi.nlm.nih.gov/pubmed/15079002', '20505134': 'http://www.ncbi.nlm.nih.gov/pubmed/20505134', '23275025': 'http://www.ncbi.nlm.nih.gov/pubmed/23275025', '24925409': 'http://www.ncbi.nlm.nih.gov/pubmed/24925409', '2887169': 'http://www.ncbi.nlm.nih.gov/pubmed/2887169', '2882428': 'http://www.ncbi.nlm.nih.gov/pubmed/2882428', '2888085': 'http://www.ncbi.nlm.nih.gov/pubmed/2888085', '2590185': 'http://www.ncbi.nlm.nih.gov/pubmed/2590185', '1612608': 'http://www.ncbi.nlm.nih.gov/pubmed/1612608', '1540578': 'http://www.ncbi.nlm.nih.gov/pubmed/1540578', '10490716': 'http://www.ncbi.nlm.nih.gov/pubmed/10490716', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '3443096': 'http://www.ncbi.nlm.nih.gov/pubmed/3443096', '3372503': 'http://www.ncbi.nlm.nih.gov/pubmed/3372503', '2835776': 'http://www.ncbi.nlm.nih.gov/pubmed/2835776', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334'}",2022-01-17 22:30:36.851408
Artemether Metabolism Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000651,http://smpdb.ca/view/SMP0000651/download?type=full_vector_image,httpsmpdbcaviewSMP0000651.svg,Drug metabolism,"{'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Formaldehyde': 'https://go.drugbank.com/drugs/DB03843', 'Artemether': 'https://go.drugbank.com/drugs/DB06697'}",Artemether Metabolism Pathway,"Artemether is a semisynthetic derivative of artemisinin, a phytoconstituent that acts as a short-acting antimalarial agent and is used to treat uncomplicated Plasmodium falciparum malaria. Artemisinin derivatives kill parasites more rapidly than conventional antimalarial drugs, and are active against both the sexual and asexual stages of the parasite cycle. However due to their short half-life (and to prevent resistance development) artemisinin compounds are often combined with long-acting antimalarial drugs. Artemeter is administered orally and as an oil-based intramuscular injection. The antimalarial activity of artemether and other artemisinin derivatives is a result of the peroxide bridge found in the active metabolite dihydroartemisinin. Dihydroartemisinin is formed from the rapid demethylation of artmether via CYP3A4 and CYP3A5. It then undergoes glucuronidation catalyzed by the UDP-glucuronosyltransferases UGT1A9 and UGT2B7 into inactive metabolites that are eliminated in the bile.",Homo sapiens,2013-09-18,2019-08-16,Drug Metabolism Pathway,"{'11069212': 'http://www.ncbi.nlm.nih.gov/pubmed/11069212', '18193915': 'http://www.ncbi.nlm.nih.gov/pubmed/18193915', '1910331': 'http://www.ncbi.nlm.nih.gov/pubmed/1910331', '11434514': 'http://www.ncbi.nlm.nih.gov/pubmed/11434514', '15815621': 'http://www.ncbi.nlm.nih.gov/pubmed/15815621', '2159463': 'http://www.ncbi.nlm.nih.gov/pubmed/2159463', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '11181494': 'http://www.ncbi.nlm.nih.gov/pubmed/11181494', '3460094': 'http://www.ncbi.nlm.nih.gov/pubmed/3460094', '3267210': 'http://www.ncbi.nlm.nih.gov/pubmed/3267210', '8569713': 'http://www.ncbi.nlm.nih.gov/pubmed/8569713', '7811260': 'http://www.ncbi.nlm.nih.gov/pubmed/7811260', '2732228': 'http://www.ncbi.nlm.nih.gov/pubmed/2732228'}",2022-01-17 22:30:53.695485
Aspartate Metabolism,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000067,http://smpdb.ca/view/SMP0000067/download?type=full_vector_image,httpsmpdbcaviewSMP0000067.svg,Metabolic,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Arginine': 'https://go.drugbank.com/drugs/DB00125', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Citrulline': 'https://go.drugbank.com/drugs/DB00155', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Asparagine': 'https://go.drugbank.com/drugs/DB00174', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'D-Aspartic Acid': 'https://go.drugbank.com/drugs/DB02655', 'beta-Alanine': 'https://go.drugbank.com/drugs/DB03107', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Acetic acid': 'https://go.drugbank.com/drugs/DB03166', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'N-Carbamoylaspartic acid': 'https://go.drugbank.com/drugs/DB04252', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299'}",Aspartate Metabolism,"Aspartate is synthesized by transamination of oxaloacetate by aspartate aminotransferase or amino acid oxidase. Aspartyl-tRNA synthetase can then couple aspartate to aspartyl tRNA for protein synthesis. The aspartate content in human proteins is about 7%. Asparagine synthase can convert aspartate to the polar amino acid asparagine. Aspartate is also a precursor for cellular signaling compounds such as, N-acetyl-aspartate, beta-alanine, adenylsuccinate, arginino-succinate and N-carbamoylaspartate. Aspartate is also a metabolite in the urea cycle and involved in gluconeogenesis. Additionally, aspartate carries the reducing equivalents in the mitochondrial malate-aspartate shuttle, which utilizes the ready interconversion of aspartate and oxaloacetate. The conjugate base of L-aspartic acid, aspartate, also acts as an excitatory neurotransmitter in the brain which activates NMDA receptors.",Homo sapiens,2013-08-01,2020-03-17,Metabolic Pathway,"{'26232224': 'http://www.ncbi.nlm.nih.gov/pubmed/26232224', '25628363': 'http://www.ncbi.nlm.nih.gov/pubmed/25628363', '24121043': 'http://www.ncbi.nlm.nih.gov/pubmed/24121043', '26146495': 'http://www.ncbi.nlm.nih.gov/pubmed/26146495', '7721088': 'http://www.ncbi.nlm.nih.gov/pubmed/7721088', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8088791': 'http://www.ncbi.nlm.nih.gov/pubmed/8088791', '1549570': 'http://www.ncbi.nlm.nih.gov/pubmed/1549570', '1683462': 'http://www.ncbi.nlm.nih.gov/pubmed/1683462', '2886907': 'http://www.ncbi.nlm.nih.gov/pubmed/2886907', '2565875': 'http://www.ncbi.nlm.nih.gov/pubmed/2565875', '9421509': 'http://www.ncbi.nlm.nih.gov/pubmed/9421509', '9801298': 'http://www.ncbi.nlm.nih.gov/pubmed/9801298', '6194510': 'http://www.ncbi.nlm.nih.gov/pubmed/6194510', '6321498': 'http://www.ncbi.nlm.nih.gov/pubmed/6321498', '11941481': 'http://www.ncbi.nlm.nih.gov/pubmed/11941481', '23643384': 'http://www.ncbi.nlm.nih.gov/pubmed/23643384', '2674137': 'http://www.ncbi.nlm.nih.gov/pubmed/2674137', '8404037': 'http://www.ncbi.nlm.nih.gov/pubmed/8404037', '10888601': 'http://www.ncbi.nlm.nih.gov/pubmed/10888601', '10090474': 'http://www.ncbi.nlm.nih.gov/pubmed/10090474', '9163533': 'http://www.ncbi.nlm.nih.gov/pubmed/9163533', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '12205125': 'http://www.ncbi.nlm.nih.gov/pubmed/12205125', '28101991': 'http://www.ncbi.nlm.nih.gov/pubmed/28101991', '8252036': 'http://www.ncbi.nlm.nih.gov/pubmed/8252036'}",2022-01-17 22:31:16.143758
Astemizole H1-Antihistamine Action,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0059897,http://smpdb.ca/view/SMP0059897/download?type=full_vector_image,httpsmpdbcaviewSMP0059897.svg,Drug action,"{'Astemizole': 'https://go.drugbank.com/drugs/DB00637', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Astemizole H1-Antihistamine Action,"Astemizole is a second-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:31:32.442138
Atenolol Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000298,http://smpdb.ca/view/SMP0000298/download?type=full_vector_image,httpsmpdbcaviewSMP0000298.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Atenolol': 'https://go.drugbank.com/drugs/DB00335', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Atenolol Action Pathway,"Atenolol, trade name Tenormin, is a beta blocker prescribed to treat hypertension. Atenolol is a selective beta-1-adrenoceptor antagonist targeting the heart and vascular smooth muscle to inhibit sympathetic activity. Binding of atenolol inhibits the G protein signalling cascade and reduces heart rate, blood pressure, cardiac output and reflex orthostatic hypotension. Beta blockers were once the first line therapy for hypertension, however, current recommendations favour calcium channel blockers and angiotensin converting enzyme inhibitors.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'15530629': 'http://www.ncbi.nlm.nih.gov/pubmed/15530629', '1720383': 'http://www.ncbi.nlm.nih.gov/pubmed/1720383', '24687542': 'http://www.ncbi.nlm.nih.gov/pubmed/24687542', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:31:55.293023
Atorvastatin Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000131,http://smpdb.ca/view/SMP0000131/download?type=full_vector_image,httpsmpdbcaviewSMP0000131.svg,Drug action,"{'Cholecalciferol': 'https://go.drugbank.com/drugs/DB00169', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Dimethylallyl Diphosphate': 'https://go.drugbank.com/drugs/DB01785', 'Formic acid': 'https://go.drugbank.com/drugs/DB01942', 'Geranyl Diphosphate': 'https://go.drugbank.com/drugs/DB02552', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Palmitic Acid': 'https://go.drugbank.com/drugs/DB03796', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'ISOPENTENYL PYROPHOSPHATE': 'https://go.drugbank.com/drugs/DB04714', 'Farnesyl diphosphate': 'https://go.drugbank.com/drugs/DB07780'}",Atorvastatin Action Pathway,"Statins are a class of medications that lower lipid levels and are administered to reduce illness and mortality in people who are at high risk of cardiovascular disease. Atorvastatin (trade name: Lipitor) is a well-tolerated orally-administered synthetic statin that reduces levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and very-low-density lipoprotein (VLDL)-cholesterol. It also increases levels of high-density lipoprotein (HDL)-cholesterol. Atorvastatin's efficacy is greater than other statins in reducing total cholesterol and LDL-cholesterol levels. This is theorized to be the result of a prolonged duration of HMG-CoA reductase inhibition. Reported side effects of atorvastatin include constipation, flatulence, dyspepsia (indigestion), abdominal pain, headache, and myalgia (muscle pain). The primary therapeutic mechanism of action of statins is the inhibition of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase in hepatocytes. HMG-CoA reductase catalyzes the conversion of HMG-CoA into mevalonic acid, a precursor for cholesterol biosynthesis. Statins bind reversibly to the active site of HMG-CoA reductase and the subsequent structural change in the enzyme effectively disables it. Due to the resulting decrease in intracellular sterol levels, the ER membrane protein INSIG no longer binds to SREBP cleavage-activating protein (SCAP) which is, itself, bound to the transcription factor sterol regulatory element-binding protein (SREBP). Freed from INSIG, SCAP escorts SREBP to the Golgi apparatus from the ER as cargo in COPII vesicles. At the Golgi membrane, two proteases, S1P and S2P, sequentially cleave the SCAP-SREBP complex, releasing the mature form of SREBP into the cytoplasm. SREBP then translocates to the nucleus where it is actively transported into the nucleoplasm by binding directly to importin beta in the absence of importin alpha. SREBP binds to the sterol regulatory element (SRE) present in the promoter region of genes involved in cholesterol uptake and cholesterol synthesis, including the gene encoding low-density lipoprotein (LDL) receptor (LDL-R). As a result, LDL-R gene transcription increases which then leads to an increased synthesis of the LDL-R protein. LDL-R localizes to the endoplasmic reticulum for transport and exocytosis to the cell surface. The elevated amount of LDL-R results in the binding of more circulating free LDL cholesterol and subsequent internalization via endocytosis. Lysosomal degradation of the internalized LDL cholesterol elevates cellular cholesterol levels to maintain homeostasis.",Homo sapiens,2020-06-10,2020-06-29,Drug Action Pathway,"{'23859617': 'http://www.ncbi.nlm.nih.gov/pubmed/23859617', '12202038': 'http://www.ncbi.nlm.nih.gov/pubmed/12202038', '24478315': 'http://www.ncbi.nlm.nih.gov/pubmed/24478315', '10397761': 'http://www.ncbi.nlm.nih.gov/pubmed/10397761', '24799396': 'http://www.ncbi.nlm.nih.gov/pubmed/24799396', '11693468': 'http://www.ncbi.nlm.nih.gov/pubmed/11693468', '10570913': 'http://www.ncbi.nlm.nih.gov/pubmed/10570913', '10570919': 'http://www.ncbi.nlm.nih.gov/pubmed/10570919', '8724849': 'http://www.ncbi.nlm.nih.gov/pubmed/8724849', '10944850': 'http://www.ncbi.nlm.nih.gov/pubmed/10944850', '7788527': 'http://www.ncbi.nlm.nih.gov/pubmed/7788527', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '7615630': 'http://www.ncbi.nlm.nih.gov/pubmed/7615630', '7627554': 'http://www.ncbi.nlm.nih.gov/pubmed/7627554', '6091915': 'http://www.ncbi.nlm.nih.gov/pubmed/6091915', '2988123': 'http://www.ncbi.nlm.nih.gov/pubmed/2988123', '10358072': 'http://www.ncbi.nlm.nih.gov/pubmed/10358072', '10601278': 'http://www.ncbi.nlm.nih.gov/pubmed/10601278', '10644574': 'http://www.ncbi.nlm.nih.gov/pubmed/10644574'}",2022-01-17 22:32:13.361802
Azatadine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0059865,http://smpdb.ca/view/SMP0059865/download?type=full_vector_image,httpsmpdbcaviewSMP0059865.svg,Drug action,"{'Azatadine': 'https://go.drugbank.com/drugs/DB00719', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Azatadine H1-Antihistamine Action,"Azatadine is a first-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:32:29.547010
Azathioprine Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000427,http://smpdb.ca/view/SMP0000427/download?type=full_vector_image,httpsmpdbcaviewSMP0000427.svg,Drug action,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenine': 'https://go.drugbank.com/drugs/DB00173', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Azathioprine': 'https://go.drugbank.com/drugs/DB00993', 'Mercaptopurine': 'https://go.drugbank.com/drugs/DB01033', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'AICA ribonucleotide': 'https://go.drugbank.com/drugs/DB01700', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', 'Xanthine': 'https://go.drugbank.com/drugs/DB02134', 'Guanine': 'https://go.drugbank.com/drugs/DB02377', 'Cyclic adenosine monophosphate': 'https://go.drugbank.com/drugs/DB02527', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Guanosine': 'https://go.drugbank.com/drugs/DB02857', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Hypoxanthine': 'https://go.drugbank.com/drugs/DB04076', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Maleic acid': 'https://go.drugbank.com/drugs/DB04299', 'Inosine': 'https://go.drugbank.com/drugs/DB04335', ""2'-Deoxyguanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB04457'}",Azathioprine Action Pathway,"Azathioprine is a purine antimetabolite prodrug that exerts cytotoxic effects via three mechanisms: via incorporation of thiodeoxyguanosine triphosphate into DNA and thioguanosine triphosphate into RNA, inhibition of de novo synthesis of purine nucleotides, and inhibition of Ras-related C3 botulinum toxin substrate 1, which induces apoptosis of activated T cells. Azathioprine is first converted _in vivo_ to mercaptopurine in the liver. Mercaptopurine then travels through the bloodstream and is transported into cells via nucleoside transporters.  Mercaptopurine is converted to thioguanosince diphosphate through a series of metabolic reactions that produces the metabolic intermediates, thioinosine 5’-monophosphate, thioxanthine monophosphate, and thioguanosine monophosphate. Thioguanosine diphosphate is then converted via a thiodeoxyguanosine diphosphate intermediate to thiodeoxyguanosine triphosphate, which is incorporated into DNA. Thioguanosine diphosphate is also converted to thioguanosine triphosphate which is incorporated into RNA. The thioguanosine triphosphate metabolite also inhibits Ras-related C3 botulinum toxin substrate 1, a plasma membrane-associated small GTPase that regulates cellular processes, inducing apoptosis in activated T cells. Finally, de novo synthesis of purine nucleotides is inhibited by the methyl-thioinosine 5’-monophosphate metabolite, which inhibits amidophosphoribosyl-transferase, the enzyme that catalyzes one of the first steps in this pathway.",Homo sapiens,2013-08-22,2019-08-30,Drug Action Pathway,"{'18506437': 'http://www.ncbi.nlm.nih.gov/pubmed/18506437', '18685564': 'http://www.ncbi.nlm.nih.gov/pubmed/18685564', '6300847': 'http://www.ncbi.nlm.nih.gov/pubmed/6300847', '2341149': 'http://www.ncbi.nlm.nih.gov/pubmed/2341149', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '11875050': 'http://www.ncbi.nlm.nih.gov/pubmed/11875050', '16384941': 'http://www.ncbi.nlm.nih.gov/pubmed/16384941', '1969416': 'http://www.ncbi.nlm.nih.gov/pubmed/1969416', '11110714': 'http://www.ncbi.nlm.nih.gov/pubmed/11110714', '8089153': 'http://www.ncbi.nlm.nih.gov/pubmed/8089153', '9453052': 'http://www.ncbi.nlm.nih.gov/pubmed/9453052', '8644731': 'http://www.ncbi.nlm.nih.gov/pubmed/8644731', '8316220': 'http://www.ncbi.nlm.nih.gov/pubmed/8316220', '2674130': 'http://www.ncbi.nlm.nih.gov/pubmed/2674130', '2108320': 'http://www.ncbi.nlm.nih.gov/pubmed/2108320', '11062023': 'http://www.ncbi.nlm.nih.gov/pubmed/11062023', '17022944': 'http://www.ncbi.nlm.nih.gov/pubmed/17022944', '23857892': 'http://www.ncbi.nlm.nih.gov/pubmed/23857892', '8248161': 'http://www.ncbi.nlm.nih.gov/pubmed/8248161', '8380692': 'http://www.ncbi.nlm.nih.gov/pubmed/8380692', '8106516': 'http://www.ncbi.nlm.nih.gov/pubmed/8106516', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '30441833': 'http://www.ncbi.nlm.nih.gov/pubmed/30441833 ', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 22531138'}",2022-01-17 22:33:12.597644
Azathioprine Metabolism Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000645,http://smpdb.ca/view/SMP0000645/download?type=full_vector_image,httpsmpdbcaviewSMP0000645.svg,Drug metabolism,"{'Azathioprine': 'https://go.drugbank.com/drugs/DB00993', 'Mercaptopurine': 'https://go.drugbank.com/drugs/DB01033'}",Azathioprine Metabolism Pathway,"Azathioprine is a purine antimetabolite prodrug that exerts cytotoxic effects via three mechanisms: via incorporation of thiodeoxyguanosine triphosphate into DNA and thioguanosine triphosphate into RNA, inhibition of de novo synthesis of purine nucleotides, and inhibition of Ras-related C3 botulinum toxin substrate 1, which induces apoptosis of activated T cells. Azathioprine is first converted _in vivo_ to mercaptopurine in the liver. Mercaptopurine then travels through the bloodstream and is transported into cells via nucleoside transporters.  Mercaptopurine is converted to thioguanosince diphosphate through a series of metabolic reactions that produces the metabolic intermediates, thioinosine 5’-monophosphate, thioxanthine monophosphate, and thioguanosine monophosphate. Thioguanosine diphosphate is then converted via a thiodeoxyguanosine diphosphate intermediate to thiodeoxyguanosine triphosphate, which is incorporated into DNA. Thioguanosine diphosphate is also converted to thioguanosine triphosphate which is incorporated into RNA. The thioguanosine triphosphate metabolite also inhibits Ras-related C3 botulinum toxin substrate 1, a plasma membrane-associated small GTPase that regulates cellular processes, inducing apoptosis in activated T cells. Finally, de novo synthesis of purine nucleotides is inhibited by the methyl-thioinosine 5’-monophosphate metabolite, which inhibits amidophosphoribosyl-transferase, the enzyme that catalyzes one of the first steps in this pathway.",Homo sapiens,2013-09-18,2019-08-16,Drug Metabolism Pathway,"{'18506437': 'http://www.ncbi.nlm.nih.gov/pubmed/18506437', '18685564': 'http://www.ncbi.nlm.nih.gov/pubmed/18685564'}",2022-01-17 22:33:25.346046
Azelastine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0060741,http://smpdb.ca/view/SMP0060741/download?type=full_vector_image,httpsmpdbcaviewSMP0060741.svg,Drug action,"{'Azelastine': 'https://go.drugbank.com/drugs/DB00972', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Azelastine H1-Antihistamine Action,"Azelastine is a second-generation H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-20,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:33:42.179727
Azithromycin Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000247,http://smpdb.ca/view/SMP0000247/download?type=full_vector_image,httpsmpdbcaviewSMP0000247.svg,Drug action,"{'Histidine': 'https://go.drugbank.com/drugs/DB00117', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Methionine': 'https://go.drugbank.com/drugs/DB00134', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'Threonine': 'https://go.drugbank.com/drugs/DB00156', 'Alanine': 'https://go.drugbank.com/drugs/DB00160', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Proline': 'https://go.drugbank.com/drugs/DB00172', 'Asparagine': 'https://go.drugbank.com/drugs/DB00174', 'Azithromycin': 'https://go.drugbank.com/drugs/DB00207', ""Guanosine-5'-Monophosphate"": 'https://go.drugbank.com/drugs/DB01972', ""Cytidine-5'-Triphosphate"": 'https://go.drugbank.com/drugs/DB02431', 'Uridine monophosphate': 'https://go.drugbank.com/drugs/DB03685', 'D-Serine': 'https://go.drugbank.com/drugs/DB03929', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Azithromycin Action Pathway,"Azithromycin, trade names include Zithromax and Azithrocin, is a semisynthetic azalide derived from erythromycin. Azalides are part of the macrolide antibiotic class. Azithromycin targets protein synthesis of bacteria by binding to the 50S subunit of the bacterial ribosome to inhibit mRNA translation and prevent bacteria growth. Macrolides are broad spectrum antibiotics. It is prescribed to treat bacterial infections including: sexually transmitted infections like chlamydia, pneumonia, strep throat, ear infections, sinusitis and more.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,{'24794904': 'http://www.ncbi.nlm.nih.gov/pubmed/24794904 '},2022-01-17 22:34:13.614691
Bafetinib Inhibition of BCR-ABL,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0031699,http://smpdb.ca/view/SMP0031699/download?type=full_vector_image,httpsmpdbcaviewSMP0031699.svg,Drug action,{'Bafetinib': 'https://go.drugbank.com/drugs/DB11851'},Bafetinib Inhibition of BCR-ABL,"Bafetinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood. The cause of CML pathophysiology is the BCR-ABL fusion protein - the result of a genetic abnormality known as the Philadelphia chromosome in which Abelson Murine Leukemia viral oncogene homolog 1 (ABL1) translocates within the Breakpoint Cluster Region (BCR) gene on chromosome 22. BCR-ABL is a cytoplasm-targeted constitutively active tyrosine kinase that activates several oncogenic pathways which promote increased cell proliferation and survival including the MAPK/ERK Pathway, the JAK-STAT Pathway, and the PI3K/Akt pathway. Bafetinib is considered a second generation BCR-ABL inhibitor (Imatinib being the progenitor) that inhibits BCR-ABL activity by binding a highly conserved ATP binding site to effectively lock the tyrosine kinase in an inactive conformation. As a result, phosphate is unable to be transferred from ATP to activate oncogenic signalling cascades. For greater detail, refer to the pathway titled BCR-ABL Action in CML Pathogenesis. Bafetinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. Notably, Bafetinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary.",Homo sapiens,2017-08-16,2021-02-08,Drug Action Pathway,"{'17853901': 'http://www.ncbi.nlm.nih.gov/pubmed/17853901', '21098337': 'http://www.ncbi.nlm.nih.gov/pubmed/21098337', '22156549': 'http://www.ncbi.nlm.nih.gov/pubmed/22156549', '1322798': 'http://www.ncbi.nlm.nih.gov/pubmed/1322798', '10051406': 'http://www.ncbi.nlm.nih.gov/pubmed/10051406', '8491186': 'http://www.ncbi.nlm.nih.gov/pubmed/8491186', '10068651': 'http://www.ncbi.nlm.nih.gov/pubmed/10068651', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '16554811': 'http://www.ncbi.nlm.nih.gov/pubmed/16554811', '22827337': 'http://www.ncbi.nlm.nih.gov/pubmed/22827337', '11868160': 'http://www.ncbi.nlm.nih.gov/pubmed/11868160', '17143285': 'http://www.ncbi.nlm.nih.gov/pubmed/17143285', '1630456': 'http://www.ncbi.nlm.nih.gov/pubmed/1630456', '8378094': 'http://www.ncbi.nlm.nih.gov/pubmed/8378094', '8657152': 'http://www.ncbi.nlm.nih.gov/pubmed/8657152', '8361759': 'http://www.ncbi.nlm.nih.gov/pubmed/8361759', '15461802': 'http://www.ncbi.nlm.nih.gov/pubmed/15461802', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '2030914': 'http://www.ncbi.nlm.nih.gov/pubmed/2030914', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '1849461': 'http://www.ncbi.nlm.nih.gov/pubmed/1849461', '8628286': 'http://www.ncbi.nlm.nih.gov/pubmed/8628286', '15534001': 'http://www.ncbi.nlm.nih.gov/pubmed/15534001', '7719937': 'http://www.ncbi.nlm.nih.gov/pubmed/7719937', '9326218': 'http://www.ncbi.nlm.nih.gov/pubmed/9326218', '15805263': 'http://www.ncbi.nlm.nih.gov/pubmed/15805263', '16424865': 'http://www.ncbi.nlm.nih.gov/pubmed/16424865'}",2022-01-17 22:34:28.051826
Bamipine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0062882,http://smpdb.ca/view/SMP0062882/download?type=full_vector_image,httpsmpdbcaviewSMP0062882.svg,Drug action,{'Calcium': 'https://go.drugbank.com/drugs/DB01373'},Bamipine H1-Antihistamine Action,"Bamipine is a first-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-24,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '18977145': 'http://www.ncbi.nlm.nih.gov/pubmed/18977145', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:34:44.027842
Benazepril Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000145,http://smpdb.ca/view/SMP0000145/download?type=full_vector_image,httpsmpdbcaviewSMP0000145.svg,Drug action,"{'Benazepril': 'https://go.drugbank.com/drugs/DB00542', 'Zinc': 'https://go.drugbank.com/drugs/DB01593'}",Benazepril Action Pathway,"Benazepril (trade name: Lotensin) belongs to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors and is used primarily to lower high blood pressure (hypertension). This drug can also be used in the treatment of congestive heart failure and type II diabetes. Benazepril is a prodrug which, following oral administration, undergoes biotransformation in vivo into its active form benazeprilat via cleavage of its ester group by the liver. Angiotensin-converting enzyme (ACE) is a component of the body's renin–angiotensin–aldosterone system (RAAS) and cleaves inactive angiotensin I into the active vasoconstrictor angiotensin II. ACE (or kininase II) also degrades the potent vasodilator bradykinin. Consequently, ACE inhibitors decrease angiotensin II concentrations and increase bradykinin concentrations resulting in blood vessel dilation and thereby lowering blood pressure.",Homo sapiens,2013-08-22,2019-08-29,Drug Action Pathway,"{'1720384': 'http://www.ncbi.nlm.nih.gov/pubmed/1720384', '1649623': 'http://www.ncbi.nlm.nih.gov/pubmed/1649623', '10769174': 'http://www.ncbi.nlm.nih.gov/pubmed/10769174', '10969042': 'http://www.ncbi.nlm.nih.gov/pubmed/10969042', '6324167': 'http://www.ncbi.nlm.nih.gov/pubmed/6324167', '3530608': 'http://www.ncbi.nlm.nih.gov/pubmed/3530608', '6391881': 'http://www.ncbi.nlm.nih.gov/pubmed/6391881', '6089875': 'http://www.ncbi.nlm.nih.gov/pubmed/6089875', '2924688': 'http://www.ncbi.nlm.nih.gov/pubmed/2924688', '1692023': 'http://www.ncbi.nlm.nih.gov/pubmed/1692023', '29190205': 'http://www.ncbi.nlm.nih.gov/pubmed/29190205', '23886814': 'http://www.ncbi.nlm.nih.gov/pubmed/23886814', '24459521': 'http://www.ncbi.nlm.nih.gov/pubmed/24459521', '19427492': 'http://www.ncbi.nlm.nih.gov/pubmed/19427492'}",2022-01-17 22:35:13.483608
Benazepril Metabolism Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000591,http://smpdb.ca/view/SMP0000591/download?type=full_vector_image,httpsmpdbcaviewSMP0000591.svg,Drug metabolism,"{'Benazepril': 'https://go.drugbank.com/drugs/DB00542', 'Zinc': 'https://go.drugbank.com/drugs/DB01593'}",Benazepril Metabolism Pathway,"Benazepril (trade name: Lotensin) belongs to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors and is used primarily to lower high blood pressure (hypertension). This drug can also be used in the treatment of congestive heart failure and type II diabetes. Benazepril is a prodrug which, following oral administration, undergoes biotransformation in vivo into its active form benazeprilat via cleavage of its ester group by the liver. Angiotensin-converting enzyme (ACE) is a component of the body's renin–angiotensin–aldosterone system (RAAS) and cleaves inactive angiotensin I into the active vasoconstrictor angiotensin II. ACE (or kininase II) also degrades the potent vasodilator bradykinin. Consequently, ACE inhibitors decrease angiotensin II concentrations and increase bradykinin concentrations resulting in blood vessel dilation and thereby lowering blood pressure.",Homo sapiens,2013-09-11,2019-08-29,Drug Metabolism Pathway,"{'1720384': 'http://www.ncbi.nlm.nih.gov/pubmed/1720384', '1649623': 'http://www.ncbi.nlm.nih.gov/pubmed/1649623', '10769174': 'http://www.ncbi.nlm.nih.gov/pubmed/10769174', '10969042': 'http://www.ncbi.nlm.nih.gov/pubmed/10969042'}",2022-01-17 22:35:25.984825
Bendroflumethiazide Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000090,http://smpdb.ca/view/SMP0000090/download?type=full_vector_image,httpsmpdbcaviewSMP0000090.svg,Drug action,"{'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Bendroflumethiazide': 'https://go.drugbank.com/drugs/DB00436', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Urea': 'https://go.drugbank.com/drugs/DB03904'}",Bendroflumethiazide Action Pathway,"Bendroflumethiazide (also known as  bendrofluazide (BAN) or Aprinox) is an organic compound that used for diuretic. It can inhibit the solute carrier family 12 member 3 (also known as sodium-chloride symporter) in the nephron to prevent water reabsorption. Solute carrier family 12 member 3 is also used for sodium reabsorption that count for 5% of total amount. Solute carrier family 12 member 3 transports chloride and sodium from lumen to epithelial cell, and sodium/potassium ATPases facilitate the export of sodium to basolateral interstitium to provide sodium gradient that will increase the osmolarity in interstitium, which lead to establishment of osmotic gradient for water reabsorption.",Homo sapiens,2013-08-22,2021-06-01,Drug Action Pathway,"{'10653443': 'http://www.ncbi.nlm.nih.gov/pubmed/10653443', '1092541': 'http://www.ncbi.nlm.nih.gov/pubmed/1092541', '8812482': 'http://www.ncbi.nlm.nih.gov/pubmed/8812482', '12112667': 'http://www.ncbi.nlm.nih.gov/pubmed/12112667', '8528245': 'http://www.ncbi.nlm.nih.gov/pubmed/8528245', '15644426': 'http://www.ncbi.nlm.nih.gov/pubmed/15644426', '17502342': 'http://www.ncbi.nlm.nih.gov/pubmed/17502342', '15914676': 'http://www.ncbi.nlm.nih.gov/pubmed/15914676', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '25318757': 'http://www.ncbi.nlm.nih.gov/pubmed/25318757', '11473623': 'http://www.ncbi.nlm.nih.gov/pubmed/11473623', '24855283': 'http://www.ncbi.nlm.nih.gov/pubmed/24855283'}",2022-01-17 22:35:45.707094
Benzocaine Action Pathway,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000392,http://smpdb.ca/view/SMP0000392/download?type=full_vector_image,httpsmpdbcaviewSMP0000392.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Benzocaine': 'https://go.drugbank.com/drugs/DB01086', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Benzocaine Action Pathway,"Benzocaine exerts its local anaesthetic effect by blocking voltage-gated sodium channels in peripheral neurons. Benzocaine diffuses across the neuronal plasma membrane in its uncharged base form. Once inside the cytoplasm, it is protonated and this protonated form enters and blocks the pore of the voltage-gated sodium channel from the cytoplasmic side. For this to happen, the sodium channel must first become active so that so that gating mechanism is in the open state. Therefore benzocaine preferentially inhibits neurons that are actively firing.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'19465198': 'http://www.ncbi.nlm.nih.gov/pubmed/19465198', '8646465': 'http://www.ncbi.nlm.nih.gov/pubmed/8646465', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:36:04.746472
Bepotastine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0060058,http://smpdb.ca/view/SMP0060058/download?type=full_vector_image,httpsmpdbcaviewSMP0060058.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Bepotastine': 'https://go.drugbank.com/drugs/DB04890'}",Bepotastine H1-Antihistamine Action,"Bepotastine is a second-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:36:19.728034
Beta Oxidation of Very Long Chain Fatty Acids,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000052,http://smpdb.ca/view/SMP0000052/download?type=full_vector_image,httpsmpdbcaviewSMP0000052.svg,Metabolic,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Levocarnitine': 'https://go.drugbank.com/drugs/DB00583', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Lauric acid': 'https://go.drugbank.com/drugs/DB03017'}",Beta Oxidation of Very Long Chain Fatty Acids,"The degradation of fatty acids occurs is many ways, but for the most part in most species it occurs mainly through the beta-oxidation cycle. Take mammals for example, in this subset of species we find that beta-oxidation takes place not only in mitochondria, but in peroxisomes as well. In contrast, it tends to be the case that in plants and fungi beta-oxidation is only seen in peroxisomes. The reason the beta-oxidation cycle is found to occur in both mitochondria and peroxisomes in mammals is thought to be that extremely long chain fatty acids will in fact undergo oxidation in both locations, an initial or first oxidation in peroxisomes and second oxidation in the mitochondria. There is however a difference between the oxidation cycle which occurs in both these organelles. Namely, that the oxidation undergone in peroxisomes does not have any coupling to ATP synthesis, unlike the corresponding oxidation which occurs in the mitochondria. We find rather that electrons are passed to molecules of oxygen, which produces hydrogen peroxide. Moreover, there is an enzyme which is found only peroxisomes which ties into this process. It can turn hydrogen peroxide back into water and oxygen and is catalase. To expound further the differences between the oxidation cycle found in the peroxisomes and the mitchondria consider the following three key differences. One, in the peroxisome the beta-oxidation cycle takes as a necessary input a special enzyme called, peroxisomal carnitine acyltransferase, which is needed to move an activated acyl group from outside the peroxisome to inside it. In mitochondrial oxidation similar but different enzymes are used called carnitine acyltransferase I and II.  Difference number two is that oxidation in the peroxisome commences with catalysis induced by an enzyme called acyl CoA oxidase. Also, it should be noted that another enzyme called beta-ketothiolase which aids in peroxisomal beta-oxidation has a substrate specificity which differs from that of the mitochondrial beta-ketothiolase. Turning now to how the oxidation cycle function in mitochondria, note that the mitochondrial beta-oxidation pathway is composed of four repeating reactions that take place with each fatty acid molecule. The oxidation of fatty acid chains is a process of progress through repetition. With each turn of the cycle two carbons are removed from the fatty acid chain and the energy of the chemical bonds once housed by the molecule is captured by the reduced energy carriers NADH and FADH2. Acetyl-CoA is created in this 4 step reaction beta-oxidation process and is sent to the TCA cycle. Once inside the TCA cycle, the process of oxidation continues until even the acetyl-CoA is oxidized to CO2. More NADH and FADH2 result.",Homo sapiens,2013-08-19,2019-09-12,Metabolic Pathway,"{'444549': 'http://www.ncbi.nlm.nih.gov/pubmed/444549', '15466478': 'http://www.ncbi.nlm.nih.gov/pubmed/15466478', '10407780': 'http://www.ncbi.nlm.nih.gov/pubmed/10407780', '10051453': 'http://www.ncbi.nlm.nih.gov/pubmed/10051453', '11673457': 'http://www.ncbi.nlm.nih.gov/pubmed/11673457', '10527927': 'http://www.ncbi.nlm.nih.gov/pubmed/10527927', '1607358': 'http://www.ncbi.nlm.nih.gov/pubmed/1607358', '8584017': 'http://www.ncbi.nlm.nih.gov/pubmed/8584017', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10486279': 'http://www.ncbi.nlm.nih.gov/pubmed/10486279', '12853948': 'http://www.ncbi.nlm.nih.gov/pubmed/12853948', '12690205': 'http://www.ncbi.nlm.nih.gov/pubmed/12690205', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '7945262': 'http://www.ncbi.nlm.nih.gov/pubmed/7945262', '9399886': 'http://www.ncbi.nlm.nih.gov/pubmed/9399886', '9837782': 'http://www.ncbi.nlm.nih.gov/pubmed/9837782', '9600456': 'http://www.ncbi.nlm.nih.gov/pubmed/9600456', '1988962': 'http://www.ncbi.nlm.nih.gov/pubmed/1988962', '1961767': 'http://www.ncbi.nlm.nih.gov/pubmed/1961767'}",2022-01-17 22:36:38.701957
beta-Alanine Metabolism,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000007,http://smpdb.ca/view/SMP0000007/download?type=full_vector_image,httpsmpdbcaviewSMP0000007.svg,Metabolic,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Histidine': 'https://go.drugbank.com/drugs/DB00117', 'Aspartic acid': 'https://go.drugbank.com/drugs/DB00128', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Pantothenic acid': 'https://go.drugbank.com/drugs/DB01783', 'Dihydrouracil': 'https://go.drugbank.com/drugs/DB01849', 'beta-Alanine': 'https://go.drugbank.com/drugs/DB03107', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Flavin mononucleotide': 'https://go.drugbank.com/drugs/DB03247', 'Uracil': 'https://go.drugbank.com/drugs/DB03419'}",beta-Alanine Metabolism,"Beta-alanine, 3-aminopropanoic acid, is a non-essential amino acid. Beta-Alanine is formed by the proteolytic degradation of beta-alanine containing dipeptides: carnosine, anserine, balenine, and pantothenic acid (vitamin B5). These dipeptides are consumed from protein-rich foods such as chicken, beef, pork, and fish. Beta-Alanine can also be formed in the liver from the breakdown of pyrimidine nucleotides into uracil and dihydrouracil and then metabolized into beta-alanine and beta-aminoisobutyrate. Beta-Alanine can also be formed via the action of aldehyde dehydrogenase on beta-aminoproionaldehyde which is generated from various aliphatic polyamines. Under normal conditions, beta-alanine is metabolized to aspartic acid through the action of glutamate decarboxylase. It addition, it can be converted to malonate semialdehyde and thereby participate in propanoate metabolism. Beta-Alanine is not a proteogenic amino acid. This amino acid is a common athletic supplementation due to its belief to improve performance by increased muscle carnosine levels.",Homo sapiens,2013-08-01,2019-08-30,Metabolic Pathway,"{'27508152': 'http://www.ncbi.nlm.nih.gov/pubmed/27508152', '16046297': 'http://www.ncbi.nlm.nih.gov/pubmed/16046297', '12975309': 'http://www.ncbi.nlm.nih.gov/pubmed/12975309', '16177791': 'http://www.ncbi.nlm.nih.gov/pubmed/16177791', '8088791': 'http://www.ncbi.nlm.nih.gov/pubmed/8088791', '1549570': 'http://www.ncbi.nlm.nih.gov/pubmed/1549570', '1683462': 'http://www.ncbi.nlm.nih.gov/pubmed/1683462', '10542323': 'http://www.ncbi.nlm.nih.gov/pubmed/10542323', '11508704': 'http://www.ncbi.nlm.nih.gov/pubmed/11508704', '15461802': 'http://www.ncbi.nlm.nih.gov/pubmed/15461802', '9718352': 'http://www.ncbi.nlm.nih.gov/pubmed/9718352', '8973361': 'http://www.ncbi.nlm.nih.gov/pubmed/8973361', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8083224': 'http://www.ncbi.nlm.nih.gov/pubmed/8083224', '9135003': 'http://www.ncbi.nlm.nih.gov/pubmed/9135003', '9464498': 'http://www.ncbi.nlm.nih.gov/pubmed/9464498', '7721088': 'http://www.ncbi.nlm.nih.gov/pubmed/7721088', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '10947204': 'http://www.ncbi.nlm.nih.gov/pubmed/10947204', '12508121': 'http://www.ncbi.nlm.nih.gov/pubmed/12508121', '8561277': 'http://www.ncbi.nlm.nih.gov/pubmed/8561277', '3582651': 'http://www.ncbi.nlm.nih.gov/pubmed/3582651', '3562250': 'http://www.ncbi.nlm.nih.gov/pubmed/3562250'}",2022-01-17 22:37:01.364656
beta-Ketothiolase Deficiency,https://go.drugbank.com/pathways?page=4,http://smpdb.ca/view/SMP0000173,http://smpdb.ca/view/SMP0000173/download?type=full_vector_image,httpsmpdbcaviewSMP0000173.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Succinic acid': 'https://go.drugbank.com/drugs/DB00139', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Pyridoxal': 'https://go.drugbank.com/drugs/DB00147', 'Leucine': 'https://go.drugbank.com/drugs/DB00149', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'Valine': 'https://go.drugbank.com/drugs/DB00161', 'Isoleucine': 'https://go.drugbank.com/drugs/DB00167', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Acetoacetic acid': 'https://go.drugbank.com/drugs/DB01762', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'alpha-Ketoisocaproic acid': 'https://go.drugbank.com/drugs/DB03229', 'alpha-Ketoisovalerate': 'https://go.drugbank.com/drugs/DB04074', 'Methylmalonic Acid': 'https://go.drugbank.com/drugs/DB04183'}",beta-Ketothiolase Deficiency,"beta-Ketothiolase Deficiency (2-Methyl-3-Hydroxybutyric Acidemia; Mitochondrial Acetoacetyl-CoA Thiolase Deficiency; MAT Deficiency; T2 Deficiency; 3-KTD Deficiency; 3-Ketothiolase Deficiency) is an autosomal recessive disease caused by a mutation in the HADHB gene which codes for beta-ketathiolase. A deficiency in this enzyme results in accumulation of ammonia and ketone bodies in blood; and 2-methyl-3-hydroxybutyric acid, 2-methylacetoacetic acid, 3-hydroxybutyric acid, tiglylglycine, and ketone bodies in urine. Symptoms include ketosis, seizures, organic acids in urine, and hyperammonemia. Treatment includes a low protein diet and L-carnitine.h3. h2.",Homo sapiens,2013-08-01,2019-09-06,Disease Pathway,"{'6422156': 'http://www.ncbi.nlm.nih.gov/pubmed/6422156', '9700610': 'http://www.ncbi.nlm.nih.gov/pubmed/9700610', '1715688': 'http://www.ncbi.nlm.nih.gov/pubmed/1715688', '10604145': 'http://www.ncbi.nlm.nih.gov/pubmed/10604145', '21104317': 'http://www.ncbi.nlm.nih.gov/pubmed/21104317', '22326532': 'http://www.ncbi.nlm.nih.gov/pubmed/22326532', '2365818': 'http://www.ncbi.nlm.nih.gov/pubmed/2365818', '8651316': 'http://www.ncbi.nlm.nih.gov/pubmed/8651316', '21844576': 'http://www.ncbi.nlm.nih.gov/pubmed/21844576', '1420356': 'http://www.ncbi.nlm.nih.gov/pubmed/1420356', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '8406489': 'http://www.ncbi.nlm.nih.gov/pubmed/8406489', '3693355': 'http://www.ncbi.nlm.nih.gov/pubmed/3693355', '3278312': 'http://www.ncbi.nlm.nih.gov/pubmed/3278312', '8617516': 'http://www.ncbi.nlm.nih.gov/pubmed/8617516', '8440722': 'http://www.ncbi.nlm.nih.gov/pubmed/8440722', '8692959': 'http://www.ncbi.nlm.nih.gov/pubmed/8692959', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005'}",2022-01-17 22:37:30.956468
beta-Mercaptolactate-Cysteine Disulfiduria,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000499,http://smpdb.ca/view/SMP0000499/download?type=full_vector_image,httpsmpdbcaviewSMP0000499.svg,Disease,"{'Pyridoxal phosphate': 'https://go.drugbank.com/drugs/DB00114', 'Pyruvic acid': 'https://go.drugbank.com/drugs/DB00119', 'Adenosine phosphate': 'https://go.drugbank.com/drugs/DB00131', 'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'gamma-Glutamylcysteine': 'https://go.drugbank.com/drugs/DB03408', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",beta-Mercaptolactate-Cysteine Disulfiduria,"Metcaptolactate-cysteine disulfiduria (MCDU) is an autosomal disorder that leads to the loss of function of the enzyme mercaptopyruvate sulfurtransferase. The condition is characterized by the urinary excretion of large amounts of a sulfur-containing amino acid, which is beta-mercaptolactate-cysteine disulfide. Patients exhibit a low IQ, grand mal seizures, flattened nasal bridge, and an excessively arched palate.",Homo sapiens,2013-08-29,2019-08-16,Disease Pathway,"{'6945862': 'http://www.ncbi.nlm.nih.gov/pubmed/6945862', '23759691': 'http://www.ncbi.nlm.nih.gov/pubmed/23759691', '16702335': 'http://www.ncbi.nlm.nih.gov/pubmed/16702335', '29530337': 'http://www.ncbi.nlm.nih.gov/pubmed/29530337 ', '1350904': 'http://www.ncbi.nlm.nih.gov/pubmed/1350904', '14574404': 'http://www.ncbi.nlm.nih.gov/pubmed/14574404', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '7826375': 'http://www.ncbi.nlm.nih.gov/pubmed/7826375', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '7524679': 'http://www.ncbi.nlm.nih.gov/pubmed/7524679', '10427686': 'http://www.ncbi.nlm.nih.gov/pubmed/10427686', '9497919': 'http://www.ncbi.nlm.nih.gov/pubmed/9497919', '1974457': 'http://www.ncbi.nlm.nih.gov/pubmed/1974457', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '12574942': 'http://www.ncbi.nlm.nih.gov/pubmed/12574942', '1339280': 'http://www.ncbi.nlm.nih.gov/pubmed/1339280', '1953758': 'http://www.ncbi.nlm.nih.gov/pubmed/1953758', '10591208': 'http://www.ncbi.nlm.nih.gov/pubmed/10591208', '18351441': 'http://www.ncbi.nlm.nih.gov/pubmed/18351441', '10673275': 'http://www.ncbi.nlm.nih.gov/pubmed/10673275', '10556299': 'http://www.ncbi.nlm.nih.gov/pubmed/10556299', '12204010': 'http://www.ncbi.nlm.nih.gov/pubmed/12204010'}",2022-01-17 22:37:56.969414
beta-Ureidopropionase Deficiency,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000172,http://smpdb.ca/view/SMP0000172/download?type=full_vector_image,httpsmpdbcaviewSMP0000172.svg,Disease,"{'L-Glutamine': 'https://go.drugbank.com/drugs/DB00130', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', '5-O-phosphono-alpha-D-ribofuranosyl diphosphate': 'https://go.drugbank.com/drugs/DB01632', 'Thymidine monophosphate': 'https://go.drugbank.com/drugs/DB01643', 'Dihydrouracil': 'https://go.drugbank.com/drugs/DB01849', 'Dihydroorotic Acid': 'https://go.drugbank.com/drugs/DB02129', 'Orotic acid': 'https://go.drugbank.com/drugs/DB02262', ""Cytidine-5'-Triphosphate"": 'https://go.drugbank.com/drugs/DB02431', 'Uridine': 'https://go.drugbank.com/drugs/DB02745', 'Orotidylic acid': 'https://go.drugbank.com/drugs/DB02957', 'Ribose-1-Phosphate': 'https://go.drugbank.com/drugs/DB03101', 'beta-Alanine': 'https://go.drugbank.com/drugs/DB03107', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Flavin mononucleotide': 'https://go.drugbank.com/drugs/DB03247', 'Uracil': 'https://go.drugbank.com/drugs/DB03419', ""Uridine-5'-Diphosphate"": 'https://go.drugbank.com/drugs/DB03435', 'Thymine': 'https://go.drugbank.com/drugs/DB03462', 'Uridine monophosphate': 'https://go.drugbank.com/drugs/DB03685', 'Deoxyuridine monophosphate': 'https://go.drugbank.com/drugs/DB03800', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'N-Carbamoylaspartic acid': 'https://go.drugbank.com/drugs/DB04252', 'Thymidine': 'https://go.drugbank.com/drugs/DB04485'}",beta-Ureidopropionase Deficiency,"Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase. A deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay.",Homo sapiens,2013-08-19,2019-09-12,Disease Pathway,"{'17065070': 'http://www.ncbi.nlm.nih.gov/pubmed/17065070', '15385443': 'http://www.ncbi.nlm.nih.gov/pubmed/15385443', '1979741': 'http://www.ncbi.nlm.nih.gov/pubmed/1979741', '15890648': 'http://www.ncbi.nlm.nih.gov/pubmed/15890648', '8619816': 'http://www.ncbi.nlm.nih.gov/pubmed/8619816', '16480261': 'http://www.ncbi.nlm.nih.gov/pubmed/16480261', '1446837': 'http://www.ncbi.nlm.nih.gov/pubmed/1446837', '7487077': 'http://www.ncbi.nlm.nih.gov/pubmed/7487077', '22539336': 'http://www.ncbi.nlm.nih.gov/pubmed/22539336', '28742282': 'http://www.ncbi.nlm.nih.gov/pubmed/28742282', '21654728': 'http://www.ncbi.nlm.nih.gov/pubmed/21654728', '17999954': 'http://www.ncbi.nlm.nih.gov/pubmed/17999954', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '10453732': 'http://www.ncbi.nlm.nih.gov/pubmed/10453732', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '11485571': 'http://www.ncbi.nlm.nih.gov/pubmed/11485571', '15164053': 'http://www.ncbi.nlm.nih.gov/pubmed/15164053'}",2022-01-17 22:38:25.223633
Betahistine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0060744,http://smpdb.ca/view/SMP0060744/download?type=full_vector_image,httpsmpdbcaviewSMP0060744.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Betahistine': 'https://go.drugbank.com/drugs/DB06698'}",Betahistine H1-Antihistamine Action,"Betahistine is a first-generation H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-20,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:38:41.316104
Betaine Metabolism,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000123,http://smpdb.ca/view/SMP0000123/download?type=full_vector_image,httpsmpdbcaviewSMP0000123.svg,Metabolic,"{'Tetrahydrofolic acid': 'https://go.drugbank.com/drugs/DB00116', 'Ademetionine': 'https://go.drugbank.com/drugs/DB00118', 'Choline': 'https://go.drugbank.com/drugs/DB00122', 'Methionine': 'https://go.drugbank.com/drugs/DB00134', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Adenosine': 'https://go.drugbank.com/drugs/DB00640', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'N,N-dimethylglycine': 'https://go.drugbank.com/drugs/DB02083', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Betaine aldehyde': 'https://go.drugbank.com/drugs/DB04401'}",Betaine Metabolism,"Betaine (or trimethylglycine) is similar to choline (trimethylaminoethanol) but differs in choline's terminal carboxylic acid group trimethylglycine is reduced to a hydroxyl group. Betaine is obtained from diet as betaine or compounds containing choline in foods such as whole grains, beets and spinach. Betaine can also be synthesized from choline in the liver and kidney.  First, choline is oxidized to betaine aldehyde by mitochondrial choline oxidase (choline dehydrogenase). Then, betaine aldehyde dehydrogenase oxidizes betaine aldehyde to betaine in the mitochondria or cytoplasm. In the liver, betaine functions as a methyl donor similar to choline, folic acid, S-adenosyl methionine and vitamin B12. Methyl donors are important for liver function, cellular replication and detoxification reactions. Betaine is also involved in the production of carnitine to protect from kidney damage and functions as an osmoprotectant in the inner medulla.",Homo sapiens,2013-08-01,2019-09-12,Metabolic Pathway,"{'26850693': 'http://www.ncbi.nlm.nih.gov/pubmed/26850693', '20207735': 'http://www.ncbi.nlm.nih.gov/pubmed/20207735', '17068770': 'http://www.ncbi.nlm.nih.gov/pubmed/17068770', '8088832': 'http://www.ncbi.nlm.nih.gov/pubmed/8088832', '12818402': 'http://www.ncbi.nlm.nih.gov/pubmed/12818402', '8798461': 'http://www.ncbi.nlm.nih.gov/pubmed/8798461', '10075673': 'http://www.ncbi.nlm.nih.gov/pubmed/10075673', '8968737': 'http://www.ncbi.nlm.nih.gov/pubmed/8968737', '8968735': 'http://www.ncbi.nlm.nih.gov/pubmed/8968735', '9013615': 'http://www.ncbi.nlm.nih.gov/pubmed/9013615', '19177456': 'http://www.ncbi.nlm.nih.gov/pubmed/19177456', '2596825': 'http://www.ncbi.nlm.nih.gov/pubmed/2596825', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '24275569': 'http://www.ncbi.nlm.nih.gov/pubmed/24275569', '11420179': 'http://www.ncbi.nlm.nih.gov/pubmed/11420179', '17456783': 'http://www.ncbi.nlm.nih.gov/pubmed/17456783', '9989271': 'http://www.ncbi.nlm.nih.gov/pubmed/9989271', '1426236': 'http://www.ncbi.nlm.nih.gov/pubmed/1426236', '16413417': 'http://www.ncbi.nlm.nih.gov/pubmed/16413417', '11337507': 'http://www.ncbi.nlm.nih.gov/pubmed/11337507', '10644686': 'http://www.ncbi.nlm.nih.gov/pubmed/10644686', '11230166': 'http://www.ncbi.nlm.nih.gov/pubmed/11230166'}",2022-01-17 22:39:01.897424
Betaxolol Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000299,http://smpdb.ca/view/SMP0000299/download?type=full_vector_image,httpsmpdbcaviewSMP0000299.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Betaxolol': 'https://go.drugbank.com/drugs/DB00195', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Betaxolol Action Pathway,"Betaxolol (also known as Betoptic or Lokren) is a selective beta blocker that can block beta1-adrenergic receptors and beta2-adrenergic receptors. Blocking of beta1-adrenergic receptors in heart and vascular smooth muscle can lead to reduced heart rate, cardiac output, and decreased blood pressure. Blocking of beta(2)-adrenergic receptors can lead to prevention of bronchospasm.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:39:24.781076
Betazole Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000736,http://smpdb.ca/view/SMP0000736/download?type=full_vector_image,httpsmpdbcaviewSMP0000736.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Betazole': 'https://go.drugbank.com/drugs/DB00272', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Acetylcholine': 'https://go.drugbank.com/drugs/DB03128'}",Betazole Action Pathway,"Betazole, also known as ametazole and Histalog, is a histamine H2 agonist that causes an increase in gastric acid secretion. Betazole is commonly used to evaluate acid production. Betazole binds to the H2 receptor to enhance the G protein signaling cascade to increase gastric secretion into the lumen. Gastric acid digests protein and absorbs calcium, iron and vitamin B12. Gastric acidity may also interfere with medication bioavailability. Measuring gastric acid secretion is useful to manage diseases involving acid production such as gastroesophageal reflux disease.",Homo sapiens,2014-06-23,2021-05-27,Drug Action Pathway,"{'14278820': 'http://www.ncbi.nlm.nih.gov/pubmed/14278820', '': 'http://www.ncbi.nlm.nih.gov/pubmed/ 6057052', '25211241': 'http://www.ncbi.nlm.nih.gov/pubmed/25211241', '1714721': 'http://www.ncbi.nlm.nih.gov/pubmed/1714721', '7755641': 'http://www.ncbi.nlm.nih.gov/pubmed/7755641', '10371214': 'http://www.ncbi.nlm.nih.gov/pubmed/10371214', '9339381': 'http://www.ncbi.nlm.nih.gov/pubmed/9339381', '22814392': 'http://www.ncbi.nlm.nih.gov/pubmed/22814392', '17945253': 'http://www.ncbi.nlm.nih.gov/pubmed/17945253', '3104879': 'http://www.ncbi.nlm.nih.gov/pubmed/3104879', '2121614': 'http://www.ncbi.nlm.nih.gov/pubmed/2121614', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '1656976': 'http://www.ncbi.nlm.nih.gov/pubmed/1656976', '15057823': 'http://www.ncbi.nlm.nih.gov/pubmed/15057823', '2160952': 'http://www.ncbi.nlm.nih.gov/pubmed/2160952', '2176086': 'http://www.ncbi.nlm.nih.gov/pubmed/2176086', '15057824': 'http://www.ncbi.nlm.nih.gov/pubmed/15057824', '8222757': 'http://www.ncbi.nlm.nih.gov/pubmed/8222757', '1280419': 'http://www.ncbi.nlm.nih.gov/pubmed/1280419', '7681836': 'http://www.ncbi.nlm.nih.gov/pubmed/7681836', '3443095': 'http://www.ncbi.nlm.nih.gov/pubmed/3443095', '3272174': 'http://www.ncbi.nlm.nih.gov/pubmed/3272174', '15014171': 'http://www.ncbi.nlm.nih.gov/pubmed/15014171', '6126875': 'http://www.ncbi.nlm.nih.gov/pubmed/6126875', '6142531': 'http://www.ncbi.nlm.nih.gov/pubmed/6142531', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '3060722': 'http://www.ncbi.nlm.nih.gov/pubmed/3060722', '27607343': 'http://www.ncbi.nlm.nih.gov/pubmed/27607343', '26376477': 'http://www.ncbi.nlm.nih.gov/pubmed/26376477', '17928547': 'http://www.ncbi.nlm.nih.gov/pubmed/17928547'}",2022-01-17 22:39:45.357594
Bevacizumab Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000420,http://smpdb.ca/view/SMP0000420/download?type=full_vector_image,httpsmpdbcaviewSMP0000420.svg,Drug action,{'Bevacizumab': 'https://go.drugbank.com/drugs/DB00112'},Bevacizumab Action Pathway,"Bevacizumab is a humanized anti-VEGF monoclonal antibody used in the treatment of cancer. Cancer cells tend to overexpress VEGF, which stimulates angiogenesis, facilitating cancer growth and metastasis. The majority of VEGF’s effects are mediated through its binding to the VEGFR-2 receptor on endothelial cell surfaces. Upon binding, the receptor autophosphorylates and initiates a signalling cascade, starting with the activation of CSK. CSK phosphorylates Raf-1, which subsequently phosphorylates MAP kinase kinase, which phosphorylates MAP kinase. The activated MAP kinase enters the nucleus and stimulates the expression of angiogenic factors resulting in increased cell proliferation, migration,  permeability, invasion, and survival.
Binding of VEGF to VEGFR-2 also activates phospholipase C PIP2 into DAG and IP3. DAG may be involved in the activation of Raf-1 leading to angiogenesis, while IP3 activates PI3K and triggers calcium release from the endoplasmic reticulum. This ultimately leads to the activation of nitric oxide synthase and the production of nitric oxide, which stimulates vasodilation and increases vascular permeability. 
In cancer, VEGF has also been shown to bind to the VEGFR-1 receptor. However, its effects on angiogenesis are unclear at the moment. There are some evidence to show that VEGFR-1 may cross-talk with VEGFR-2 and initiate the signalling cascades described above.
Bevacizumab exerts its effect by binding to extracellular VEGF and preventing its binding to receptors on the endothelial cell surfaces. This in turns inhibits the MAP and IP3  and supresses angiogenesis.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'15585754': 'http://www.ncbi.nlm.nih.gov/pubmed/15585754', '16842197': 'http://www.ncbi.nlm.nih.gov/pubmed/16842197', '2479986': 'http://www.ncbi.nlm.nih.gov/pubmed/2479986', '2479987': 'http://www.ncbi.nlm.nih.gov/pubmed/2479987', '1711045': 'http://www.ncbi.nlm.nih.gov/pubmed/1711045', '1417831': 'http://www.ncbi.nlm.nih.gov/pubmed/1417831', '7929439': 'http://www.ncbi.nlm.nih.gov/pubmed/7929439', '9160888': 'http://www.ncbi.nlm.nih.gov/pubmed/9160888', '2158038': 'http://www.ncbi.nlm.nih.gov/pubmed/2158038', '8248162': 'http://www.ncbi.nlm.nih.gov/pubmed/8248162', '10471394': 'http://www.ncbi.nlm.nih.gov/pubmed/10471394'}",2022-01-17 22:39:55.411345
Bevantolol Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000668,http://smpdb.ca/view/SMP0000668/download?type=full_vector_image,httpsmpdbcaviewSMP0000668.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Bevantolol': 'https://go.drugbank.com/drugs/DB01295', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Bevantolol Action Pathway,"Bevantolol hydrocholride, also known as bevantolol, is a cardioselective beta blocker prescribed to treat angina pectoris and hypertension. Bevantolol is an antagonist of beta-1 adrenoreceptors to block the G protein signalling cascade and inhibit epinephrine induced sympathetic activation such as, increased heart rate. It does not have intrinsic sympathomimetic activity therefore does not stimulate beta-adrenergic receptors. This results in a decrease in preload and blood pressure.",Homo sapiens,2014-04-20,2019-09-12,Drug Action Pathway,"{'2888789': 'http://www.ncbi.nlm.nih.gov/pubmed/2888789', '2871786': 'http://www.ncbi.nlm.nih.gov/pubmed/2871786', '1977302': 'http://www.ncbi.nlm.nih.gov/pubmed/1977302', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:40:16.305564
Bilastine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0060170,http://smpdb.ca/view/SMP0060170/download?type=full_vector_image,httpsmpdbcaviewSMP0060170.svg,Drug action,"{'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Bilastine': 'https://go.drugbank.com/drugs/DB11591'}",Bilastine H1-Antihistamine Action,"Bilastine is a second-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-19,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '28467671': 'http://www.ncbi.nlm.nih.gov/pubmed/28467671', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:40:32.470928
Bile Acid Biosynthesis,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000035,http://smpdb.ca/view/SMP0000035/download?type=full_vector_image,httpsmpdbcaviewSMP0000035.svg,Metabolic,"{'Glycine': 'https://go.drugbank.com/drugs/DB00145', 'NADH': 'https://go.drugbank.com/drugs/DB00157', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Iron': 'https://go.drugbank.com/drugs/DB01592', 'Taurine': 'https://go.drugbank.com/drugs/DB01956', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Cholic Acid': 'https://go.drugbank.com/drugs/DB02659', 'Flavin adenine dinucleotide': 'https://go.drugbank.com/drugs/DB03147', 'Palmitic Acid': 'https://go.drugbank.com/drugs/DB03796', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160', 'Taurocholic acid': 'https://go.drugbank.com/drugs/DB04348', 'Cholesterol': 'https://go.drugbank.com/drugs/DB04540', 'Chenodeoxycholic acid': 'https://go.drugbank.com/drugs/DB06777', 'Taurochenodeoxycholic acid': 'https://go.drugbank.com/drugs/DB08833'}",Bile Acid Biosynthesis,"A bile acids life begins as cholesterol is catabolized, as bile acid is a derivative of cholesterol. This pathway occurs in the liver, beginning with cholesterol being converted to 7a-hydroxycholesterol through the enzyme cholesterol-7-alpha-monooxygenase, after being transported into the liver cell. 7a-hydroxycholesterol then becomes 7a-hydroxy-cholestene-3-one, which is made possible by the enzyme 3-beta-hydroxysteroid dehydrogenase type 7. 7a-hydroxy-cholestene-3-one then is used in two different chains of reactions. The first, continuing in the liver, uses the enzyme 3-oxo-5-beta-steroid-4-deydrogenase to become 7a-hydroxy-5b-cholestan-3-one. After that, aldo-keto reductase family 1 member C4 is used to create 3a,7a-dihydroxy-5b-cholestane. In the mitochondria of the cell, sterol 26-hydroxylase converts 3a,7a-dihydroxy-5b-cholestane to 3a,7a,26-trihydroxy-5b-cholestane, which is then converted to 3a,7a-dihydroxy-5b-cholestan-26-al by the same enzyme used in the previous reaction. This enzyme is used another time, to create 3a,7a-dihydroxycoprostanic acid. Then, bile acyl-CoA synthetase teams up with 3a,7a-dihydroxycoprostanic acid to create 3a,7a-dihydroxy-5b-cholestanoyl-CoA. 3a,7a-dihydroxy-5b-cholestanoyl-CoA remains intact while alpha-methylacyl-CoA racemase moves it along through the peroxisome. Peroxisomal acyl coenzyme A oxidase 2 converts 3a,7a-dihydroxy-5b-cholestanoyl-CoA into 3a,7a-dihydoxy-5b-cholest-24-enoyl-CoA. With the help of water, peroxisomal multifunctional enzyme type 2 turns 3a,7a-dihydoxy-5b-cholest-24-enoyl-CoA into 3a,7a,24-trihydoxy-5b-cholestanoyl-CoA. This compound then uses peroxisomal multifunctional enzyme type 2 to create chenodeoxycholoyl-CoA. From there, propionyl-CoA and chenodeoxycholoyl-CoA join forces and enlist the help of non-specific lipid transfer protein to further chenodeoxycholoyl-CoAâ€TMs journey in the peroxisome. It is then transported back into intracellular space, where after its used in 3 different reactions, its derivatives interact with intestinal microflora in the extracellular space to become lithocholyltaurine, lithocholic acid glycine conjugate, and lithocholic acid. Revisiting 7a-hydroxy-cholestene-3-one, the second chain of reactions it is involved in follows a similar path as the first, moving through the mitochondria, endoplasmic reticulum and peroxisome until choloyl-CoA is formed, which then is used in three reactions so that its derivatives may leave the cell to interact with intestinal microflora and become taurodeoxycholic acid, deoxycholic acid glycine conjugate and deoxycholic acid. There are two more important components of this pathway, both depicting the breakdown of cholesterol into bile acid. These components of the pathway occur in the endoplasmic reticulum membrane, although 2 enzymes, 25-hydroxycholesterol 7-alpha-hydroxylase and sterol 26 hydroxylase, are found in the mitochondria. Bile acids play a very important part in the digestion of foods, and are responsible for the absorption of water soluble vitamins in the small intestine. Bile acids also help absorb fats into the small intestine, a crucial part of any vertebrates diet.",Homo sapiens,2013-08-19,2019-08-20,Metabolic Pathway,"{'23897684': 'http://www.ncbi.nlm.nih.gov/pubmed/23897684', '8274401': 'http://www.ncbi.nlm.nih.gov/pubmed/8274401', '7650035': 'http://www.ncbi.nlm.nih.gov/pubmed/7650035', '7626489': 'http://www.ncbi.nlm.nih.gov/pubmed/7626489', '20522910': 'http://www.ncbi.nlm.nih.gov/pubmed/20522910', '18407998': 'http://www.ncbi.nlm.nih.gov/pubmed/18407998', '18848863': 'http://www.ncbi.nlm.nih.gov/pubmed/18848863', '21411718': 'http://www.ncbi.nlm.nih.gov/pubmed/21411718', '1708392': 'http://www.ncbi.nlm.nih.gov/pubmed/1708392', '7690968': 'http://www.ncbi.nlm.nih.gov/pubmed/7690968', '10479480': 'http://www.ncbi.nlm.nih.gov/pubmed/10479480', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '15057824': 'http://www.ncbi.nlm.nih.gov/pubmed/15057824', '11060344': 'http://www.ncbi.nlm.nih.gov/pubmed/11060344', '10655068': 'http://www.ncbi.nlm.nih.gov/pubmed/10655068', '15880524': 'http://www.ncbi.nlm.nih.gov/pubmed/15880524', '27647924': 'http://www.ncbi.nlm.nih.gov/pubmed/27647924', '8943006': 'http://www.ncbi.nlm.nih.gov/pubmed/8943006', '7487879': 'http://www.ncbi.nlm.nih.gov/pubmed/7487879', '9089413': 'http://www.ncbi.nlm.nih.gov/pubmed/9089413', '9880674': 'http://www.ncbi.nlm.nih.gov/pubmed/9880674'}",2022-01-17 22:41:07.471290
Biotin Metabolism,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000066,http://smpdb.ca/view/SMP0000066/download?type=full_vector_image,httpsmpdbcaviewSMP0000066.svg,Metabolic,"{'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Lysine': 'https://go.drugbank.com/drugs/DB00123', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Biotin Metabolism,"Biotin is a vitamin that is an essential nutrient for humans. Biotin can be absorbed from consuming various foods such as: legumes, soybeans, tomatoes, romaine lettuce, eggs, cow's milk, oats and many more. Biotin acts as a cofactor for enzymes to catalyze carboxylation reactions involved in gluconeogenesis, amino acid catabolism and fatty acid metabolism. Biotin deficiency has been associated with many human diseases. These diseases may be caused by dysfunctional biotin metabolism due to enzyme deficiencies. Some research suggests biotin may play a role in transcription regulation or protein expression which may lead to biotin related diseases.",Homo sapiens,2013-08-01,2019-08-13,Metabolic Pathway,"{'12459313': 'http://www.ncbi.nlm.nih.gov/pubmed/12459313', '16134170': 'http://www.ncbi.nlm.nih.gov/pubmed/16134170', '7842009': 'http://www.ncbi.nlm.nih.gov/pubmed/7842009', '9037601': 'http://www.ncbi.nlm.nih.gov/pubmed/9037601', '7509806': 'http://www.ncbi.nlm.nih.gov/pubmed/7509806', '9530634': 'http://www.ncbi.nlm.nih.gov/pubmed/9530634', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '11042152': 'http://www.ncbi.nlm.nih.gov/pubmed/11042152', '8632014': 'http://www.ncbi.nlm.nih.gov/pubmed/8632014'}",2022-01-17 22:41:22.354419
Biotinidase Deficiency,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000174,http://smpdb.ca/view/SMP0000174/download?type=full_vector_image,httpsmpdbcaviewSMP0000174.svg,Disease,"{'Biotin': 'https://go.drugbank.com/drugs/DB00121', 'Lysine': 'https://go.drugbank.com/drugs/DB00123', 'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Pyrophosphoric acid': 'https://go.drugbank.com/drugs/DB04160'}",Biotinidase Deficiency,"Biotinidase deficiency (Multiple carboxylase deficiency) is an autosomal recessive disease caused by a mutation in the BTD gene which codes for biotinidase. A deficiency in this enzyme results in accumulation of ammonia and ketone bodies in blood; 3-hydroxyisovaleric acid in plasma, spinal fluid, and urine; hydroxypropionic acid, 2-hydroxybutyric acid, 3-Hydroxybutyric acid, and citric acid in spinal fluid; and 3-methylcrotonylglycine, hydroxypropionic acid, and L and D-lactic acid in urine. Symptoms, which can present from birth into adulthood include hypotonia, ketosis, hyperammonemia, motor retardation, coma, and seborrhoic skin rash. Treatment includes biotin.",Homo sapiens,2013-08-01,2019-08-16,Disease Pathway,"{'3930842': 'http://www.ncbi.nlm.nih.gov/pubmed/3930842', '1729884': 'http://www.ncbi.nlm.nih.gov/pubmed/1729884', '11668630': 'http://www.ncbi.nlm.nih.gov/pubmed/11668630', '9396567': 'http://www.ncbi.nlm.nih.gov/pubmed/9396567', '20301497': 'http://www.ncbi.nlm.nih.gov/pubmed/20301497', '22579707': 'http://www.ncbi.nlm.nih.gov/pubmed/22579707', '12459313': 'http://www.ncbi.nlm.nih.gov/pubmed/12459313', '16134170': 'http://www.ncbi.nlm.nih.gov/pubmed/16134170', '7842009': 'http://www.ncbi.nlm.nih.gov/pubmed/7842009', '9037601': 'http://www.ncbi.nlm.nih.gov/pubmed/9037601', '7509806': 'http://www.ncbi.nlm.nih.gov/pubmed/7509806', '9530634': 'http://www.ncbi.nlm.nih.gov/pubmed/9530634', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '11042152': 'http://www.ncbi.nlm.nih.gov/pubmed/11042152', '8632014': 'http://www.ncbi.nlm.nih.gov/pubmed/8632014'}",2022-01-17 22:41:41.053266
Bisoprolol Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000300,http://smpdb.ca/view/SMP0000300/download?type=full_vector_image,httpsmpdbcaviewSMP0000300.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Bisoprolol': 'https://go.drugbank.com/drugs/DB00612', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378'}",Bisoprolol Action Pathway,"Bisoprolol (also known as Zebeta) is a selective beta blocker that can block beta1-adrenergic receptors and beta2-adrenergic receptors. Blocking of beta1-adrenergic receptors in heart and vascular smooth muscle can lead to reduced heart rate, cardiac output, and decreased blood pressure. Blocking of beta(2)-adrenergic receptors can lead to prevention of bronchospasm.",Homo sapiens,2013-08-22,2019-09-12,Drug Action Pathway,"{'2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:42:03.259668
Bivalirudin Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000277,http://smpdb.ca/view/SMP0000277/download?type=full_vector_image,httpsmpdbcaviewSMP0000277.svg,Drug action,"{'Bivalirudin': 'https://go.drugbank.com/drugs/DB00006', 'Phylloquinone': 'https://go.drugbank.com/drugs/DB01022', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Bivalirudin Action Pathway,"Bivalirudin, trade name angiomax, is a direct thrombin inhibitor. It is often prescribed to patients who cannot take unfractionated or low molecular weight heparin. Bivalirudin does not need cofactor antithrobin to act. It binds circulating and clot-bound thrombin at the catalytic site and the anion binding exosite. The inhibition of fibrin prevents the cleavage of fibrinogen into fibrin which activates Factor XIII and Factor XIIIa. This destabilizes the thrombus and inhibits the promotion of thrombin production and platelet activation. As a result, bivalirudin prevents or reduces clot formation.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'18520712': 'http://www.ncbi.nlm.nih.gov/pubmed/18520712', '12173205': 'http://www.ncbi.nlm.nih.gov/pubmed/12173205', '28102475': 'http://www.ncbi.nlm.nih.gov/pubmed/28102475', '28052306': 'http://www.ncbi.nlm.nih.gov/pubmed/28052306', '2888762': 'http://www.ncbi.nlm.nih.gov/pubmed/2888762', '15372022': 'http://www.ncbi.nlm.nih.gov/pubmed/15372022', '3754331': 'http://www.ncbi.nlm.nih.gov/pubmed/3754331', '9443882': 'http://www.ncbi.nlm.nih.gov/pubmed/9443882', '2843432': 'http://www.ncbi.nlm.nih.gov/pubmed/2843432', '2339700': 'http://www.ncbi.nlm.nih.gov/pubmed/2339700', '3521732': 'http://www.ncbi.nlm.nih.gov/pubmed/3521732', '11031105': 'http://www.ncbi.nlm.nih.gov/pubmed/11031105', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '6959130': 'http://www.ncbi.nlm.nih.gov/pubmed/6959130', '6687940': 'http://www.ncbi.nlm.nih.gov/pubmed/6687940', '6329734': 'http://www.ncbi.nlm.nih.gov/pubmed/6329734', '19372258': 'http://www.ncbi.nlm.nih.gov/pubmed/19372258', '12787532': 'http://www.ncbi.nlm.nih.gov/pubmed/12787532'}",2022-01-17 22:42:18.458401
Blue Diaper Syndrome,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000583,http://smpdb.ca/view/SMP0000583/download?type=full_vector_image,httpsmpdbcaviewSMP0000583.svg,Disease,"{'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Urea': 'https://go.drugbank.com/drugs/DB03904'}",Blue Diaper Syndrome,"Blue diaper syndrome is a recessive metabolic disorder that has not yet been determined to be X-linked or autosomal. This syndrome is caused by a mutation in the large neutral amino acids transporter small subunit 1 protein, which allows tryptophan, among other amino acids, to be reabsorbed in the kidneys. The excess tryptophan found in the intestine is digested by bacteria which excrete indole, which can undergo oxidation to produce indigo blue. This is seen in the diapers of infants affected by blue diaper syndrome, due to the increased levels of indole in their urine or feces. Other symptoms can include bacterial infections, damage to various parts of the eye, hypercalcemia, and impaired kidney function due to this. Treatment can include a calcium restricted diet in order to prevent hypercalcemia, and a tryptophan restricted diet to prevent all systems. If bacterial infections are common, antibiotics may be prescribed.",Homo sapiens,2013-08-29,2021-06-01,Disease Pathway,"{'14246093': 'http://www.ncbi.nlm.nih.gov/pubmed/14246093', '4626127': 'http://www.ncbi.nlm.nih.gov/pubmed/4626127', '25318757': 'http://www.ncbi.nlm.nih.gov/pubmed/25318757', '11473623': 'http://www.ncbi.nlm.nih.gov/pubmed/11473623', '24855283': 'http://www.ncbi.nlm.nih.gov/pubmed/24855283', '8812482': 'http://www.ncbi.nlm.nih.gov/pubmed/8812482', '12112667': 'http://www.ncbi.nlm.nih.gov/pubmed/12112667', '8528245': 'http://www.ncbi.nlm.nih.gov/pubmed/8528245', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458'}",2022-01-17 22:42:43.946164
Bopindolol Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000657,http://smpdb.ca/view/SMP0000657/download?type=full_vector_image,httpsmpdbcaviewSMP0000657.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Bopindolol': 'https://go.drugbank.com/drugs/DB08807'}",Bopindolol Action Pathway,"Bopindolol (also known as Sandonorm) is a selective β1 adrenergic receptor antagonist (beta blocker), which can be used for treatment of high blood pressure (hypertension) and irregular heartbeats (arrhythmias). Bopindolol also has the ability to mild intrinsic sympathomimetic activity (ISA) with effective range of dosage. Adrenaline (also known as epinephrine) can activate β1 adrenergic receptor so that the heart rate and output will be increased. Renin is a hormone that generated from kidney, which could lead to constriction of blood vessels. Beta blockers could efficiently prohibit renin release.",Homo sapiens,2014-04-19,2019-09-12,Drug Action Pathway,"{'11752352': 'http://www.ncbi.nlm.nih.gov/pubmed/11752352', '14608456': 'http://www.ncbi.nlm.nih.gov/pubmed/14608456', '1687398': 'http://www.ncbi.nlm.nih.gov/pubmed/1687398', '2148726': 'http://www.ncbi.nlm.nih.gov/pubmed/2148726', '8884690': 'http://www.ncbi.nlm.nih.gov/pubmed/8884690', '2907348': 'http://www.ncbi.nlm.nih.gov/pubmed/2907348', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:43:06.995474
Bosutinib Inhibition of BCR-ABL,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0031698,http://smpdb.ca/view/SMP0031698/download?type=full_vector_image,httpsmpdbcaviewSMP0031698.svg,Drug action,{'Bosutinib': 'https://go.drugbank.com/drugs/DB06616'},Bosutinib Inhibition of BCR-ABL,"Bosutinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood. The cause of CML pathophysiology is the BCR-ABL fusion protein - the result of a genetic abnormality known as the Philadelphia chromosome in which Abelson Murine Leukemia viral oncogene homolog 1 (ABL1) translocates within the Breakpoint Cluster Region (BCR) gene on chromosome 22. BCR-ABL is a cytoplasm-targeted constitutively active tyrosine kinase that activates several oncogenic pathways which promote increased cell proliferation and survival including the MAPK/ERK Pathway, the JAK-STAT Pathway, and the PI3K/Akt pathway. Bosutinib is considered a second generation BCR-ABL inhibitor (Imatinib being the progenitor) that inhibits BCR-ABL activity by binding a highly conserved ATP binding site to effectively lock the tyrosine kinase in an inactive conformation. As a result, phosphate is unable to be transferred from ATP to activate oncogenic signalling cascades. For greater detail, refer to the pathway titled BCR-ABL Action in CML Pathogenesis. Bosutinib is able to bind ABL with greater affinity than Imatinib, perhaps due to its ability to bind both inactive and intermediate conformations of the protein. It is therefore administered to patients with Imatinib resistance. Bosutinib may have a safer toxicity profile than both Imatinib and Dasatinib because it does not significantly inhibit the receptors KIT and PDGFR. Notably, Bosutinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary.",Homo sapiens,2017-08-16,2021-03-02,Drug Action Pathway,"{'17853901': 'http://www.ncbi.nlm.nih.gov/pubmed/17853901', '21098337': 'http://www.ncbi.nlm.nih.gov/pubmed/21098337', '22156549': 'http://www.ncbi.nlm.nih.gov/pubmed/22156549', '1322798': 'http://www.ncbi.nlm.nih.gov/pubmed/1322798', '10051406': 'http://www.ncbi.nlm.nih.gov/pubmed/10051406', '8491186': 'http://www.ncbi.nlm.nih.gov/pubmed/8491186', '10068651': 'http://www.ncbi.nlm.nih.gov/pubmed/10068651', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '16554811': 'http://www.ncbi.nlm.nih.gov/pubmed/16554811', '22827337': 'http://www.ncbi.nlm.nih.gov/pubmed/22827337', '11868160': 'http://www.ncbi.nlm.nih.gov/pubmed/11868160', '17143285': 'http://www.ncbi.nlm.nih.gov/pubmed/17143285', '1630456': 'http://www.ncbi.nlm.nih.gov/pubmed/1630456', '8378094': 'http://www.ncbi.nlm.nih.gov/pubmed/8378094', '8657152': 'http://www.ncbi.nlm.nih.gov/pubmed/8657152', '8361759': 'http://www.ncbi.nlm.nih.gov/pubmed/8361759', '15461802': 'http://www.ncbi.nlm.nih.gov/pubmed/15461802', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '2030914': 'http://www.ncbi.nlm.nih.gov/pubmed/2030914', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '1849461': 'http://www.ncbi.nlm.nih.gov/pubmed/1849461', '8628286': 'http://www.ncbi.nlm.nih.gov/pubmed/8628286', '15534001': 'http://www.ncbi.nlm.nih.gov/pubmed/15534001', '7719937': 'http://www.ncbi.nlm.nih.gov/pubmed/7719937', '9326218': 'http://www.ncbi.nlm.nih.gov/pubmed/9326218', '15805263': 'http://www.ncbi.nlm.nih.gov/pubmed/15805263', '16424865': 'http://www.ncbi.nlm.nih.gov/pubmed/16424865'}",2022-01-17 22:43:21.583035
Bromfenac Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000102,http://smpdb.ca/view/SMP0000102/download?type=full_vector_image,httpsmpdbcaviewSMP0000102.svg,Drug action,"{'Glutamic acid': 'https://go.drugbank.com/drugs/DB00142', 'Glutathione': 'https://go.drugbank.com/drugs/DB00143', 'Dinoprostone': 'https://go.drugbank.com/drugs/DB00917', 'Bromfenac': 'https://go.drugbank.com/drugs/DB00963', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Zinc': 'https://go.drugbank.com/drugs/DB01593', 'Prostaglandin D2': 'https://go.drugbank.com/drugs/DB02056', 'Mesoheme': 'https://go.drugbank.com/drugs/DB02577', 'Prostaglandin G2': 'https://go.drugbank.com/drugs/DB03866', 'Arachidonic Acid': 'https://go.drugbank.com/drugs/DB04557'}",Bromfenac Action Pathway,"Bromfenac (also named Prolensa, Bromday or Xibrom) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to reduce ocular inflammation and pain after cataract surgery. Bromfenac is also a type of ophthalmic anti-inflammatory medicines. Bromfenac can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of bromfenac.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'2512924': 'http://www.ncbi.nlm.nih.gov/pubmed/2512924', '1907252': 'http://www.ncbi.nlm.nih.gov/pubmed/1907252', '1734857': 'http://www.ncbi.nlm.nih.gov/pubmed/1734857', '8181472': 'http://www.ncbi.nlm.nih.gov/pubmed/8181472', '8473346': 'http://www.ncbi.nlm.nih.gov/pubmed/8473346', '1380156': 'http://www.ncbi.nlm.nih.gov/pubmed/1380156', '10492403': 'http://www.ncbi.nlm.nih.gov/pubmed/10492403', '10860554': 'http://www.ncbi.nlm.nih.gov/pubmed/10860554', '10833273': 'http://www.ncbi.nlm.nih.gov/pubmed/10833273', '3654641': 'http://www.ncbi.nlm.nih.gov/pubmed/3654641', '2821541': 'http://www.ncbi.nlm.nih.gov/pubmed/2821541', '7628486': 'http://www.ncbi.nlm.nih.gov/pubmed/7628486', '8052639': 'http://www.ncbi.nlm.nih.gov/pubmed/8052639', '7937884': 'http://www.ncbi.nlm.nih.gov/pubmed/7937884', '8626689': 'http://www.ncbi.nlm.nih.gov/pubmed/8626689', '2904146': 'http://www.ncbi.nlm.nih.gov/pubmed/2904146', '2907498': 'http://www.ncbi.nlm.nih.gov/pubmed/2907498', '2563599': 'http://www.ncbi.nlm.nih.gov/pubmed/2563599', '10220143': 'http://www.ncbi.nlm.nih.gov/pubmed/10220143', '12496980': 'http://www.ncbi.nlm.nih.gov/pubmed/12496980', '3658677': 'http://www.ncbi.nlm.nih.gov/pubmed/3658677', '8185632': 'http://www.ncbi.nlm.nih.gov/pubmed/8185632', '11281454': 'http://www.ncbi.nlm.nih.gov/pubmed/11281454', '11780052': 'http://www.ncbi.nlm.nih.gov/pubmed/11780052', '1902577': 'http://www.ncbi.nlm.nih.gov/pubmed/1902577', '1385416': 'http://www.ncbi.nlm.nih.gov/pubmed/1385416', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12045397': 'http://www.ncbi.nlm.nih.gov/pubmed/12045397', '11451964': 'http://www.ncbi.nlm.nih.gov/pubmed/11451964', '9588707': 'http://www.ncbi.nlm.nih.gov/pubmed/9588707', '1899973': 'http://www.ncbi.nlm.nih.gov/pubmed/1899973'}",2022-01-17 22:43:53.604293
Bromodiphenhydramine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0058813,http://smpdb.ca/view/SMP0058813/download?type=full_vector_image,httpsmpdbcaviewSMP0058813.svg,Drug action,"{'Bromodiphenhydramine': 'https://go.drugbank.com/drugs/DB01237', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Bromodiphenhydramine H1-Antihistamine Action,"Bromodiphenhydramine (Bromazine) is a first-generation ethanolamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-18,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:44:08.841210
Brompheniramine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0057579,http://smpdb.ca/view/SMP0057579/download?type=full_vector_image,httpsmpdbcaviewSMP0057579.svg,Drug action,"{'Brompheniramine': 'https://go.drugbank.com/drugs/DB00835', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Brompheniramine H1-Antihistamine Action,"Brompheniramine is a first-generation alkylamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-15,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:44:24.822036
Buclizine H1-Antihistamine Action,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0058964,http://smpdb.ca/view/SMP0058964/download?type=full_vector_image,httpsmpdbcaviewSMP0058964.svg,Drug action,"{'Buclizine': 'https://go.drugbank.com/drugs/DB00354', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Buclizine H1-Antihistamine Action,"Buclizine is a first-generation piperazine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.",Homo sapiens,2017-09-18,2021-05-06,Drug Action Pathway,"{'22035879': 'http://www.ncbi.nlm.nih.gov/pubmed/22035879', '7913608': 'http://www.ncbi.nlm.nih.gov/pubmed/7913608', '2174351': 'http://www.ncbi.nlm.nih.gov/pubmed/2174351', '11118617': 'http://www.ncbi.nlm.nih.gov/pubmed/11118617', '10760467': 'http://www.ncbi.nlm.nih.gov/pubmed/10760467', '9628581': 'http://www.ncbi.nlm.nih.gov/pubmed/9628581', '27108799': 'http://www.ncbi.nlm.nih.gov/pubmed/27108799', '3095147': 'http://www.ncbi.nlm.nih.gov/pubmed/3095147', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '10833460': 'http://www.ncbi.nlm.nih.gov/pubmed/10833460', '17974005': 'http://www.ncbi.nlm.nih.gov/pubmed/17974005', '15489334': 'http://www.ncbi.nlm.nih.gov/pubmed/15489334', '8280179': 'http://www.ncbi.nlm.nih.gov/pubmed/8280179', '8003029': 'http://www.ncbi.nlm.nih.gov/pubmed/8003029', '7925364': 'http://www.ncbi.nlm.nih.gov/pubmed/7925364', '19078957': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957', '22307269': 'http://www.ncbi.nlm.nih.gov/pubmed/22307269', '8825633': 'http://www.ncbi.nlm.nih.gov/pubmed/8825633'}",2022-01-17 22:44:41.187899
Bumetanide Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000088,http://smpdb.ca/view/SMP0000088/download?type=full_vector_image,httpsmpdbcaviewSMP0000088.svg,Drug action,"{'Cysteine': 'https://go.drugbank.com/drugs/DB00151', 'Bumetanide': 'https://go.drugbank.com/drugs/DB00887', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Urea': 'https://go.drugbank.com/drugs/DB03904'}",Bumetanide Action Pathway,"Bumetanide, trade name Bumex, is a loop diuretic that increases urine production by inhibiting the reabsorption of water in the nephron. In the thick ascending limb of the loop of Henle, the sodium-potassium-chloride cotransporter (NKCC2) is competitively inhibited at the chloride binding site blocking sodium transport from the lumen to the interstitium. This results in the lumen becoming hypertonic and a decreased osmotic gradient thereby reducing the water reabsorption. In the nephron, the think ascending limb reabsorbs 25% of sodium and is a good target for diuretics.",Homo sapiens,2013-08-22,2021-06-01,Drug Action Pathway,"{'10653443': 'http://www.ncbi.nlm.nih.gov/pubmed/10653443', '1092541': 'http://www.ncbi.nlm.nih.gov/pubmed/1092541', '15644426': 'http://www.ncbi.nlm.nih.gov/pubmed/15644426', '17502342': 'http://www.ncbi.nlm.nih.gov/pubmed/17502342', '15914676': 'http://www.ncbi.nlm.nih.gov/pubmed/15914676', '8640224': 'http://www.ncbi.nlm.nih.gov/pubmed/8640224', '16572171': 'http://www.ncbi.nlm.nih.gov/pubmed/16572171', '21613606': 'http://www.ncbi.nlm.nih.gov/pubmed/21613606', '8812482': 'http://www.ncbi.nlm.nih.gov/pubmed/8812482', '12112667': 'http://www.ncbi.nlm.nih.gov/pubmed/12112667', '8528245': 'http://www.ncbi.nlm.nih.gov/pubmed/8528245', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '25318757': 'http://www.ncbi.nlm.nih.gov/pubmed/25318757', '11473623': 'http://www.ncbi.nlm.nih.gov/pubmed/11473623', '24855283': 'http://www.ncbi.nlm.nih.gov/pubmed/24855283'}",2022-01-17 22:45:01.167039
Bupivacaine Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000393,http://smpdb.ca/view/SMP0000393/download?type=full_vector_image,httpsmpdbcaviewSMP0000393.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Bupivacaine': 'https://go.drugbank.com/drugs/DB00297', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Bupivacaine Action Pathway,"Bupivacaine exerts its local anaesthetic effect by blocking voltage-gated sodium channels in peripheral neurons. Bupivacaine diffuses across the neuronal plasma membrane in its uncharged base form. Once inside the cytoplasm, it is protonated and this protonated form enters and blocks the pore of the voltage-gated sodium channel from the cytoplasmic side. For this to happen, the sodium channel must first become active so that so that gating mechanism is in the open state. Therefore bupivacaine preferentially inhibits neurons that are actively firing.",Homo sapiens,2013-08-22,2019-08-16,Drug Action Pathway,"{'19465198': 'http://www.ncbi.nlm.nih.gov/pubmed/19465198', '8646465': 'http://www.ncbi.nlm.nih.gov/pubmed/8646465', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:45:20.148840
Bupranolol Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000670,http://smpdb.ca/view/SMP0000670/download?type=full_vector_image,httpsmpdbcaviewSMP0000670.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373', 'Magnesium cation': 'https://go.drugbank.com/drugs/DB01378', 'Bupranolol': 'https://go.drugbank.com/drugs/DB08808'}",Bupranolol Action Pathway,"Bupranolol is a nonselective beta-blocker with structural similarity to propanolol. Both drugs do not have intrinsic sympathomimetic activity. It competes with catecholamines for binding beta-1 adrenergic receptors in the heart to inhibit sympathetic activation. This inhibition causes decreased heart rate, cardiac output, blood pressure",Homo sapiens,2014-04-21,2019-09-12,Drug Action Pathway,"{'26456674': 'http://www.ncbi.nlm.nih.gov/pubmed/26456674', '2825170': 'http://www.ncbi.nlm.nih.gov/pubmed/2825170', '10477438': 'http://www.ncbi.nlm.nih.gov/pubmed/10477438', '15164054': 'http://www.ncbi.nlm.nih.gov/pubmed/15164054', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '12953268': 'http://www.ncbi.nlm.nih.gov/pubmed/12953268', '12539047': 'http://www.ncbi.nlm.nih.gov/pubmed/12539047', '15174025': 'http://www.ncbi.nlm.nih.gov/pubmed/15174025', '22842232': 'http://www.ncbi.nlm.nih.gov/pubmed/22842232', '23409136': 'http://www.ncbi.nlm.nih.gov/pubmed/23409136', '24468074': 'http://www.ncbi.nlm.nih.gov/pubmed/24468074', '12119109': 'http://www.ncbi.nlm.nih.gov/pubmed/12119109', '16175638': 'http://www.ncbi.nlm.nih.gov/pubmed/16175638', '16710414': 'http://www.ncbi.nlm.nih.gov/pubmed/16710414', '3008098': 'http://www.ncbi.nlm.nih.gov/pubmed/3008098', '2559024': 'http://www.ncbi.nlm.nih.gov/pubmed/2559024', '8305453': 'http://www.ncbi.nlm.nih.gov/pubmed/8305453', '8918259': 'http://www.ncbi.nlm.nih.gov/pubmed/8918259', '9524271': 'http://www.ncbi.nlm.nih.gov/pubmed/9524271', '8798450': 'http://www.ncbi.nlm.nih.gov/pubmed/8798450', '9457675': 'http://www.ncbi.nlm.nih.gov/pubmed/9457675', '11112438': 'http://www.ncbi.nlm.nih.gov/pubmed/11112438', '9048881': 'http://www.ncbi.nlm.nih.gov/pubmed/9048881', '11062458': 'http://www.ncbi.nlm.nih.gov/pubmed/11062458', '15173218': 'http://www.ncbi.nlm.nih.gov/pubmed/15173218', '4610574': 'http://www.ncbi.nlm.nih.gov/pubmed/4610574', '25646377': 'http://www.ncbi.nlm.nih.gov/pubmed/25646377'}",2022-01-17 22:45:40.712040
Buprenorphine Action Pathway,https://go.drugbank.com/pathways?page=5,http://smpdb.ca/view/SMP0000684,http://smpdb.ca/view/SMP0000684/download?type=full_vector_image,httpsmpdbcaviewSMP0000684.svg,Drug action,"{'ATP': 'https://go.drugbank.com/drugs/DB00171', 'Norepinephrine': 'https://go.drugbank.com/drugs/DB00368', 'Buprenorphine': 'https://go.drugbank.com/drugs/DB00921', 'Dopamine': 'https://go.drugbank.com/drugs/DB00988', 'Potassium cation': 'https://go.drugbank.com/drugs/DB01345', 'Calcium': 'https://go.drugbank.com/drugs/DB01373'}",Buprenorphine Action Pathway,"Buprenorphine, trade name subutex, suboxone, zubsolv and bunavail, is a partial agonist of mu-opioid receptors and a kappa-opioid receptor antagonist and is prescribed for opioid addiction to prevent cravings and symptoms of withdrawal. The binding of these receptors causes hyperpolarization and decreased neuronal excitability. Buprenorphine has a longer duration of action due to its slow dissociation from the receptor. This long rate of action causes a long clinical effect and decreases physical dependence. Buprenorphine can also prevent opioid use by inhibiting exogenous opioid effects. This elimination of the rush from the opioid can block the reinforcing behaviour of the drug and may treat opioid addiction. Buprenorphine is available on its own or in combination with naloxone.",Homo sapiens,2014-04-26,2019-08-16,Drug Action Pathway,"{'27199497': 'http://www.ncbi.nlm.nih.gov/pubmed/27199497', '28070862': 'http://www.ncbi.nlm.nih.gov/pubmed/28070862', '24654720': 'http://www.ncbi.nlm.nih.gov/pubmed/24654720', '7905839': 'http://www.ncbi.nlm.nih.gov/pubmed/7905839', '7957926': 'http://www.ncbi.nlm.nih.gov/pubmed/7957926', '7891175': 'http://www.ncbi.nlm.nih.gov/pubmed/7891175', '11176968': 'http://www.ncbi.nlm.nih.gov/pubmed/11176968', '10049321': 'http://www.ncbi.nlm.nih.gov/pubmed/10049321', '8898206': 'http://www.ncbi.nlm.nih.gov/pubmed/8898206', '1385409': 'http://www.ncbi.nlm.nih.gov/pubmed/1385409', '1309651': 'http://www.ncbi.nlm.nih.gov/pubmed/1309651', '7916667': 'http://www.ncbi.nlm.nih.gov/pubmed/7916667', '9880589': 'http://www.ncbi.nlm.nih.gov/pubmed/9880589', '10766861': 'http://www.ncbi.nlm.nih.gov/pubmed/10766861', '10762351': 'http://www.ncbi.nlm.nih.gov/pubmed/10762351', '9839820': 'http://www.ncbi.nlm.nih.gov/pubmed/9839820', '16641997': 'http://www.ncbi.nlm.nih.gov/pubmed/16641997', '21248752': 'http://www.ncbi.nlm.nih.gov/pubmed/21248752', '7851891': 'http://www.ncbi.nlm.nih.gov/pubmed/7851891', '19710327': 'http://www.ncbi.nlm.nih.gov/pubmed/19710327', '29992740': 'http://www.ncbi.nlm.nih.gov/pubmed/29992740', '9843794': 'http://www.ncbi.nlm.nih.gov/pubmed/9843794', '10470851': 'http://www.ncbi.nlm.nih.gov/pubmed/10470851', '10551270': 'http://www.ncbi.nlm.nih.gov/pubmed/10551270', '11287421': 'http://www.ncbi.nlm.nih.gov/pubmed/11287421', '10676964': 'http://www.ncbi.nlm.nih.gov/pubmed/10676964', '11263977': 'http://www.ncbi.nlm.nih.gov/pubmed/11263977', '2430951': 'http://www.ncbi.nlm.nih.gov/pubmed/2430951', '7536695': 'http://www.ncbi.nlm.nih.gov/pubmed/7536695', '14702039': 'http://www.ncbi.nlm.nih.gov/pubmed/14702039', '23584863': 'http://www.ncbi.nlm.nih.gov/pubmed/23584863', '18472347': 'http://www.ncbi.nlm.nih.gov/pubmed/18472347', '20628619': 'http://www.ncbi.nlm.nih.gov/pubmed/20628619'}",2022-01-17 22:46:02.040466
